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Abstract1,2 
The ribosome translates genomic information into structural and catalytic protein 
molecules. In addition to its role in protein synthesis, the ribosome also produces small non-
catalytic peptides that exert antimicrobial properties. The recent surge in the availability of 
genome sequences from a wide variety of bacterial sources has led to the rapid discovery of 
ribosomally-synthesized and post-translationally modified peptides (RiPPs). The biosynthetic 
machinery of RiPPs offers a new platform for the discovery and engineering of peptidic natural 
products. Although rapid advances have been made in elucidating biosynthetic pathways 
generating various RiPPs, investigations with respect to enzyme chemistry and action are still in 
their nascent stage. The novel chemistry via which post translational modifications (PTMs) are 
introduced into RiPPs emphasizes the synthetic potential found in nature. One such class of 
RiPPs are the lantibiotics, lanthipeptides with antimicrobial activity. The unifying PTMs found 
in lanthipeptides are thioether crosslinks, called lanthionine and methyl lanthionine. The 
crosslinks are formed via the dehydration of serine and threonine residues to dehydroalanine 
(Dha) and dehydrobutyrine (Dhb) residues, respectively, followed by Michael-type addition of 
cysteines to the dehydrated residues. Nisin, a class I lantibiotic produced by Lactococcus lactis, 
is one of the oldest known antibiotics. In this study, we have developed a production strategy for 
class I lantibiotics in Escherichia coli and show successful production of nisin as a proof of 
concept.  
1Parts of this chapter have been adapted with permission from: 
1. Garg N, Tang W, Goto Y, Nair SK, van der Donk WA,. Proc Natl Acad Sci U S A. 2012 Apr 3; 109(14):5241-6. Reproduced 
with permission of the publisher and available from http://www.pnas.org/ (DOI: 10.1073/pnas.1116815109). 
2. Garg N, Salazar-Ocampo LMA, van der Donk WA. Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7258-63. Reproduced with 
permission of the publisher and available from http://www.pnas.org/ (DOI: 10.1073/pnas.1222488110). 
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The dehydration reaction in class I lantibiotics, thiopeptides, and goadsporin is catalyzed 
by LanB or LanB-like proteins. Although LanB proteins have been studied since 1992, in vitro 
reconstitution of their dehydration activity has been elusive. Herein, we demonstrate the in vitro 
activity of NisB, the dehydratase involved in the biosynthesis of nisin. NisB requires glutamate, 
adenosine-5’-triphosphate, Mg2+, and the ribosomal/membrane fraction of bacterial cell extract 
to dehydrate its substrate peptide NisA. Mutation of 23 highly conserved residues of NisB 
identified a number of amino acids that are essential for dehydration activity. In addition, these 
mutagenesis studies identified three mutants, R786A, R826A, and H961A that result in multiple 
glutamylations of the NisA substrate. Glutamylation was observed both during E. coli co-
expression of NisA with these mutants and during in vitro assays. Treatment of the glutamylated 
substrate with wild type NisB resulted in dehydrated NisA suggesting that the glutamylated 
peptide is an intermediate in dehydration. Collectively, these studies suggest that dehydration 
involves glutamylation of the side chains of Ser and Thr followed by elimination. The proposed 
reaction mechanism is unprecedented for lanthipeptide dehydration and these findings facilitate 
mechanistic investigations for other LanB proteins that are involved in the biosynthesis of 
lantibiotics, thiopeptides, and goadsporin. 
Nisin is used extensively for food preservation and is also FDA-approved for the 
treatment of bovine mastitis. Despite its commercial use for more than 55 years, no evidence of 
significant resistance to nisin has emerged. Unfortunately, the stability of nisin is limited at pH 
7.0 and elevated temperatures, which hinders its broader application. Conceivably, lanthipeptides 
from thermophilic bacteria, or bacteria which live in harsher ecological niches than L. lactis, 
might not suffer from the limitations of nisin. In this study, using genome mining, we discovered 
two novel lantibiotics, geobacillin I and geobacillin II, from a thermophilic bacterium 
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Geobacillus thermodenitrificans NG80-2 that has an optimal growth temperature of 65 °C. The 
heterologous production system that was developed for nisin in E. coli enabled their production, 
and biochemical and structural characterization. Geobacillin I is a class I lantibiotic and 
resembles nisin in structure, but it contains seven thioether crosslinks, two more than nisin and 
the most crosslinks found in any lantibiotic to date. Compared to nisin, geobacillin I displayed 
increased activity against Streptococcus dysgalactiae, one of the causative agents of bovine 
mastitis. Geobacillin I also demonstrated increased stability compared to nisin A at temperatures 
of 37 °C and 60 °C at pH 7.0. Despite the lack of a hinge region that has been reported as 
important for the pore-formation activity of nisin, geobacillin I was found to form pores in the 
membranes of Gram-positive bacteria. Geobacillin II is a class II lantibiotic, and was found to 
have a ring topology unlike any known lantibiotic, as determined by tandem mass spectrometry. 
It contains unusual stereochemistry at the first lanthionine ring. Interestingly, geobacillin II has a 
narrow spectrum of antibacterial action as it only demonstrates antimicrobial activity against 
Bacillus strains amongst the bacteria tested. The activity of the class II lanthionine synthetase 
catalyzing the PTMs in geobacillin II was reconstituted in vitro and the enzyme was found to be 
active at temperatures up to 80 °C. Seven Geobacillus strains were screened for production of the 
geobacillins using whole cell MALDI-MS and five were shown to produce geobacillin I; none 
produced geobacillin II.  
In summary, a strategy was developed for the production of class I lantibiotics in E. coli. 
Using this methodology, two novel lantibiotics, geobacillin I and geobacillin II were produced 
and characterized. Further, NisB-catalyzed dehydration and GeoM-catalyzed 
dehydration/cyclization was investigated in vitro and provided insights into the mechanism of 
catalysis. 
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Chapter 1: Introduction 
1.1 Ribosomally-synthesized and post-translationally modified peptides  
Natural products have a diverse variety of applications, such as their use as antibiotics 
(1), anticancer agents (2), sunscreens (3), and are produced by all domains of life. They often 
possess a biological activity that can be exploited for pharmaceutical drug design and discovery.  
Natural products usually have more hetero-atoms, more stereogenic centers, and more fused 
rings than synthetic small molecules. In some cases, they also satisfy Lipinski’s “rule of five” (4-
5). Thus, natural products possess interesting properties from a pharmaceutical standpoint. The 
golden era of antibiotic natural product discovery was the 1940’s and 1950’s.  Statistical analysis 
performed by Watve et al. in 2001 predicted that the exclusive screening of Streptomyces would 
result in the discovery of 15-20 new antibiotics each year for the next 50 years (6). However, 
slow discovery rates because of the potential for rediscovery were projected to be economically 
unviable and hence, pharmaceutical companies lost interest in natural product discovery. 
Recently, the explosion in availability of genome sequences, development of high-throughput 
screening methods, novel culture methods, heterologous DNA-based methods, and strategies 
such as metagenomics have led to renewed interest in antibiotic discovery (7). Fanning the fire is 
the growing emergence of antibiotic-resistant infectious bacterial strains. The emergence of 
vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus 
(MRSA) (8-9), have highlighted the importance of developing novel pharmacophores towards 
which the odds of developing resistance would be very low. One approach towards this goal 
involves identification of antibiotics with multiple modes of actions such that it would be 
difficult for bacteria to reprogram multiple biological targets to develop resistance. This 
approach would require designing new screens and possibly exploring untouched habitats and 
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classes of microorganisms. Efforts directed towards developing new scaffolds rather than re-
engineering existing ones may provide a long term solution to the problem of emerging 
resistance against antibiotics. One such promising opportunity is provided by a relatively new 
class of natural peptide antibiotics termed ribosomally-synthesized and post-translationally 
modified peptides (RiPPs). In order to survive in their niche and obtain nutrients, bacteria have 
to constantly fight against competing bacteria. To achieve this, bacteria produce a number of 
small molecules including RiPPs. The in silico studies made possible by the recent surge in 
availability of genome sequences has revealed that RiPPs are much more widespread than 
previously suggested (10-13). The post-translational modifications expand the chemical space of 
ribosomal peptides, which is typically restricted by the use of only twenty naturally occurring 
amino acids, and provide these molecules with restricted conformations for tighter target 
binding, and enhanced biological and chemical stability.  
Interestingly, RiPPs are produced by all domains of life including humans (14) and 
possess vast structural and functional diversity. The various biological activities possessed by 
these molecules include antimicrobial, antitumor, antiviral, anti-inflammatory, and 
morphological activities. Despite the structural and functional diversity and the difference in 
sources of origin, the biosynthetic logic leading to generation of RiPPs has been conserved 
among all classes of these molecules. RiPPs are smaller than 10 kDa in size and range in amino 
acid length between 20 and 110 amino acid residues. The ribosomally-synthesized precursor 
peptide can be subdivided into various segments. Each segment has its own unique functions but 
not all segments are present in the biosynthesis of a given molecule. Most RiPPs contain an N-
terminal leader sequence, which guides the enzymatic tailoring of the C-terminal core region 
and/or export of the natural product (11). Typically, it is the core region that finally becomes the 
3 
 
bioactive molecule. Bottromycins are the only known class of RiPPs that contains a C-terminal 
rather than an N-terminal leader region and hence this region is called a “follower peptide”.  
Some RiPPs also contain an N-terminal signal sequence for guiding subcellular localization and 
a C-terminal recognition sequence, which can be removed in processes such as macrocyclization.  
The annotation of RiPPs with the associated biosynthetic pathways in recent years has 
significantly enhanced the knowledge of diversity and breadth of post-translational modifications 
found in these products. The biosynthetic pathways for RiPPs are amenable to in vivo or in vitro 
engineering. Some of the tailoring enzymes are shared between pathways of different classes of 
RiPPs, for instance, lanthipeptide dehydratases, radical-SAM methyl transferases, and 
cyclodehydratases (11). Most tailoring enzymes are promiscuous and can modify core regions 
with varied amino acid sequences. Thus, a non-silent change at the nucleotide level of the 
precursor peptide directly translates into a change in the final RiPP produced. Such engineering 
is a relatively facile process since these pathways are relatively short and a single enzyme can 
carry out a number of modifications.  
1.2 Lanthipeptides 
Amongst the pool of known RiPPs, lanthipeptides are peptide antibiotics (15) that contain 
two alanine residues crosslinked via thioether bridges called lanthionine, or thioether crosslinks 
between alanine and ethylglycine termed methyllanthionine. Lanthipeptides derive their name 
from the presence of the universal lanthionine motif. Lanthipeptides that possess antimicrobial 
activity are termed lantibiotics (11). The first lantibiotic, nisin, was discovered in 1928, isolated 
in 1947, and used as food preservative since 1951 (16-20). Although the first lanthipeptide gene 
cluster was sequenced in 1988 (21), the protein-like ribosomal synthesis of nisin was first 
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suggested as early as 1966 (22), and its structure was elucidated in 1971 (17). Lanthipeptides are 
small peptides typically 19-38 amino acids long and contain extensive post-translational 
modifications (Figure 1.1). The defining modifications include 2,3-dehydroalanine (Dha), (Z)-
2,3-didehydrobutyrine (Dhb), and the thioether containing residues lanthionine (Lan) and 3-
methyllanthionine (MeLan). Apart from the lanthionine modifications, some lantibiotics also 
contain other modifications such as chlorination, hydroxylation, and the formation of labionin, 
D-alanine, lysinoalanine, 2-oxo-propionyl, and S-aminovinyl-D-cysteine (Figure 1.1) (23).  
1.3 Biosynthesis of lanthipeptides 
The thioether bridges in lanthipeptides are enzymatically installed either by the action of 
two separate enzymes termed dehydratases (LanB) and cyclases (LanC) or by the action of 
bifunctional enzymes (LanM, LanL, or LabKC/RamC), which carry out both dehydration and 
cyclization activities. Each lanthipeptide gene cluster contains a precursor peptide LanA and at 
least one of these tailoring enzymes; lanthipeptides are classified depending on which of these 
tailoring enzymes is present in the biosynthetic gene cluster. Their domain architecture is 
depicted in Figure 1.2. A few examples of each lanthipeptide class are shown in Figure 1.3.  
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Figure 1.1. The post-translational modifications found in lanthipeptides. The color scheme used for these drawings 
is also followed in Figure 1.3.  
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Figure 1.2. Schematic representation of the domain architecture of tailoring enzymes present in different classes of 
lanthipeptides. Individual domains are labeled. The conserved residues in pSer/pThr lyase and kinase domains are 
shown as light green bars. The conserved zinc ligands present in the LanC cyclase of class I, and in the LanC-like 
domains of class II and IV proteins are shown with dark green bars. Adapted from reference (24). 
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Figure 1.3. Structures of select examples of class I (nisin, and epilancin 15X), class II (actagardine, and 
cinnamycin), class III (labyrinthopeptin A2), and class IV (venezuelin) lanthipeptides. 
The class I lanthipeptides are defined by the presence of a dedicated dehydratase 
generically termed LanB and a cyclase termed LanC. A more specific designation is used for 
each lanthipeptide, e.g. GeoB and GeoC for geobacillin I. In the biosynthesis of class I 
lanthipeptides, leader peptide removal and transport of the final molecule is performed by a 
protease LanP and an adenosine-5’-triphosphate (ATP)-binding cassette (ABC) transporter 
LanT, respectively (25). The leader peptide can be proteolytically removed either intracellularly 
or extracellularly. For example, the leader peptide of nisin is removed extracellularly whereas the 
leader peptide of epilancin 15 X is removed intracellularly (26). Some gene clusters, such as the 
gene cluster of subtilin, lack a LanP, and the leader peptide is suggested to be removed by a non- 
specific protease found elsewhere in the genome (27-28). Recently, gene clusters with multiple 
LanAs and LanBs have been reported (10).  
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Formation of the thioether bridges in class II, III and IV lanthipeptides is catalyzed by 
bifunctional lanthionine synthetases. The bifunctional LanM enzymes involved in the 
biosynthesis of class II lanthipeptides have an N-terminal dehydration domain that does not 
display sequence homology with known enzymes in the database and a C-terminal cyclization 
domain that displays homology with the LanC cyclases of the class I machinery. A bifunctional 
transporter/protease, which is involved in leader peptide removal and transport, is found in most 
class II lanthipeptide gene clusters. In certain cases, a second proteolysis event is required to 
completely remove the leader peptide (29). Biosynthetic gene clusters with two LanAs and two 
LanMs have been extensively characterized, and such lantibiotics are termed two-component 
lantibiotics. Recently, gene clusters with more than two LanAs and LanMs have also been 
reported (10). 
The individual domains of the lanthipeptide synthetases involved in the biosynthesis of 
class III (30) and class IV (24, 31) lanthipeptides are more familiar and have known counterparts 
in the protein database. The dehydration reaction is achieved by phosphorylation of 
serines/threonines by a central kinase domain, followed by elimination of phosphate by an N-
terminal phosphoSer/phosphoThr lyase domain (24, 31). The class III and IV lanthipeptide 
synthetases differ in their C-terminal cyclase domains. Although the cyclization domains of all 
four classes show significant sequence homology, the cyclization domains of class III enzymes 
lack the three conserved metal binding residues that are fully conserved in class I, II and IV 
enzymes (32-35). A unique cyclization reaction catalyzed by some of the class III enzymes also 
has been characterized recently. It is proposed that these enzymes catalyze the formation of a 
carbon-carbon crosslink by the attack of an intermediate enolate onto a second dehydroalanine. 
The genes responsible for secretion and leader peptide removal are not yet characterized for class 
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III and class IV lanthipeptides, but genes with sequence homology to ATP transporters do occur 
in the biosynthetic gene clusters (30).  
1.4 Lanthipeptide leader peptides 
Although the precursor peptides contain dehydratable residues in both the leader and core 
region, only residues present in the core region undergo dehydration. The leader peptide varies in 
length and is usually between 23-59 residues (36). Various roles have been proposed for the 
leader peptides of RiPPs. The leader peptide of nisin has been demonstrated to play important 
roles in maturation, transport, and proteolysis (37). A recent study demonstrated that the NisA 
leader was not sufficient to pull down the NisB/C complex suggesting that the tailoring enzymes 
NisB and NisC recognize both leader and core (38). The binding studies between NisB and 
different segments of modified and unmodified precursor peptide demonstrated that NisB had 
greater affinity for dehydrated prenisin but did not bind modified nisin lacking the leader region 
(39).  
1.5 Mechanism of dehydration and cyclization in lanthipeptide biosynthesis 
 The lanthipeptide synthetases catalyzing the biosynthesis of all four classes of 
lanthipeptides described above involve dehydration and cyclization steps to install lanthionine 
and methyllanthionine bridges. The LanB enzymes do not have sequence homology with known 
enzymes in protein database, their structures have not been solved, in vitro activity has not been 
reconstituted, and no reaction intermediates have been isolated from the in vivo studies. Hence, 
the mechanism of action of these enzymes is still unknown. In contrast, the first study reporting 
the in vitro reconstitution of a LanM enzyme (40-41) in 2004 shed light on the catalytic 
mechanism of the dehydration domain of LanM enzymes. The synthetase LctM involved in the 
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biosynthesis of lacticin 481 phosphorylates the hydroxyl group of Ser/Thr in the core peptide 
followed by elimination of phosphate resulting in dehydro amino acids. Extensive site directed 
mutagenesis of the conserved residues of LctM was performed to gain insights into the 
mechanism of dehydration (42). A base catalyzed deprotonation of the hydroxyl group of 
Ser/Thr followed by attack on the γ-phosphate of ATP would produce a phosphorylated peptide 
and adenosine-5’-diphosphate (ADP) (Figure 1.4). In contrast to hydrolysis of the phosphate 
ester, which is a common biological reaction, base-catalyzed elimination of phosphate is 
proposed to yield a dehydrated Ser/Thr. In the case of LctM, either Asp242 or Asp259 is 
proposed to be the first base involved in deprotonation of Ser/Thr. Arg399 or Asp 259 could act 
as second base and deprotonate the α-carbon of pSer/pThr, generating an enolate, which 
subsequently eliminates the phosphate group. Lys159 and/or Mg2+ may possibly aid by acting as 
general acid in the reaction.  
 The dehydration reaction catalyzed by LanL enzymes that belong to class IV 
lanthipeptides was recently characterized (24, 31). The domain architecture of these enzymes as 
described above also suggests a phosphorylation and elimination mechanism. The cyclization 
domain of VenL, the synthetase involved in venezuelin production in Steptomyces venezuelae, 
was deleted and the N-terminal bifunctional kinase/lyase domain was isolated (31). In vitro assay 
with this domain resulted in dehydrations of Ser/Thr in the substrate peptide. Mutagenesis 
studies in this domain suggested that Lys80 could deprotonate the α-carbon of pSer/pThr aided 
by Lys51, which coordinates to the carbonyl group of the pSer/pThr based on the 
crystallographic structure of a pThr lyase involved in virulence (43). Further, a role of His53 in 
protonating the phosphate leaving group was proposed. Interestingly, the synthetase AciKC 
involved in the biosynthesis of the class III lanthipeptide catenulipeptin in Catenulispora 
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acidiphila DSM 44928, was shown to utilize all four NTPs as co-substrates (44). Based on 
sequence homology and domain architecture of this class of synthetases, the dehydration was 
proposed to take place by a similar phosphorylation and elimination mechanism (44-45).  
 
Figure 1.4. Proposed mechanism of catalysis of lanthipeptide synthetases. A)  Mechanism for the dehydration of Ser 
by LctM (42). B) Mechanism of dehydration of Ser by VenL (24). 
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 The lanthipeptide cyclase enzymes LanC, and the C-terminal cyclase domain of LanM, 
LanL, and LanKC enzymes catalyze the regio- and stereoselective Michael-type addition of 
cysteine side chains onto dehydroamino acids. The in vitro reconstitution of the cyclization 
reaction, and the first and only X-ray crystal structure of a LanC enzyme involved in the 
biosynthesis of a lanthipeptide was first described in 2006 for nisin (33). NisC was shown to be a 
zinc-containing metalloprotein. The zinc ion was proposed to lower the pKa of thiol groups of 
cysteine allowing the nucleophilic addition of activated thiols onto unsaturated amino acids and 
hence was proposed to play a catalytic role. Zinc ligands such as Cys284, Cys330, and His331 in 
NisC and Cys781, Cys836, and His837 in LctM are very well conserved in lanthipeptide 
cyclases. Interestingly, the cyclization domain of ProcM, a lanthipeptide synthetase involved in 
the cyclization of twenty nine different substrate peptides, contains three cysteines (Cys924, 
Cys970, and Cys971) as zinc ligands rather than two cysteines and one histidine as found in all 
other LanC enzymes and cyclase domains of LanM enzymes (46). This difference may be the 
reason for the highly promiscuous cyclization activity of ProcM. With respect to catalysis, a 
conserved His residue (His212 in NisC/His725 in LctM) was proposed to be the catalytic base 
that deprotonates the cysteine thiol of the substrate or the catalytic acid that protonates the 
enolate (35). The mechanism of the cyclization reaction of LanKC enzymes is unknown  and 
may be different from the mechanism of LanC, LanM, and LanL enzymes since LanKC proteins 
lack the conserved zinc ligands found in these enzymes. 
1.6 Mechanism of action of lanthipeptides 
Lanthipeptides are known to function as antibacterials (25), signaling molecules (47), 
enzyme inhibitors (48), and morphogenic peptides (49). The most studied biological function of 
lanthipeptides is their antibacterial activity. Lantibiotics such as nisin, microbisporicin, epilancin 
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15X, and haloduracin are known to display nanomolar minimal inhibitory activities against 
pathogens of clinical interest (50-52). Originally, the capability of lantibiotics to inhibit bacterial 
growth was attributed to binding of these cationic peptides with the negatively charged 
phospholipids in the cell wall of bacterial cells. A large amount of experimental evidence 
collected in the past 15 years has shed more light onto the mechanism of action of select 
lantibiotics. Nisin was the first lantibiotic whose specific target was found to be lipid II (53). 
Lipid II is a membrane-anchored cell wall precursor that is essential for peptidoglycan 
biosynthesis (Figure 1.5). The peptidoglycan of all bacteria consists of a polymer of alternating 
amino sugars, N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). The glycan 
polymers of GlcNAc and MurNAc chains are cross-linked by a pentapeptide typically with the 
sequence L-alanyl-γ-D-glutamyl-diaminopimelyl-(or L-lysyl)-D-alanyl-D-alanine that is attached 
to the MurNAc sugar (54). This crosslinking provides the cell with the required structural 
rigidity and mechanical strength. The precursor, lipid II, is comprised of an undecaprenyl 
membrane anchor, a pyrophosphate group, the sugars GlcNAc and MurNAc, and a pentapeptide 
chain (Figure 1.5). Nisin has been used as food preservative since 1951 but significant resistance 
to nisin outside of laboratory conditions has not been observed. Lipid II is biosynthesized in ten 
enzymatic steps, which are highly conserved between different bacterial species. This 
complexity may explain why development of resistance against nisin is more challenging. By 
binding to the pyrophosphate moiety of lipid II nisin blocks the transglycosylation step wherein 
peptidoglycan glycosyltransferases catalyze the polymerization of lipid II to the growing 
peptidoglycan (55). 
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Figure 1.5. Proposed mechanism of action of the lantibiotic nisin (15, 53). The pyrophosphate of lipid II is shown 
with circles labeled P. The hexagons represent the sugars GlcNAc and MurNAc. The MurNAc carries a 
pentapeptide that is represented by circles. 
 
Nisin also sequesters lipid II and removes it from its functional location (53). 
Sequestering of lipid II by nisin also allows nisin to form transient holes in the bacterial 
membrane (Figure 1.5) (56). Specifically the A and B rings of nisin bind to the pyrophosphate of 
lipid II as determined by the solution NMR structure of nisin bound to a truncated lipid II variant 
with only three isoprene units (57). Furthermore, the hinge region of nisin, comprised of amino 
acid residues Asn20, Met21, and Lys22 (Figure 1.3), allows it the flexibility to adopt a 
conformation required for the C-terminus to insert in the bacterial membrane and hence form 
pores 2 nm in diameter (56, 58-59). A study using liposomes demonstrated that the presence of 
lipid II in a membrane increases the pore-forming efficiency of nisin 1000-fold (53).  The 
significant increase of pore forming activity of nisin was demonstrated when only two lipid II 
molecules per 105 phospholipid molecules greatly enhanced the release of dyes from vesicles. 
Lipid II-mediated change in the orientation of nisin from parallel to perpendicular with respect to 
the membrane surface (60) is believed to result in formation of a stable pore structure.  
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The importance of lipid II as target for antibacterials is emphasized by the fact that lipid 
II is targeted by four different classes of antibacterials including glycopeptides (61). Nisin does 
not show cross-reactivity with these peptides since it binds to the pyrophosphate of lipid II, 
which is not recognized by other classes of lipid II-targeting antibiotics. Some lipid II targeting 
lantibiotics such as actagardine and mersacidin lack pore formation activity (62-63). An 
investigation of the mechanism of action of mersacidin revealed that the binding site on lipid II is 
the GlcNAc sugar instead of the pyrophosphate moiety (64). An interesting mechanism of action 
has been suggested for two-component lantibiotics. Studies with haloduracin have demonstrated 
that the alpha component of haloduracin binds to lipid II and the beta component binds the alpha 
component in complex with lipid II and results in pore formation (65). Studies have also 
uncovered examples of non-lipid II-mediated biological activity of lantibiotics. One such 
example is the inhibition of phospholipase A2 by cinnamycin (48). Cinnamycin binds to 
phosphatidylethanolamine with 1:1 stoichiometry and hence prevents phospholipase A2-
catalyzed release of arachidonic acids. Other lanthipeptides such as SapB and SapT lack 
antibacterial activity but have morphogenic activity and result in the formation of aerial hyphae 
in Streptomycetes (49, 66).  
1.7 Regulation and Immunity 
 Unlike Trojan horse antibiotics (67-68), lanthipeptides are processed to active forms by 
the producer organism, which necessitates the presence of biosynthetic regulation and self- 
immunity mechanisms within the producer cells to prevent self death. The gene clusters 
encoding lanthipeptides code for a variety of regulatory proteins, unique to each cluster. 
Biosynthesis of some lantibiotics such as nisin (69) and subtilin (70) is regulated by a two-
component regulatory system. This system comprises of a transmembrane receptor histidine 
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kinase (LanK) and a transcriptional response regulator (LanR). The extracellular lantibiotic can 
be detected by NisK, which initiates a signal transduction cascade by autophosphorylation of a 
histidine residue. Further, transfer of the phosphoryl group by LanK to an aspartate residue of 
LanR promotes the binding of LanR to the promoter elements of the biosynthetic gene cluster. 
The gene encoding LanK is absent from some gene clusters, for instance, from the gene cluster 
of the lantibiotic epidermin. The biosynthesis of epidermin is regulated by binding of EpiQ to the 
EpiA promoter (71). The gene cluster of mersacidin encodes for two LanR type proteins (MrsR1 
and MrsR2) and one LanK sensor protein (MrsK) (72). The biosynthesis of lacticin 3147 and 
cytolysin is regulated by repressor proteins rather than activators, termed LtnR (73) and 
CylR1/R2 (74), respectively. The activation of promoters in the biosynthesis of mutacin II is 
regulated by the MutR protein and currently unknown components of the growth medium (75-
76). MutR is homologous to the family of Rgg (regulator gene of glucosyltransferase) 
transcription regulators. Conversely, the production of lacticin 481 is independent of regulatory 
proteins and is rather activated by the acidic pH of the environment (77). Thus, regulation of the 
biosynthesis of lanthipeptides is controlled by a wide variety of different regulatory mechanisms. 
 The study of self-immunity conferring mechanisms for lanthipeptides is in its nascent 
stage. Similar to regulatory mechanisms, self-resistance mechanisms vary significantly among 
lanthipeptide gene clusters. Self-immunity of some lantibiotics such as nisin, subtilin, epidermin, 
mersacidin, lacticin 481, and mutacin II is provided by the expression of an ATP-dependent 
transporter protein LanFEG (73, 78-81). A second immunity protein LanI, either by itself or 
along with LanFEG proteins, also is encoded in certain gene clusters such as NisI in nisin, SpaI 
in subtilin, and PepI in the Pep5 biosynthetic cluster (25). A more complex immunity mechanism 
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was recently reported for protection against epilancin 15X and may involve the expression of 
three genes, namely elx1, elx2, and elx3 (26).  
1.8 In vivo engineering of nisin 
The biosynthetic pathways of lanthipeptides are highly evolvable and have immense 
potential for engineering in laboratory settings (82). This promise is in part due to leader peptide-
guided biosynthesis. The tailoring enzymes recognize the leader peptide and by doing so can 
modify core regions containing variable amino acid substitutions. Various analogues of nisin 
containing mutations in the amino acid residues of the A-ring, the C-ring, and the hinge region 
between the C- and D-rings have been generated, and display enhanced biological activity. All 
ring B analogues generated to date have poor biological activity as compared to wild type nisin 
(83).  The substitution of Dha5 by Dhb in nisin Z resulted in 2-10-fold lower biological activity 
against a number of strains (84), whereas replacement of Dhb2 for Dha resulted in 2-fold 
enhanced biological activity (85). The substitution of amino acids at position 3, 4 and 5 in ring A 
generated three mutants, KSL, KFI and VFG, that resulted in loss of immunity in the producer 
organisms (83). These analogues also had enhanced biological activity against some strains of 
Staphylococcus and Lactococcus. The double mutation M17Q/G18T (84) resulted in generation 
of two nisin Z analogues, one with Dhb at position 18 and another with Thr at position 18.  The 
variant with Dhb at position 18 had biological activity comparable to wild type nisin Z. Thus, an 
additional dehydroresidue at position 18 does not enhance or reduce biological activity. The 
mutant with threonine at this position had 3-fold higher activity against Micrococcus flavus. The 
most interesting structure-activity relationships were observed for analogues with substitutions in 
the hinge region. Site-saturated mutagenesis was performed in the hinge region at positions 20, 
21, and 22. Noteworthy mutations are M21V (patented as Nisin V) and K22T (patented as nisin 
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T) (86-87). The K22T mutant showed enhanced activity against the human and bovine pathogen 
Streptococcus agalactiae. The M21V mutation resulted in enhanced activity against a wide 
variety of pathogenic bacteria including MRSA, VRE, heterogeneous vancomycin-intermediate 
S. aureus (hVISA), Clostridium difficile, Listeria monocytogenes, and S. agalactiae. The 
mutations N20K and M21K resulted in enhanced biological activity against Gram-negative 
bacteria including Shigella, Pseudomonas and Salmonella spp (88). The mutation N20P 
displayed enhanced bioactivity against MRSA, S. aureus ST528, and DPC5425, but reduced 
activity against S. agalactiae (56). 
1.9 Summary of investigations presented in this thesis 
Through the studies described herein, we have attempted to build an appreciation for the 
immense untapped potential for the discovery of enzymatic chemistry involved in lanthipeptide 
biosynthesis. This thesis will describe efforts towards development of technologies for the in 
vivo and in vitro production of class I (chapter 2 and 3) and class II lanthipeptides (chapter 4), 
and utilization of this technology to produce novel lanthipeptides, including structural and 
functional characterization and investigation of structure-activity relationships. In addition, this 
thesis will describe new insights into the dehydration reaction catalyzed by LanB enzymes and 
demonstrate the power of genome mining for new lanthipeptides. Sequencing of microbial 
genomes to discover silent gene clusters, together with metagenomic approaches to discover 
lanthipeptide gene clusters within the microbial metabolome, will further enrich this field.
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Chapter 2: In vitro reconstitution, biochemical, and mechanistic characterization of the 
nisin dehydratase NisB 1 
2.1 Introduction 
Nisin is the best characterized member of the lantibiotics family and has been used in the 
food industry for over 40 years to combat food-borne pathogens (1). Nisin is biosynthesized by 
NisB-catalyzed dehydration of Ser and Thr residues in the core peptide of the precursor peptide 
yielding dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues, respectively (Figure 2.1).  
Figure 2.1. Biosynthesis of nisin. (A) NisB dehydrates Ser and Thr residues in the core peptide of NisA, and NisC 
catalyzes the addition of Cys to Dha and Dhb. Then NisP removes the leader peptide. Although the figure is drawn 
with all dehydrations being completed before cyclization commences, it is likely that dehydration and cyclization 
are alternating activities in lantibiotic biosynthesis (2-4). (B) Ser and Thr residues are first dehydrated to generate 
Dha and Dhb, respectively. Subsequent intramolecular addition of the thiols of Cys residues to the Dha and Dhb 
results in the formation of lanthionine (Lan) and methyllanthionine (MeLan) structures, respectively. Abu stands for 
2-aminobutyric acid.  
 
1Parts of this chapter have been adapted with permission from: 
1. Shi Y, Yang X, Garg N, & van der Donk WA. J Am Chem Soc. 2011 Mar 2;133(8):2338-41. Reproduced with  permission of the 
publisher and available from http://pubs.acs.org/journal/jacsat (DOI: 10.1021/ja109044r). 
2. Neha G, Salazar-Ocampo LMA, van der Donk WA. Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7258-63. Reproduced with 
permission of the publisher and available from http://www.pnas.org/ (DOI: 10.1073/pnas.1222488110). 
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Subsequent Michael-type addition of cysteine side chains to the dehydrated residues by the 
action of NisC results in the formation of lanthionine and methyllanthionine (Figure 2.1).  
Engineering of nisin has been very fruitful in generating analogues with advantageous 
properties and has been accomplished by manipulation of the sequence of the NisA precursor 
peptide in native host strains and heterologous expression systems (5-8). To be able to take full 
advantage of in vivo or in vitro introduction of non-proteinogenic amino acids, production of 
nisin in Escherichia coli or reconstitution of the nisin biosynthetic pathway in vitro would be 
highly desirable. As described in chapter 1, lanthipeptides have been divided into four classes 
based on distinct biosynthetic enzymes that carry out the dehydration and cyclization reactions 
(9). The biosyntheses of class II, III, and IV lanthipeptides have all been reconstituted in vitro 
(10-12), but in vitro reconstitution of the biosynthesis of class I lanthipeptides that include nisin 
has been elusive. In vivo production of lanthipeptides in E. coli has been reported for a truncated 
analogue of the class II lantibiotic nukacin ISK-1(13), for bovicin HJ 50 (14), and for 
lichenicidin (15). Genetic and bioengineering studies have demonstrated that NisB carries out the 
dehydration reaction and does not need any other lanthipeptide biosynthetic enzymes for this 
activity (16-17). The cyclization reaction catalyzed by NisC, the LanC involved in nisin 
biosynthesis, has been reconstituted in vitro (18) (Figure 2.1A). However, despite considerable 
effort in multiple laboratories, reconstitution of the activity of LanB dehydratases has been 
unsuccessful (19-23), and hence no information is available about their mechanism of catalysis. 
The LanB dehydratases are 115-120 kDa proteins that do not share homology with the 
dehydratases from class II-IV lanthipeptides nor with other proteins in the databases. The 
sequence identity across the LanB family is only about 30%. Genes encoding homologous LanB-
like enzymes are also present in the gene clusters of non-lantibiotic peptide natural products, 
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such as the thiopeptides (24-27) and goadsporin (28). The presence of dehydro-amino acids in 
ribosomally synthesized natural products render the peptides proteolytically more stable and 
enhance the biological activity (29). Furthermore, dehydroamino acids can be used as promising 
targets for synthesis of non-natural amino acids by serving as potential sites for modification. 
The organic synthesis of dehydro-amino acids is not only cumbersome but also expensive, and 
involves a multistep procedure for which use of protecting groups is essential. Also, the chemical 
methods are usually limited to synthesis of smaller peptides. A potential alternative route to 
synthesis of dehydro-amino acids is through the biosynthetic machinery of lantibiotics. Various 
medically relevant nonlantibiotic peptides fused to the nisin leader peptide have been shown to 
be effectively dehydrated thus demonstrating the possible exploitation of LanB’s in production 
of dehydroamino acid-containing peptides (16). Thus, in this study we undertook the task of 
production of nisin in E. coli and in vitro reconstitution of the dehydratase NisB.  
2.2 Experimental procedures 
2.2.a Construction of pRSFDuet-1/His6-NisA+NisB and pACYCDuet-1/NisC 
PCR amplification of nisA, nisB and nisC was performed using the following PCR cycle 
conditions: denaturation (98 °C for 20 s), annealing (60 °C for 20 s), and extension (72 °C for 30 
s for nisA, 120 s for nisB, and 60 s for nisC) using the primers listed in Table 2.1 at the end of 
this chapter and genomic DNA of Lactococcus lactis 6F3 as DNA template. The PCR reaction 
included 1× Phusion GC buffer (Finnzymes), DMSO (2%), Phusion hot start high fidelity DNA 
polymerase (0.05 U/µL) and primers (1 µM each). The amplification products were run on a 1% 
agarose gel and the products were purified using a QIAquick Gel Extraction Kit (QIAGEN). The 
amplified nisA DNA fragment and the pRSFDuet-1 vector were digested with BamHI and 
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HindIII; PCR-amplified nisC and pACYCDuet-1 vector were digested with BglII and XhoI; and 
PCR amplified nisB was digested with NdeI and XhoI at 37 °C for 12 h. The digests were run on 
an agarose gel and the desired products extracted using a QIAquick Gel Extraction Kit. The 
resulting DNA inserts were ligated with the respective digested vector at 4 °C for 15 h using T4 
DNA ligase (Invitrogen). The ligation reaction mixtures were diluted 6-fold with water prior to 
transformation. E. coli DH5α cells were transformed with the ligation product using heat shock 
and were plated on Luria Bertani (LB)-kanamycin agar plates and grown at 37 °C for 15 h. Five 
colonies were picked and incubated in 5 mL of LB-kanamycin medium at 37 °C for 10 h, 
followed by isolation of the plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The 
sequences of the resulting plasmids were confirmed by DNA sequencing using the appropriate 
primers by the Biotechnology Center of the University of Illinois at Urbana-Champaign. The 
plasmid vector pRSFDuet-1 containing the nisA gene was digested with NdeI and XhoI and 
ligated with PCR-amplified nisB digested with NdeI and XhoI. The ligation and transformation 
of E. coli DH5α cells was carried out as described above. The colonies were analyzed for insert 
by colony PCR and plasmid was isolated from 5 colonies and sequenced (also see notebook 3, 
page 33, 38, 45). 
2.2.b Overexpression and purification of modified nisin 
Chemically competent E. coli BL21(DE3) cells were co-transformed with pRSFDuet-1 
containing the nisA and nisB genes and pACYCDuet-1 containing nisC. Overnight culture grown 
from a single colony transformant was used as inoculum to grow 1.5 L of terrific broth (TB) 
medium containing 50 mg/L kanamycin and 25 mg/L chloramphenicol at 37 °C until the OD600 
reached about 0.6. The incubation temperature was then changed to 18 °C and the culture was 
induced with 0.5 mM IPTG. The induced cells were shaken continually at 18 °C for an 
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additional 15 h. The cells were harvested by centrifugation (11,900 × g for 10 min, Beckman 
JLA-10.500 rotor). The cell pellet was resuspended in 45 mL of start buffer (20 mM Tris, pH 
8.0, 500 mM NaCl, 10% glycerol, containing a protease inhibitor cocktail from Roche Applied 
Science) and lysed by MultiFlex C3 homogenizer (Avestin). The sample was centrifuged at 
23,700 × g  for 30 min at 4 °C. The supernatant was loaded onto a HiTrap HP nickel affinity 
column (GE Healthcare) pre-equilibrated with start buffer. Following loading, the column was 
washed with wash buffer (start buffer + 30 mM  imidazole). The peptide was eluted from the 
column using elution buffer (start buffer + 1 M imidazole). The pellet was homogenized using a 
sonicator (35% amplitude, 4.4 s pulse, 9.9 s pause for total 20 min) in start buffer to remove any 
soluble proteins. The pellet from this step was resuspended in 30 mL of denaturing buffer (6 M 
guanidine hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, pH 7.5). The insoluble portion was 
removed by centrifugation and the supernatant was loaded onto a HiTrap HP nickel affinity 
column. The column was washed with denaturing buffer containing 30 mM imidazole and eluted 
with 15 mL of denaturing buffer containing 1 M imidazole. Desalting of the eluent from both 
supernatant and pellet fractions was performed using preparative scale reversed phase high 
performance liquid chromatography (RP-HPLC) using a Waters Delta-pak C4, 15 µm, 300 Å, 
25×100 mm, PrepPak Cartridge. A gradient of 2-100% of solvent B (0.086% TFA in 80% 
acetonitrile/20% water) was used (solvent A: 0.1 % TFA in water). Modified prenisin began to 
elute at 52% B. The fractions containing modified prenisin were lyophilized and analyzed by 
matrix-assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) (also see 
notebook 5 page 3). 
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2.2.c Cleavage of modified prenisin with trypsin and antimicrobial activity assay 
An aliquot of 100 µL of 500 µM modified NisA was incubated with 3 µL of 30 µM 
trypsin (Worthington Biochemicals) at room temperature for 3 h. The resulting mixture was 
checked by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS) 
and the  proteolytic fragment corresponding to mature nisin was observed calcd: 3354 (nisin); 
found 3356 (M+H). Antimicrobial activity assays were carried out using solid agar diffusion. 
GM17 agar was melted in a microwave, cooled to 45 °C and mixed with 150 µL of overnight 
grown Lactococcus lactis HP (108-109 cfu). After the agar was solidified, 10 µL of 50 µM and 
500 µM of heterologously expressed and trypsin cleaved NisA was spotted on the surface. As a 
control, nisin purified from commercial Nisaplin (Danisco) using RP-HPLC was also spotted 
(also see notebook 5 page 8). 
2.2.d Tandem mass spectrometry analysis to confirm the correct ring topology of nisin 
Commercial, HPLC-purified nisin and in vivo produced (E. coli) nisin were subjected to 
ESI-MSMS analysis using collision induced dissociation. To carry out ESI-MSMS, 10 μL of 
each nisin preparation was  injected onto a BEH C8 column (1.7 μm, 1.0 × 100 mm), and 
separated by UPLC using a gradient of 3% mobile phase A (0.1% formic acid in water) to 97% 
mobile phase B (0.1% formic acid in methanol) over 12 min. The instrument settings used 
included capillary voltage and cane voltage of 3500 V and 40 V, respectively; 120 °C  as source 
temperature; 300 °C as desolvation temperature; cone gas flow of 150 L/h; and desolvation gas 
flow of 600 L/h. A transfer collision energy of 4 V was used for both MS and tandem MS, while 
the trap collision energy was set to 6 V for MS and a fixed voltage 28.4 V was used for MSMS 
(also see notebook 5 page 9).  
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2.2.e Construction of pRSFDuet-1/His6-NisB+ NisA expression plasmid 
The PCR amplification of nisA and nisB was performed by PCR using the conditions as 
described above with genomic DNA of Lactococcus lactis 6F3 as DNA template. The primer 
sequences are given in Table 2.1. The amplifications were analyzed on a 1% agarose gel and the 
products were purified using a QIAquick Gel Extraction Kit. The amplified nisA DNA fragment 
and the pRSFDuet-1 vector were digested with NdeI and XhoI in multiple cloning site (MCS) -2 
at 37 °C for 12 h. The reaction mixtures were run on agarose gel and the desired bands extracted 
using a QIAquick Gel Extraction Kit. The resulting double-digested nisA DNA insert was ligated 
with the digested vector at 4 °C for 15 h using T4 DNA ligase (Invitrogen). E. coli DH5α cells 
were transformed with the ligation product using heat shock and were plated on LB-kanamycin 
agar plates and grown at 37 °C for 15 h. Colonies were picked up and incubated in 5 mL of LB-
kanamycin medium at 37 °C for 10 h, followed by isolation of the plasmids using a QIAprep 
Spin Miniprep Kit (QIAGEN). The desired sequences of the resulting plasmids (pRSFDuet-1-
NisA) were confirmed by DNA sequencing using the appropriate primers by the Biotechnology 
Center of the University of Illinois at Urbana-Champaign. pRSFDuet-1/NisA containing the nisA 
gene was digested with BamHI and NotI (MCS-1) and ligated with the nisB PCR product 
digested with BamHI and NotI. The ligation and transformation of E. coli DH5α cells was 
performed as described above. Colonies were analyzed for the presence of insert and plasmid 
was isolated and sequenced (also see notebook 5 page 5). 
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2.2.f Purification of unmodified His6-NisA and His6-NisA modified by wild type and mutant 
NisB 
The plasmid pET15 His6-NisA encoding unmodified NisA was obtained from former lab 
member Dr. Trent J. Oman. The peptide NisA was expressed and purified using methodology as 
described above for expression and purification of modified nisin. The plasmid pRSFDuet-His6-
NisA/His6-NisB was constructed using the same procedure as described above except that nisA 
was inserted in MCS1 and nisB in MCS2. In order to introduce a hexahistidine tag at the N-
terminus of NisB, an oligonucleotide sequence encoding hexahistidine was incorporated in the 5’ 
end of the primer immediately before the start codon of nisB. Site directed mutagenesis was 
carried out on pRSFDuet-His6-NisA/His6-NisB to replace conserved polar residues in NisB with 
alanine using Phusion DNA polymerase and the primers listed in Table 2.1. Chemically 
competent BL21(DE3) cells were transformed with pRSFDuet-His6-NisA/His6-NisB containing 
the nisB variant genes. An overnight culture grown from a single colony transformant was used 
as inoculum for 1.5 L of TB medium containing 50 µg/L kanamycin and 25 µg/L 
chloramphenicol, and the culture was grown at 37 °C until the OD600 reached about 0.6. The 
incubation temperature was then changed to 18 °C and the culture was induced with 0.5 mM 
IPTG. The induced cells were shaken continually at 18 °C for an additional 15 h. The cells were 
harvested by centrifugation (11,900 × g for 10 min, Beckman JLA-10.500 rotor). The cell pellet 
was resuspended in 45 mL of start buffer and dehydrated non-cyclized prenisin was purified as 
described above. The fractions containing modified NisA were lyophilized and analyzed by 
MALDI-TOF MS (also see notebook 5 page 2).  
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2.2.g Overexpression and purification of His6-NisB and mutants R83A, R87A, T89A, 
D121A, D299A, R464A, R505A, E751A, R786A, H961A, R966A, and R972A 
Single colony transformants of E. coli BL21 (DE3) containing pRSFDuetHis6-NisB/His6-
NisA or the corresponding NisB mutants were grown in a 37 oC shaker for 12-15 h in 30 mL of 
LB medium supplemented with 50 μg/mL kanamycin and 25 μg/mL chloramphenicol. These 
cultures were used to inoculate 4 L of TB media and grown at 37 oC until the OD600 was ~ 0.7. 
IPTG was added to a final concentration of 0.5 mM and the cultures were grown at 18 oC for an 
additional 20 h. Cells were harvested by centrifugation at 11,900 × g for 25 min at 4 oC. The cell 
paste was resuspended in 20 mM Tris-HCl, 500 mM NaCl, and 10% glycerol, pH 8.0. The cells 
were lysed using a C3 Homogenizer (Avestin Inc.). The lysed cells were pelleted by 
centrifugation at 23,700 x g for 25 min. The purification by nickel column chromatography was 
accomplished using a 5 mL HiTrap chelating HP nickel affinity column (GE Healthcare) on an 
AKTA FPLC system (Amersham Pharmacia Biosystems). The supernatant from the 
centrifugation step was applied to the column using a 50 mL superloop. The protein was detected 
by absorbance at 280 nm. The column was washed with buffer A containing 1 M NaCl, 20 mM 
Tris-HCl, pH 8.0, and 30 mM imidazole to remove any non-specifically bound proteins until a 
flat baseline was observed. A gradient of 0-100% B over 30 min was used to elute the bound 
proteins where buffer B contained 1 M NaCl, 20 mM Tris-HCl, pH 8.0, and 200 mM imidazole.  
The most concentrated fraction (4 mL) was loaded onto an S-200 gel filtration column 
(Amersham Biosciences) equilibrated in 20 mM HEPES pH 7.5, 300 mM NaCl. The eluted 
protein was stored at −80 ˚C until use. The mutants were purified using the procedure described 
above (also see notebook 5 page 6 and notebook 7 page 39 and 42). 
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2.2.h In vitro dehydration activity assay 
The activity assay contained 200 µM His6-NisA, 5 µM His6-NisB, 50 mM HEPES pH 
7.5, 10 µL E. coli cell extract, 1 mM TCEP, 10 mM MgCl2, 1.5 mM spermidine, 175 mM 
glutamate, and 5 mM ATP. The activity assays were incubated at 30 °C for 4-6 h with gentle 
shaking. The cell extract of E. coli BL21 codon-plus RIL was prepared as reported previously 
(30) (see notebook 7 page 35, 52, and 63). 
2.2.i Fractionation of cell extract into small molecule and macromolecule fractions 
The cell extract (300 µL) was passed through a 3 kDa amicon filter. The retentate on the 
filter was brought to a final volume of 300 L with 10 mM Tris-acetate buffer (pH 8.2) 
containing 14 mM Mg(OAc)2, 60 mM KOAc, and 5 mM DTT. In a second experiment, the cell 
extract was also passed through a Sephadex G-25 PD10 column (bed volume 8.3 mL; GE 
healthcare) pre-equilibrated with 10 mM Tris-acetate buffer (pH 8.2) containing 14 mM 
Mg(OAc)2, 60 mM KOAc, and 5 mM DTT. The excluded volume fraction collected was 3.5 mL 
and included volume fraction collected was 7 mL. The different fractions thus obtained were 
used as the cell extract substitutes in the activity assays, which were carried out as described 
above (also see notebook 7 page 37). 
2.2.j Fractionation of cell extract into cytoplasmic and membrane fractions 
The cell extract (200 µL) was fractionated using a Beckman ultracentrifuge with a TLA 
100 rotor. The extract was centrifuged for 2 h at 75,000 rpm (~ 200,000 × g). The supernatant 
was carefully removed. The pellet, which presumably contains inner and outer membrane 
components and ribosomes, was dissolved in 100 µL of 1 M Trisethanol amine acetate buffer, 
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pH 7.5. The different fractions thus obtained were used as substitutes for untreated cell extract in 
the activity assays, which were carried out as described above (also see notebook 7 page 38). 
2.2.k Glutamate elimination assay 
His6-NisA carrying several +129 Da adducts was produced in E. coli by coexpression of 
His6-NisB-R786A with His6-NisA. The peptide was purified by RP-HPLC and incubated with 
His6-NisB or its Ala-mutants in HEPES buffer, pH 7.5, for 1.5 h. The assay mixture was desalted 
using a µC18 ZipTip and analyzed by MALDI-MS (also see notebook 7 page 58). 
2.3 Results 
2.3.a Heterologous production of nisin in E. coli   
The genes encoding His6-NisA and NisB were inserted into the pRSFDUET-1 vector and the 
nisC gene was inserted into a pACYCDUET-1 plasmid. E. coli BL21 (DE3) cells were 
transformed with both plasmids, grown on LB medium, and induced with IPTG. After harvesting 
the cells, lysis, and IMAC purification, 24 mg of fully modified NisA was obtained per liter of 
culture. The production strategy is summarized in Figure 2.2. The leader peptide was then 
removed using trypsin (18), and the final product was analyzed by tandem MS and bioassays. 
Similar fragmentation patterns in tandem MS and similar zones of inhibition in antimicrobial 
assays were observed for authentic nisin and for nisin produced in E. coli demonstrating the 
formation of authentic nisin (Figure 2.3 and 2.4). These experiments also demonstrate that active 
NisB can be expressed in E. coli opening up in vitro reconstitution and mechanistic studies.  
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Figure 2.2. Strategy for nisin production in E. coli.   
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Figure 2.3. Production and characterization of nisin produced in E. coli. A) MALDI-MS spectrum of NisA 
modified in E. coli and treated with trypsin to remove the leader peptide. B) Antimicrobial assays against L. lactis 
HP of authentic nisin (positive control, PC-40 µM), nisin produced in E. coli (50 µM, 500 µM), and NC (negative 
control, reaction buffer containing trypsin). C) HPLC trace showing the purity of nisin produced in E. coli. The peak 
at 33 min is fully modified nisin. 
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Figure 2.4. Tandem MS analysis of nisin produced in E. coli and commercial nisin. ESI-MSMS analysis of 
commercial nisin (top) and nisin produced in E. coli (bottom). The b3 ion seen in both samples and the y30 ion seen 
in the bottom sample are uncommon for lanthionine rings but are consistently observed for intact nisin. Dha5 may 
be involved in this unusual cleavage of the A-ring in nisin. 
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2.3.b In vitro reconstitution of dehydration activity of NisB 
The successful production of nisin in E. coli was achieved by co-expression of 
hexahistidine tagged NisA (His6-NisA) and untagged NisB from a pRSFDuet-1 vector, and 
untagged NisC from a pACYC vector as described above (31). For the purpose of in vitro studies 
on NisB, these constructs were altered such that the gene for a hexahistidine tagged NisB (His6-
NisB) was cloned into the multiple cloning site 1 (MCS-1) of pRSFDUET-1 and the gene for 
His6-tagged precursor peptide NisA was inserted into MCS-2. Using this plasmid, His6-NisA and 
His6-NisB were co-expressed in E. coli and analysis of the cell extracts indicated full 
dehydration of the His6-NisA peptide indicating that the His6-tag on NisB did not interfere with 
in vivo NisB activity (Figure 2.5). The dehydration efficiency was slightly lower when omitting 
co-expression with NisC (compare Figure 2.3A and 2.5). His6-NisB was then purified from the 
cytoplasmic fraction of the E. coli cells using nickel affinity chromatography followed by gel 
filtration chromatography. Curiously, incubation of the purified enzyme with His6-NisA in the 
presence of ATP and Mg2+ did not result in any dehydration activity. Omitting the gel filtration 
step also did not provide active enzyme, nor could any dehydrated peptide be detected after 
addition of His6-NisA to purified His6-NisB in the presence of crude cell extracts of the E. coli 
cells that produced His6-NisB and fully dehydrated His6-NisA. These results are similar to the 
previously reported unsuccessful attempts to achieve in vitro activity of LanB enzymes (19-23). 
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Figure 2.5. Nisin produced in E. coli. MALDI-MS spectrum of NisA dehydrated in E. coli by NisB and treated in 
vitro with trypsin to remove the leader peptide. The efficiency of dehydration is slightly lower as compared to 
dehydrations in the presence of NisC. Also, partial dehydration of Ser29 is also observed leading to nine-fold 
dehydrated peptide. 
Because the His6-tagged NisB did dehydrate His6-NisA in E. coli, we reasoned that some 
property of the intracellular environment of the bacteria must contribute to activity. After 
evaluating a host of different possibilities such as addition of ribosomes and crowding agents 
without success, conditions used to optimize in vitro protein biosynthesis (32) were assessed. 
When glutamate (175 mM), the most abundant metabolite in E. coli (33), and spermidine (1.5  
mM), a polyamine involved in modulating various cellular functions, were added to His6-NisB (5 
M), His6-NisA (200 M), ATP (5 mM), Mg2+ (10 mM), and E. coli cell extract prepared 
according to a previously reported procedure that stabilizes cellular components (30), NisA was 
dehydrated eight and nine times as determined by matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry (MS) (Figure 2.6). Nisin produced in the producing organism  
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Figure 2.6. In vitro reconstitution of dehydration activity of NisB. MALDI mass spectrum of His6-NisA 
incubated with His6-NisB, ATP, Mg2+, glutamate, and E. coli cell extract. 
 
Lactococcus lactis and in E. coli is dehydrated eight times, with Ser29 in the core peptide 
escaping dehydration (Figure 2.1). The observation of a partial ninth dehydration in vitro may be 
caused by the absence of rings D and E, which may prevent dehydration of Ser29. Omitting ATP 
resulted in unmodified His6-NisA as the only observed peptide (Figure 2.7A ). Loss of activity 
also occurred when cell extract was replaced with water (Figure 2.7B), but using cell extract 
from E. coli cells that did not contain any exogenous lantibiotic genes did result in full 
dehydration. Complete loss in activity was also observed on omitting NisB from activity assays 
(Figure 2.7D). Furthermore, spermidine was not essential for NisB activity as it could be omitted 
from the assay without affecting the dehydration activity. Because the cell extract contained 
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significant amounts of glutamate, its importance could not be determined at this stage, but it was 
later shown to be required (vide infra). 
 
Figure 2.7. Determination of the required ingredients in the generic NisB activity assay. A) In vitro NisB 
activity assay in the absence of ATP. B) In vitro NisB activity assay in the absence of cell extract prepared as 
described in the reference (34). C) In vitro enzyme activity assay of NisB in the absence of glutamate. The cell 
extract was passed through a PD10 column in order to remove residual glutamate present in the extract.  D) In vitro 
activity assay in the absence of NisB (but including all other ingredients). The peak at m/z 7273 in panels A and D 
originates from the E. coli cell extract (35). 
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2.3.c Fractionation of cell extract to investigate the cellular component required for 
dehydration activity 
The cell extract was fractionated into small molecule and macromolecule fractions using 
two methods. First, cell extract was passed through a 3 kDa amicon ultracentrifugation filter. 
Full dehydration activity was observed when the retentate was used in the assay mixture instead 
of cell extract (Figure 2.8A), whereas no activity was seen when the flow-through was used 
(Figure 2.8B). The cell extract was also passed through a Sephadex G-25 PD10 column, and the 
macromolecule fraction was collected separately from the small molecule fraction. Again, 
dehydration activity was observed by adding the macromolecule fraction to the NisB activity 
assay, whereas no activity was observed with the small molecule fraction. The observation that 
the macromolecule fraction contained the ingredient(s) needed for activity also allowed a test of 
the requirement for glutamate. Addition of the macromolecular fraction of the gel filtration 
experiment to the activity assay in the absence of glutamate did not result in dehydration of NisA 
(Figure 2.7C), whereas inclusion of Glu (175 mM) again resulted in full dehydration activity. 
In an attempt to identify the ingredient in the macromolecular fraction that is necessary 
for activity, the cell extract was fractionated using ultracentrifugation at 200,000 × g. Addition of 
the fraction that contains the membrane components as well as ribosomes to the activity assay 
afforded dehydrated NisA peptides (Figure 2.8C), but activity was not observed when the 
cytoplasmic fraction was added to the assay mixture (Figure 2.8D). Further fractionation of the 
membrane fraction resulted in loss of activity. Moreover, addition of purified ribosomes to the 
activity assay instead of cell extract did not result in dehydration activity and neither could cell 
extract be replaced by exogenously added commercial polar lipids consisting of 67% 
phosphatidylethanolamine, 23.2% phosphatidylglycerol, 9.8% cardiolipin (100600 P). Hence, at 
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present the ingredient present in the crude membrane fraction that is required for activity is not 
known. 
 
Figure 2.8. Investigation of the active ingredient(s) in cell extract. A) Full dehydration activity was observed 
when using the retentate of an ultrafiltration experiment with a membrane with a 3 kDa molecular weight cut-off for 
the in vitro NisB assay. B) MALDI-MS spectrum of His6-NisA incubated with His6-NisB, ATP, Mg2+, Glu and the 
flow through fraction of the ultrafiltration experiment. C) MALDI-mass spectrum of His6-NisA incubated with His6-
NisB, ATP, Mg2+, Glu and the crude membrane fraction of an ultracentrifugation experiment at 200,000 x g. D) 
MALDI-mass spectrum of His6-NisA incubated with His6-NisB, ATP, Mg2+, Glu and the cytoplasmic fraction of the 
ultracentrifugation experiment. 
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2.3.d Alanine substitution of highly conserved residues in NisB 
A previous study on the effects of mutagenesis of five conserved amino acids in NisB on 
the dehydration reaction was performed in a Lactococcus lactis heterologous host (36). In the 
current study, we interrogated the role of 23 additional highly conserved residues with side 
chains that could be involved in the dehydration activity of NisB (Figure 2.9), including several 
residues identified in a previous bioinformatics study (37). Because of ease of manipulation, the 
previously described E. coli expression system (31) was used as an initial test. Mutation of 
residues Arg575, Ser581, and Asp648 of His6-NisB to Ala did not affect the dehydration activity 
as the product was eight-fold dehydrated His6-NisA. Mutation of Glu44, Lys68, Lys116, Glu133, 
Arg505, Lys741, Glu823, Ser958, and Glu975 to Ala resulted in partially dehydrated products, 
suggesting these residues are important but not essential for dehydration (Figure 2.10). 
Conversely, individual replacement of residues Arg14, Arg83, Arg87, Thr89, Asp121, Asp299, 
Arg464, and Arg966 with Ala resulted in abolishment of dehydration (Figure 2.11), suggesting 
they are important for catalysis. The most interesting observations were made with the NisB 
mutants R786A, R826A, and H961A.  MALDI-MS analysis of the His6-NisA peptides that were 
purified after co-expression with these mutants demonstrated multiple adducts of 129 Da (Figure 
2.12).  The inactive mutants and the mutants that led to adducts of 129 Da were selected for 
further in vitro investigation. They were expressed with an N-terminal hexahistidine tag and 
purified using nickel affinity column chromatography and gel filtration chromatography, 
resulting in similar yields as wild type protein. Thus, the observed loss of activity or generation 
of adducts was not a consequence of poor expression or solubility. 
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Figure 2.9. Continued on page 48. 
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Figure 2.9. Continued on page 49. 
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Figure 2.9. Sequence alignment of NisB with select other class I lantibiotic dehydratase enzymes. The residues mutated in this study are boxed with NisB 
residue numbers on top in blue. Mutations at positions resulting in adducts corresponding to 129 Da are denoted by a star under the residues. 
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Figure 2.10. Continued on page 51.  
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Figure 2.10. Modification of His6-NisA by NisB containing mutations at conserved residues in E. coli. MALDI-
MS analysis of Ala mutants of NisB at positions (A) Glu44, (B) Lys68, (C) Lys116, (D) Glu133, (E) Arg505, (F) 
Lys741, (G) Glu823, (H) Ser958, and (I) Glu975. 
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Figure 2.11. Continued on page 53 
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Figure 2.11. Modification of His6-NisA by NisB containing mutations at conserved residues in E. coli. MALDI-
MS analysis of Ala mutants of NisB at positions (A) Arg14, (B) Arg83, (C) Arg87, (D) Thr89, (E) Asp121, (F) 
Asp299, (G) Arg464, and (H) Arg966. 
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 Figure 2.12. Modification of His6-NisA by NisB-R786A, R826A, and H961A in E. coli. MALDI mass spectra of 
His6-NisA co-expressed with (A) NisB-R786A, (B) NisB-R826A, and (C) NisB-H961A. 
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2.3.e Mechanistic investigation of NisB 
To investigate the identity of the 129 Da adducts, the His6-NisA peptide that was 
modified by the mutant NisB-R786A in E. coli was purified using nickel affinity 
chromatography and RP-HPLC. The purified peptide was digested with trypsin and analysis of 
the resulting fragments indicated that all the +129 Da adducts were present in the core peptide. 
The observed masses are reminiscent of polyglutamylation of eukaryotic proteins, which 
involves consecutive additions of glutamate to the side chain of Glu residues in proteins via 
amide linkages between the -carboxy and the -amino groups of Glu (38). But unlike such 
polyglutamylation, the 129 Da adducts on NisA could be readily removed by treatment with 
base, suggesting that if the 129 Da adducts are associated with glutamylation, the linkage is more 
likely to involve an ester, thioester, or anhydride. To confirm that Glu was the source of the 
adducts, in vitro assays were performed. Incubation of His6-NisB-R786A with His6-NisA, ATP, 
Mg2+, cell extract, and [2,3,3,4,4-d5]-Glu and subsequent MALDI-MS analysis showed multiple 
+134 adducts on NisA (Figure 2.13). Thus, glutamate was confirmed as the source of the adducts 
that are produced during co-expression in E. coli and in vitro assays. 
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Figure 2.13. In vitro activity assays of NisB-R786A with unlabeled and deuterium-labeled glutamate. MALDI 
mass spectra of His6-NisA incubated in vitro with NisB-R786A, ATP, Mg2+, cell extract and (A) glutamate or (B) 
2,3,3,4,4-d5 glutamate. 
  
57 
 
To test whether the adducts could be intermediates in the dehydration process, His6-NisA 
obtained from coexpression with NisB-R786A was again purified (Figure 2.14A), and the 
modified peptide containing the multiple 129 Da adducts was incubated with purified wild type 
His6-NisB.  MALDI-MS analysis demonstrated conversion of NisA containing the adducts to 
dehydrated peptide (Figure 2.14B). None of the other components of the in vitro NisB assay 
mixture that are important for dehydration (glutamate, cell extract, Mg2+, or ATP) was required 
for glutamate elimination. We also tested the in vitro glutamate elimination activity of the His6-
NisB mutants, which were all expressed in E. coli and purified. The alanine mutants of Arg83, 
Arg87, Thr89, Asp121, Asp299, Arg 464, and Arg966 were confirmed to be inactive with 
respect to dehydration of His6-NisA, but they had similar glutamate elimination activity as the 
wild type protein on glutamylated His6-NisA (Figure 2.15). The alanine mutants of Lys116, and 
Glu97 displayed partial dehydration activity but they again had similar glutamate elimination 
activity as wild type NisB. The only mutants that exhibited only very low glutamate elimination 
activity were the same mutants that in E. coli resulted in observation of glutamylated NisA: 
Arg786Ala, Arg826Ala, and His961Ala (Figure 2.14). 
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Figure 2.14. Investigation of the in vitro elimination activity of wild type and alanine mutants of His6NisB. (A) 
RP-HPLC purified glutamylated peptide. MALDI-MS spectra showing the product from incubation of His6-NisA 
carrying several +129 Da adducts produced by His6-NisB-R786A with (B) wild type His6-NisB, (C) His6-NisB-
His961Ala, (D) His6-NisB-Arg786Ala, and (E) His6-NisB-Arg826Ala. 
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Figure 2.15. Continued on page 60. 
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Figure 2.15. Investigation of the in vitro elimination activity of alanine mutants of His6NisB. MALDI-MS 
spectra showing the products from incubation of His6-NisA carrying several +129 Da adducts produced by His6-
NisB-Arg786Ala mutant with (A) His6-NisB-Arg83Ala, (B) His6-NisB-Arg87Ala, (C) His6-NisB-Thr89Ala, (D) 
His6-NisB-Lys116Ala, (E) His6-NisB-Asp121Ala, (F) His6-NisB-Asp299Ala, (G) His6-NisB-Arg464Ala, (H) His6-
NisB-Arg966Ala, (I) His6-NisB-Arg972Ala, and (J) His6-NisB-Glu975Ala. 
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When the products of the glutamate elimination assay containing glutamylated His6-NisA 
and wild type NisB were incubated with L-glutamic acid dehydrogenase and NAD+, a clear 
increase in absorbance at 340 nm was observed (Figure 2.16) suggesting oxidation of glutamate 
that had been released from the NisA peptide by wild type NisB. Attempts to determine the sites 
of glutamylation within the core peptide were unsuccessful as the Glu adducts were removed in 
tandem MS experiments before any fragmentation of the peptide bonds. This observation once 
again suggests that the linkage of Glu to NisA is not by an amide bond. Moreover, the observed 
production of dehydrated peptide upon treatment with wild type NisB is most consistent with an 
ester linkage to Ser/Thr. Further, various small metabolites were tested for dehydration activity 
and the results are summarized in Table 2.1. Replacement of glutamate with the citric acid cycle 
intermediates α-ketoglutarate, malate, and succinate did not result in dehydration activity. 
Incubation with amino acids glutamine and iso-glutamine in place of glutamate resulted in partial 
dehydration activity whereas incubation with aspartate resulted in up to 3 dehydrations (Figure 
2.17). 
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Figure 2.16. Glutamic acid dehydrogenase assay to confirm identity of 129 Da adducts. Increase in absorbance 
at 340 nM upon incubation of the reaction mixture from Figure 2.13B with L-glutamic acid dehydrogenase and 
NAD+ (black curve). The increase in absorbance at 340 nm was not observed when the incubation was performed in 
the absence of His6-NisA carrying adducts (blue curve). 
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 Figure 2.17.  Continued on page 64.  
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Figure 2.17. Investigation of the activity of small metabolites as potential co-substrates for dehydration 
activity of NisB. MALDI-MS spectra showing the product from incubation of His6-NisA with His6-NisB, ATP, 
Mg2+, macromolecule fraction of E. coli cell extract, and (A) glutamine, (B) aspartate, (C) isoglutamine, (D) 
glutarate, (E) α-ketoglutarate, (F) malate and, (G) succinate. The cell extract was passed through a PD10 column in 
order to remove residual glutamate present in the extract. The peaks corresponding to M-14 and M-28 in penel E 
and G are MALDI-MS artifact peaks and are not observed with ESI-MS. 
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2.4 Discussion 
NisB was initially isolated from membrane vesicles of the nisin producer L. lactis in 1992 
(19) and was recently also purified in soluble form (23), but reconstitution of its activity in vitro 
has remained elusive. In this study, we demonstrate the successful production of authentic nisin 
in E. coli using coexpression of the precursor peptide NisA with tailoring enzymes NisB and 
NisC. This methodology may be useful for cryptic type I lanthipeptides that cannot be isolated 
from the producer strain, for compounds that are produced in very low abundancies, or for 
preparing these compounds in isotopically labeled forms. Furthermore, NisB activity was 
successfully reconstituted in vitro and required the membrane fraction of cell extract, ATP, 
Mg2+, and glutamate. A direct role of glutamate in the physiological dehydration process is 
suggested by several experimental observations. First, multiple glutamate adducts to the NisA 
substrate are observed both in vitro and in E. coli with the NisB mutants R786A, R826A, and 
H961A. Furthermore, small amounts of +129 Da adducts are also observed with wild type NisB 
(Figure 2.6). Adducts of 130/131 Da were also present in the MALDI-MS spectra of NisA 
products generated by the truncated NisB mutants Δ887-892 and Δ838-851 in a previous study 
in L. lactis that showed that these truncated proteins were unable to dehydrate (36). The authors 
suggested that the M+130/131 Da peaks were associated with NisA that still contained the N-
terminal Met, but no explanation was offered for the presence of ions of M+(2×130/131) Da, 
which cannot be explained by incomplete removal of Met. Given that these truncations were in 
the same C-terminal region of NisB as the single mutants that generated glutamylated products in 
this study, we suggest that the observed peaks in L. lactis were glutamylated peptides. The 
difference between the observed mass adducts of 130/131 Da and the calculated 129 Da adducts 
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for glutamylation could be a consequence of the experimental error in MALDI spectra of 
peptides of this size.  
A key observation in this study was that wild type NisB converted glutamylated NisA to 
dehydrated NisA, demonstrating glutamylation generates a chemically competent intermediate. 
Because none of the required ingredients for the dehydration reaction (ATP, Mg2+, Glu and cell 
extract) were needed for glutamate elimination, a process that involves hydrolysis of the ester 
followed by dehydration of the regenerated Ser/Thr residues can be ruled out. Collectively, we 
believe that these data provide support for glutamylation of Ser/Thr as a required step for 
dehydration.  His961, Arg786, and Arg826 are clearly important for elimination of glutamate, 
since alanine substitutions at these positions resulted in greatly diminished elimination activity in 
vitro as well as in vivo. The His961Ala mutant of His6-NisB was also the least active in 
glutamylation of His6-NisA (Figure 2.14) suggesting the mutation may have either a general 
deleterious effect on protein structure or that this residue is important for both glutamylation and 
elimination.  
On the basis of our results, we propose that one of the carboxylic acid groups of 
glutamate is activated by ATP and subsequently reacts with the side chains of serine and 
threonine residues that are targeted for dehydration, resulting in glutamate esters (Figure 2.18A). 
Upon deprotonation of the alpha proton of the glutamylated Ser or Thr residues, elimination of 
glutamate results in dehydroalanine/dehydrobutyrine residues. It is possible that glutamylation 
and elimination occur in different domains as is also observed for class III and IV lanthipeptides 
that contain separate kinase and lyase domains (12, 39). If so, then the C-terminus of NisB 
contains the likely lyase domain. The leader peptide binding site has been previously shown to 
not be located in this C-terminal domain (36). The proposed activation mechanism for LanB  
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Figure 2.18.  General mechanism for the elimination reaction. (A) The proposed mechanism for NisB catalyzed 
elimination of glutamate resulting in Dha/Dhb residue. Following addition of glutamate to serine and threonine in 
the precursor peptide, the abstraction of alpha proton leads to the formation of Dha and Dhb residues respectively 
via an enolate intermediate. (B) Reaction catalyzed by virginiamycin B lyase, the resistance protein to virginiamycin 
B. The elimination of the carboxylate is initiated by abstraction of the alpha proton and results in Z-dehydrobutyrine. 
Although not explicitly shown, the overall reaction may occur with an enolate intermediate (40). 
  
 
dehydratases stands in contrast to the activation of the hydroxyl groups of Ser and Thr by 
phosphorylation during the dehydration process of class II, III, and IV lanthipeptides (11-12, 41). 
Why glutamylation of Ser/Thr would evolve as an alternative means of Ser/Thr activation is 
unclear. One possibility is that it is a remnant of the use of activated Glu for other chemistry by 
the ancestors of LanB proteins. Although unexpected in the context of Ser and Thr dehydration, 
the elimination of a carboxylate from an ester linkage to the side chain of Thr in peptides has 
precedent in the resistance protein to the cyclic hexadepsipeptide virginiamycin (42-43) as well 
as related streptogramin antibiotics (44-45). The virginiamycin B lyase (Vgb) from 
Staphylococcus aureus catalyzes an elimination reaction of the macrolactone that is formed by 
an ester bond between the hydroxy group of a Thr and the C-terminal carboylic acid (Figure 
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2.18B). This anti elimination reaction generates a Z-dehydrobutyrine (42), the same 
stereochemistry that is also generated by NisB in nisin (46-47). Vgb requires a Mg2+ for its 
elimination reaction (42), whereas NisB catalyzes the elimination of Glu in the absence of Mg2+. 
The Vgb crystal structure illustrates that the Mg2+ binds a 2-hydroxypicolinic acid group in 
virginiamycin B (43) that is not present in the substrates for NisB, providing an explanation as to 
why Mg2+ is not needed for the elimination step in NisB.   
Whether NisB activates Glu itself or whether this is carried out by an enzyme in the 
membrane fraction of the E. coli cell extract is currently not known because attempts to detect 
Glu activation in the absence of cell extract have thus far been unsuccessful. Because of the 
required presence of cell extract, I also have not been able to determine which of the two 
carboxylates of Glu is activated and whether this activation involves adenylation or 
phosphorylation. Nevertheless, this study provides the long-sought in vitro activity of a LanB 
protein and a unique mode of Ser/Thr activation that provides the basis for further investigation. 
By providing the conditions needed for in vitro activity, this study will also aid research on 
several classes of natural products that utilize LanB proteins (48). 
 Future directions 
In this study, I have demonstrated the in vitro dehydration activity of NisB, and have 
shown that NisB catalyzed dehydration required the addition of a membrane-containing fraction 
of E. coli cell extract, glutamate, ATP and Mg2+. Future studies should focus on determining the 
role of the membrane-containing fraction, the mode by which ATP is utilized to activate 
glutamate i.e. via adenylation or phosphorylation, and which carboxyl group of glutamate is 
attached to the hydroxyl of serines/threonines undergoing dehydration. 
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2.5. Tables  
  
Table 2.1. Sequences of oligonucleotide primers used for site-directed mutagenesis. 
 
Primer name Primer sequence 
NisB_BamHI_F GTA GAC AGG GAT CCG ATG ATA AAA AGT TCA TTT AAA GCT CAA C 
NisB_NotI_R AAT CAT AAG CGG CCG CTC ATT TCA TGT ATT CTT CCG AAA CAA AC 
NisA_NdeI_F AAG CAG CCG CAT ATG AGT ACA AAA GAT TTT AAC TTG G 
NisA_XhoI_R CTA GCT CGA GTT ATT TGC TTA CGT GAA TAC TAC 
NisA_BamHI_F CTA GAT GGA TCC GAT GAG TAC AAA AGA TTT TAA CTT GG 
NisA_HindIII_R CTA GAA GCT TTT ATT TGC TTA CGT GAA TAC TAC AAT G 
NisB_NdeI_F 
AAG CAG CCG CAT ATG CAT CAT CAT CAT CAT CAT  ATA AAA AGT TCA 
TTT AAA GCT CAA C 
NisB_XhoI_R CTA GCT CGA GTC ATT TCA TGT ATT CTT CCG AAA CAA ACA ACC 
NisC_BglII_F CTA GGG AAG ATC TGA TGA ATA AAA AAA ATA TAA AAA GAA ATG TTG 
NisC_XhoI_R CTA GCT CGA GTC ATT TCC TCT TCC CTC CTT TCA AAA AAT  CGT C 
NisB_R14A_F GCT CAA CCG TTT TTA GTA GCG AAT ACA ATT TTA TCT CC 
NisB_R14A_R TAC TAA AAA CGG TTG AGC TTT AAA TGA AC 
NisB_E44A_F GTA AAA ATA AAG TTT TTT TGG CGC AGT TAC TAC TAG CTA ATC C 
NisB_E44A_R CAA AAA AAC TTT ATT TTT ACT TAC AGT CTC 
NisB_K68A_F GCT GGT CTG TTA AAG AAG GCG AGG GTT AAA AAA TTA TTT G 
NisB_K68A_R CAA ATA ATT TTT TAA CCC TCG CCT TCT TTA ACA GAC CAG C 
NisB_R83A_F CTA TTT ACA AGT ATT ATA AGG CGA GTT ATT TAC GAT CAA CTC 
NisB_R83A_R CTT ATA ATA CTT GTA AAT AGA TTC AAA TAA TTT TTT AAC 
NisB_R87A_F GTA TTA TAA GAG AAG TTA TTT AGC GTC AAC TCC ATT TGG ATT ATT TAG 
NisB_R87A_R CTA AAT AAT CCA AAT GGA GTT GAC GCT AAA TAA CTT CTC TTA TAA TAC 
NisB_T89A_F GAG AAG TTA TTT ACG ATC AGC GCC ATT TGG ATT ATT TAG TG 
NisB_T89A_R CAC TAA ATA ATC CAA ATG GCG CTG ATC GTA AAT AAC TTC TC 
NisB_K116A_F GTT AAT GGG AAA GAC TAC AGC GGG TAT AAG ATT GGA TAC TC 
NisB_K116A_R GAG TAT CCA ATC TTA TAC CCG CTG TAG TCT TTC CCA TTA AC 
NisB_D121A_F CAA AGG GTA TAA GAT TGG CGA CTC AGT GGT TGA TTC GCC 
NisB_D121A_F GGC GAA TCA ACC ACT GAG TCG CCA ATC TTA TAC CCT TTG 
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Table 2.1 (cont.)  
NisB_E133A_F CGC CTA GTT CAT AAA ATG GCG GTA GAT TTC TCA AAA AAG 
NisB_E133A_R CTT TTT TGAG AAA TCT ACC GCC ATT TTA TGA ACT AGG CG 
NisB_R505A_F GTA TTT CTT CCA GAA AAT ATC GCG CAT GCT AAC GTT ATG CAT AC 
NisB_R505A_R GTATGCATAACGTTAGCATGCGCGATATTTTCTGGAAGAAATAC 
NisB_R575A_F CGT TAT TCA GTA ATG AGC TAG CGT TTC TTT ACG AAA TTT C 
NisB_R575A_R TAG CTC ATT ACT GAA TAA CGT TTT ATT GTA C 
NisB_R581A_F CTA AGA TTT CTT TAC GAA ATT GCG TTA GAT GAC AAG TTT GG 
NisB_R581A_R CCA AAC TTG TCA TCT AAC GCA ATT TCG TAA AGA AAT CTT AG 
NisB_D648A_F GAG TTT TAT ATT GTC AAT GGA GCG AAT AAA GTT TAT TTA TCA C 
NisB_D648A_R GTG ATA AAT AAA CTT TAT TCG CTC CAT TGA CAA TAT AAA ACT C 
NisB_K741A_F CCC TTT AAC GAG TGG CTT TAT CTA GCG TTG TAC ATT TCT ATA AAT CG 
NisB_K741A_R CGA TTT ATA GAA ATG TAC AAC GCT AGA TAA AGC CAC TCG TTA AAG GG 
NisB_R786A_F CCA CAT ATT AGA TTG GCG ATA AAA TGT TCA GAT TTA TTT TTA G 
NisB_R786A_R CTA AAA ATA AAT CTG AAC ATT TTA TCG CCA ATC TAA TAT GTG G 
NisB_E823A_F GAT ATT TCT ATT TAT GAT CAA GCG GTA GAA AGA TAT GGT GG 
NisB_E823A_R CCACCATATCTTTCTACCGCTTGATCATAAATAGAAATATC 
NisB_R826A_F GAT CAA GAA GTA GAA GCG TAT GGT GGA TTT GAT AC 
NisB_R826A_R GTA TCA AAT CCA CCA TAC GCT TCT ACT TCT TGA TC 
NisB_S958A_F GTT TAT TCA ATT ATT GAC GCG ATC ATT CAT GTC CAT AAT AAC 
NisB_S958A_R GTT ATT ATG GAC ATG AAT GAT CGC GTC AAT AAT TGA ATA AAC 
NisB_H961A_F CAA TTA TTG ACA GTA TCA TTG CGG TCC ATA ATA ACC GAC TAA TTG 
NisB_H961A_R CAA TTA GTC GGT TAT TAT GGA CCG CAA TGA TAC TGT CAA TAA TTG 
NisB_R966A_F CAT TCA TGT CCA TAA TAA CGC GCT AAT TGG TAT TGA ACG AG 
NisB_R966A_R CTC GTT CAA TAC CAA TTA GCG CGT TAT TAT GGA CAT GAA TG 
NisB_E975A_F GGT ATT GAA CGA GAT AAA GCG AAA TTA ATT TAT TAC ACA C 
NisB_E975A_R GTG TGT AAT AAA TTA ATT TCG CTT TAT CTC GTT CAA TAC C 
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Table 2.2. Activity of cellular small metabolites as co-substrates for NisB catalyzed 
dehydration reaction. 
  
Metabolites tested Number of dehydrations observed   
α-ketoglutarate 0  
Malate 0  
Succinate 0  
Glutamine 3-8  
Isoglutamine 0 - 8  
Aspartate 0 - 3  
Glutarate 0  
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Chapter 3: Discovery, heterologous production, and characterization of a novel type I 
lantibiotic geobacillin I 1 
3.1 Introduction 
The lantibiotic nisin, the most extensively studied member of the lantibiotic family, was 
first approved for use as a food preservative to combat food-borne pathogens in 1969 and is 
currently used in over 80 countries (1). Despite its use for over 50 years, reports of significant 
resistance against nisin have not appeared (2-3). The lack of resistance may stem from the dual 
mode of action of nisin. Nisin exhibits antimicrobial activity by binding to the pyrophosphate 
moiety of lipid II (4), a membrane bound advanced intermediate involved in the biosynthesis of 
the cell wall. By doing so, nisin inhibits the transglycosylation step in cell wall biogenesis and 
sequesters lipid II from its functional location (5-6). Furthermore, the nisin-lipid II complex 
leads to formation of pores in the membrane causing cell death. The mechanism-of action of 
nisin is described in greater detail in Chapter 1. Resistance mechanisms such as efflux pumps 
and enzyme mutations will not affect nisin as it acts on the outside of the bacterial cell and has a 
small molecule as target. In addition to its use as a food preservative, the Center for Veterinary 
Medicine of the U.S. Food and Drug Administration recently ruled positively on application of 
nisin for intramammary treatment of subclinical mastitis in dairy cattle (7-8). After approval of 
the  pending New Animal Drug Application, a nisin-containing product would allow treatment of 
bovine mastitis with a zero milk discard time and zero meat withdrawal period (i.e. milk and/or 
1Parts of this chapter have been adapted with permission from: 
Garg N, Tang W, Goto Y, Nair SK, van der Donk WA,. Proc Natl Acad Sci U S A. 2012 Apr 3; 109(14):5241-6. 
Reproduced with permission of the publisher and available from http://www.pnas.org/ (DOI: 10.1073/pnas.1116815109). 
 
78 
 
meat from treated cattle would not have to be discarded). One drawback that has been noted for 
nisin is its limited stability at pH 7 (9-13).  Hence, more stable analogues may prove more 
effective.  
Reported herein is the structure of a lantibiotic from Geobacillus thermodenitrificans 
NG80-2 termed geobacillin I that is an analogue of nisin with two additional crosslinks. The 
compound was produced heterologously in E. coli, its ring topology was determined by NMR 
spectroscopy, and its activity against various bacteria was assessed. The compound is three-fold 
more active than nisin against Streptococcus dysgalactiae, one of the main contagious causative 
agents of clinical bovine mastitis (14). Geobacillin I also demonstrated increased stability 
compared to nisin. Similar to nisin, geobacillin I was found to bind lipid II and disrupt the 
membrane of Gram-positive bacteria.  
 
3.2 Experimental procedures 
3.2.a Construction of pRSFDuet-1/His6-GeoAI+GeoB and pACYCDuet-1/GeoC 
 Codon-optimized synthetic genes for GeoAI, GeoB, and GeoC were synthesized by 
GeneArt (Invitrogen, USA). The nucleotide sequences are given at the end of this chapter. For 
geobacillin I production, geoAI was inserted in MCS1 of a pRSFDuet-1 vector using BamHI and 
HindIII restriction sites, geoB in MCS2 using NdeI and XhoI sites, and geoC in MCS2 of 
pACYCDuet-1 using NdeI and XhoI sites. Site directed mutagenesis was performed to mutate 
Asn at the −1 position to Lys (for primers see Table 3.1, also see notebook 7 page 5).  
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3.2.b Screening of Geobacillus strains for lantibiotic production 
 Seven Geobacillus strains were purchased from the Bacillus Genetic Stock Center. The 
strains were streaked on tryptose blood agar base (TBAB) and modified LB (mLB) plates. The 
composition of mLB media was tryptone (10 g), yeast extract (5 g), NaCl (5 g), agar (15 g), 
NaOH (1.25 mL of 10% w/v), nitrilotriacetic acid (1.05 M), MgSO4.7H2O (0.59 M), CaCl2.2H2O 
(0.91 M), FeSO4.7H2O (0.04 M), and water 995 mL.  Nitriloacetic acid, MgSO4 .7H2O, 
CaCl2.2H2O, and FeSO4.7H2O were filter sterilized and added to the media after autoclaving. A 
small amount of cells from a colony was picked from the plate with a pipette tip and was spotted 
on a MALDI plate. The sample was overlaid with 2 µL of a 9:1 mixture of 2,5-dihydroxybenzoic 
acid and 2-hydroxy-5-methoxybenzoic acid matrix prepared in 60% acetonitrile/0.1% TFA in 
water (80 mg/mL). A heat gun was used to dry the sample, and the samples were analyzed by 
MALDI-MS (also see notebook 5 page 41). 
3.2.c Production and purification of geobacillin I  
 Single colony transformants of E. coli BL21 (DE3) containing plasmids pRSFDuet-1 
(GeoAI/GeoB) and pACYCDuet-1 (GeoC) were picked and grown in LB media overnight. The 
culture was used to inoculate 6 L of TB media containing 50 mg/L kanamycin and 34 mg/L 
chloramphenicol. The culture was shaken at 200 rpm at 37 °C until the OD600 reached between 
0.8 and 1.0. At this point, the culture was induced with 1 mM IPTG. The induced cells were 
shaken continually at 37 °C for an additional 2 h, and the cells were harvested by centrifugation 
(11,900×g for 10 min, Beckman JLA-10.500 rotor). The cell pellet was resuspended in 50 mL of 
start buffer (20 mM Tris, pH 8.0, 500 mM NaCl, and 10% glycerol), and cell lysis was carried 
out using a MultiFlex C3 homogenizer (Avestin). The lysed cells were centrifuged at 23,700×g 
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for 30 min at 4 °C. The supernatant was loaded onto a HiTrap HP nickel affinity column (GE 
Healthcare) pre-equilibrated with start buffer. The column was washed with wash buffer (start 
buffer containing 30 mM imidazole), and the peptide was eluted from the column with elution 
buffer (start buffer containing 1 M imidazole) (also see notebook 5 page 42).  
To increase the yield, modified GeoAI was also recovered from the insoluble fraction 
after cell lysis. The pellet was homogenized using a sonicator (35% amplitude, 4.4 s pulse, 9.9 s 
pause for 20 min total) in start buffer to remove any soluble proteins. The suspension was 
centrifuged and the pellet was homogenized in 30 mL of denaturing buffer (4 M guanidine 
hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, pH 7.5). The supernatant after centrifugation 
was loaded onto a HiTrap HP nickel affinity column, the column was washed with denaturing 
buffer containing 30 mM imidazole, and the product was eluted with 15 mL of denaturing buffer 
containing 1 M imidazole. Small aliquots of eluent were desalted using a ZipTip (µC18) and 
analyzed for the presence of geobacillin I using MALDI-MS. For large scale purification, the 
eluent was desalted using preparative scale RP-HPLC using a Waters Delta-pak C4 15 μm; 300 
Å; 25x100 mm PrepPak Cartridge. Following injection, the column was kept at 2% solvent A 
(solvent A = 0.086% TFA in 2% ACN/98% water) for 2 min followed by a gradient of 2-100% 
of solvent B (0.086% TFA in 80% ACN/20% water) over 45 min. The fractions containing 
modified GeoAI were lyophilized.  
3.2.d Cleavage of modified GeoAI and antimicrobial activity assay. 
 A solution of 500 µM posttranslationally modified GeoAI-N−1K in 50 mM HEPES 
buffer (pH 8.0) was treated with 0.5 µM trypsin for 2 h. The product was analyzed using 
MALDI-MS. The nine-fold dehydrated and cyclized core peptide was purified using RP-HPLC 
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in order to remove incompletely dehydrated peptide and leader peptide using a Phenomenex 
Luna C18 column (250x10 mm, 10 micron) operating at a flow rate of 8 mL/min. The program 
used was 3 min of solvent A (2% MeCN/0.1% TFA) followed by a gradient of 2-100% solvent B 
(80% MeCN/0.1% TFA) over 50 min (also see see notebook 5 page 47). 
3.2.e Specific activity of geobacillin I and nisin 
 For minimal inhibitory concentration (MIC) calculations, a 48-well plate (300 µL well 
size) was used with shaking and a 96-well plate (200 µL well size) was used for non-shaking 
conditions, depending on the indicator strain. Serial dilutions of nisin and geobacillin I were 
prepared in sterile deionized water (SDW). The 48/96 plate wells contained 50/75 μL of diluted 
peptide at defined concentrations and 150/225 μL of a 1:10 dilution (approximately 1 x 108 CFU 
mL-1) of a culture of indicator strain diluted in fresh growth medium. Growth medium blank and 
negative controls lacking the lantibiotics were also prepared. Plates were incubated under 
appropriate growth conditions (Table 3.2), and MIC calculations were performed by monitoring 
the OD600. For agar diffusion bioactivity assays, the appropriate agar media was melted in a 
microwave, kept at 45 °C for 10 min, and mixed with 150 μL of overnight culture of indicator 
organisms (108-109 cfu). After solidification, 10 µL of a solution of 100 M peptide was spotted 
on the plate (also see notebook 5 page 54). 
3.2.f Chemical stability of geobacillin I and nisin 
 Stock solutions of nisin and geobacillin I (30 µM) were prepared in 50 mM sodium 
phosphate buffer, 100 mM NaCl at pH 7.0 and 8.0. The stock solutions were divided into 200 µL 
aliquots in sterile eppendorf tubes and were incubated at 37 °C and 60 °C. At set time points, a 
tube was opened and analyzed by agar diffusion growth inhibition assay. The agar diffusion 
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growth inhibition assay was carried out in sterile Nunc OmniTrays. Molten agar (20 mL) was 
inoculated with 200 µL of overnight culture of B. subtilis ATCC 6633 diluted to OD600 of 1.0. 
An additional 30 mL of molten agar combined with 300 µL cells was poured over the solidified 
agar.  A sterile 96 well PCR plate was carefully placed on the upper molten agar layer. 
Following solidification, the PCR plate was removed and 20 µL of peptide solution was added to 
the wells. After 20 min, another 20 µL of peptide solution was added. This procedure was 
repeated one more time to add a combined total volume of 60 µL. The earlier time points from 
samples at 37 oC were also analyzed by HPLC. The stability tests for geobacillin I S5F/L6I and 
nisin I4K/S5F/L6I were performed as described above with a minor variation. Stock solutions of 
geobacillin I, nisin,  geobacillin I S5F/L6I and nisin I4K/S5F/L6I (50 μM) were prepared in 
MOPS buffer, 100 mM NaCl at pH 7.0 instead of phosphate buffer (also see notebook 5 page 
61). 
3.2.g Membrane disruption assay 
 The fluorescent dye 3,3′-diethyloxacarbocyanine iodide (DiOC2) was used to investigate  
disruption of the membrane potential of B. subtilis ATCC 6633. An overnight culture of B. 
subtilis ATCC 6633 grown in LB at 37 °C was diluted to OD600 of 1.0 with fresh LB. The 
membrane disruption assay mixture containing DiOC2 (final concentration 2 μM), HEPES (1 
mM), and glucose (1 mM), was incubated with the cells (final OD600 of 0.1) for 20 min at room 
temperature. The final volume of the mixture was adjusted to 300 µL with LB medium. The 
lantibiotics nisin and geobacillin I were added to final concentrations of 0.2, 2.0, and 20 μM and 
the samples were incubated for an additional 15 min. A negative control containing water instead 
of antibiotic was also prepared in similar manner. The mean fluorescence intensity (MFI) was 
recorded with a BD Biosciences LSR II flow cytometer, using excitation at 488 nm with an 
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argon laser and measurement of emission through a band-pass filter at 530/30 nm. A minimum 
of 80,000 events were detected for each sample, and experiments were performed in triplicate. 
Data analysis to calculate the MFI of gated cell populations was performed using FCS Express 
version 4.00. The fluorescent dye propidium iodide (PI) was used to detect pore formation in the 
membrane of B. subtilis ATCC6633. The assay mixture contained PI (final concentration 25 
μM), phosphate buffered saline, nisin/geobacillin I (13, 10, 5, 2,5 , 1.25, 0.63, 0.31, 0.16, 0.08, 
and 0 μM) and B. subtilis ATCC 6633 cells diluted to a final OD600 of 0.1. The final volume of 
the mixture was adjusted with LB medium to 300 μL. The assay mixture was incubated for 10 
min at room temperature. The data was recorded and analyzed as mentioned above with emission 
recorded through a band-pass filter at 695/40 nm (also see notebook 5 page 73).  
3.2.h Inhibition of penicillin binding protein (PBP1b) by geobacillin I 
 A transglycosylation assay to investigate binding of nisin and geobacillin I to lipid II 
using the transglycosylase PBP1b from E. coli was performed by a former lab member Dr. Trent 
Oman in Prof. Suzanne Walker’s laboratory at Harvard Medical School, Boston, Massachusetts 
as previously described (15-17). Briefly, chemo-enzymatically prepared [14C]-GlcNAc-labeled 
heptaprenyl lipid II analogue was incubated with varying concentrations of nisin and geobacillin 
I. The inhibition of transglycosylase activity of PBP1b was monitored as previously described 
(17). 
3.2. i  Chiral gas chromatography/mass spectrometry (GC/MS) analysis 
Wild type GeoAI  fully modified by GeoB and GeoC in E. coli and with its leader 
attached (1.2 mg) was dissolved in 6 mL of 6 M HCl. The mixture was heated at 110 °C in a 
sealed tube for 24 h. The reaction was cooled and dried under nitrogen overnight. Methanol (5 
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mL) was chilled in an ice-water bath, and acetyl chloride (1.5 mL) was added dropwise. This 
solution was added to the hydrolyzed geobacillin I and the resulting solution was heated at 110 
°C for 1 h. The sample was cooled and dried under a stream of nitrogen. CH2Cl2 (3 mL) and 
pentafluoropropionic anhydride (1 mL) was added and the material was heated at 110 °C for 40 
min. The reaction was allowed to cool and dried under a stream of nitrogen. The hydrolyzed and 
derivatized geobacillin I was taken up in methanol. Nisin (0.3 mg) purified from commercial 
nisaplin was also derivatized using the procedure described above. The derivatized amino acids 
from geobacillin I, nisin, as well as synthetic (methyl)lanthionine standards prepared by Weixin 
Tang (18) were analyzed by GC/MS using an Agilent HP 5973 mass spectrometer and a Varial 
CP-Chirasil-L-Val 25 m × 0.25 mm × 0.15 µM silica column. The samples were introduced to 
the instrument via a pulsed splitless injection at an inlet temperature of 200 °C and flow rate of 2 
mL/min of helium gas. The temperature gradient used was 160 °C for 5 min, then 160 °C to 200 
°C at 3 °C/min. The MS was operated in simultaneous scan/single-ion monitoring (SIM) mode, 
monitoring at fragment masses of 365 for lanthionine and 379 for methyllanthionine (18) (also 
see notebook 5 page 56).  
3.3 Results 
3.3.a Description of the gene cluster of geobacillin I from Geobacillus thermodenitrificans 
NG80-2 
 G. thermodenitrificans sp. are thermophilic Gram-positive bacteria that have been found 
in diverse niches such as oil reservoirs, geothermal areas, and marine environments. They have 
gained recent interest as a potential source for industrially useful thermostable enzymes. G. 
thermodenitrificans NG80-2 was isolated from the Dagang oil fields in China. Its genome was 
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recently sequenced (19) and two groups of genes were annotated in the deposition to the 
National Center for Biotechnology Information database as lantibiotic biosynthetic genes. The 
enzymes encoded in one cluster were annotated as homologs of the biosynthetic enzymes of the 
class I lantibiotic subtilin produced by B. subtilis 6633 (GenBank accession numbers 
YB_001124395-Y_001124403). The second cluster is described in Chapter 4. The gene cluster 
for geobacillin I was noted in bioinformatic genome mining studies (20), but the product of the 
gene cluster is unknown.  The gene cluster for geobacillin I contains a short open reading frame 
for the precursor peptide, which we designated geoAI (Figure 3.1A). The core peptide of the 
GeoAI precursor peptide has homology with nisin and subtilin, in particular in the N-terminal 
region. However, GeoAI is predicted to have two more Cys residues than the precursor peptides 
for these known lantibiotics (Figure 3.1B). The 23-residue leader peptide of GeoAI has high 
homology to the leader peptides for the lantibiotics ericin S and subtilin (Figure 3.1C). On the 
basis of these sequence alignments, the site for proteolytic removal of the leader peptide was 
predicted as ProAsn↓Val (Figure 3.1B and C); this prediction was confirmed by detection of the 
lantibiotic by colony mass spectrometry of other Geobacillus strains (vide infra).  
 Genes typically found in lantibiotic biosynthetic gene clusters are present downstream of 
geoAI including genes encoding a dehydratase (geoB), ABC transporter (geoT), cyclase (geoC), 
a two-component transcriptional regulator (geoR and geoK), and self-resistance proteins (geoI, 
geoG, geoE, and geoF) (Figure 3.1A). Similar gene clusters with nearly identical precursor 
peptides (the only difference being a Val for Ile change) were also found in other genomes of 
Geobacillus (Figure 3.1B and C), but some of these clusters have frameshifted biosynthetic 
genes (20). No gene was identified that encodes for a typical class I lantibiotic protease to 
remove the leader peptide. 
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Figure 3.1. Gene cluster and primary sequence alignment of the precursor peptide of geobacillin I from G. 
thermodenitrificans NG80-2. A) Gene cluster for the biosynthesis of geobacillin I. The gene for the precursor 
peptide is shown in red, modification enzymes in yellow, transporter/protease in purple, regulatory proteins in blue, 
and immunity proteins in green. B) Sequence alignment of the core peptides of selected known class I lantibiotics 
with that of GeoAI. Serines and threonines undergoing dehydration are in blue, cysteines involved in ring formation 
are in red. The additional two cysteines not found in nisin are highlighted in yellow. C) Sequence alignment of the 
leader peptides of select class I lantibiotics with the leader peptide of geobacillin I.   
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3.3.b Screening of Geobacillus strains for lantibiotic production 
 Because G. thermodenitrificans NG80-2 was not available to us, seven different 
Geobacillus strains (21) were screened for production of the predicted geobacillins (G. 
thermodenitrificans DSM465, G. thermodenitrificans OHT-1, Geobacillus sp. M10EXG, G. 
thermodenitrificans OH2-1, G. thermodenitrificans OH5-2, G. thermodenitrificans NM16-2, and 
G. kaustophilus DSM7263). The bacteria were grown at 55 °C on TBAB and mLB media for 48 
h. Whole-cell MALDI-MS (22) was used to investigate the production of geobacillin I after 12, 
24, and 48 h. A mass corresponding to GeoAI after nine dehydrations and removal of the leader 
peptide at the predicted site was observed in both media for five of the strains after 24 h. Only G. 
thermodenitrificans NM16-2 and G. kaustophilus DSM7263 did not produce geobacillin I under 
the conditions used. A representative MALDI mass spectrum is shown in Figure 3.2. All five 
organisms produced peptides of the same mass, consistent with the near-identical sequences of 
GeoAI observed in the currently sequenced genomes (Figure 3.1B). All five observed peptides 
had masses consistent with a Val at position 15 rather than an Ile. These observations along with 
the genome data suggest very high conservation of the sequence of geobacillin I in the 
Geobacillus genus. The mass spectrum in Figure 3.2 also shows peaks corresponding to eight-
fold and seven-fold dehydrated peptide, reminiscent of incomplete dehydration of nisin in 
Lactococcus lactis 6F3 (23). 
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Figure 3.2. Geobacillin I production in native and heterologous producers. MALDI-MS spectra showing 
geobacillin I production by a native producer in black and by the heterologous E. coli host in red (section 3.3.c). 
Purified nine-fold dehydrated and cyclized core peptide is shown in blue. Nine-fold, eight-fold, and seven-fold 
dehydrated peptides are denoted by *, #, and •, respectively.  
 
3.3.c Heterologous production of geobacillin I in E. coli 
 Given our success in producing nisin by coexpression in E. coli (Chapter 2) (24), 
synthetic genes encoding the precursor peptide GeoAI and the dehydratase GeoB were inserted 
into the MCS-1 and MCS-2 of a pRSFDuet-1 vector, respectively. This construct results in a 
hexa-histidine-tagged precursor peptide (His6-GeoAI) and an untagged GeoB protein. A 
synthetic gene encoding the cyclase GeoC was inserted into MCS-2 of a pACYCDuet-1 vector, 
resulting in an untagged GeoC enzyme. Site-directed mutagenesis was performed to mutate Asn 
at the −1 position of the GeoAI peptide (Figure 3.1C) to Lys to incorporate a trypsin cleavage 
site in the precursor peptide to be used for leader peptide removal. E. coli BL21 (DE3) cells were 
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transformed with both plasmids and after induction of protein expression, His6-GeoAI was 
purified from the cell lysate using nickel affinity chromatography followed by reverse phase high 
performance liquid chromatography (RP-HPLC). The modified precursor peptide was treated 
with trypsin and MALDI-MS analysis of the resultant peptide demonstrated a nine-fold 
dehydrated core peptide (red line, Figure 3.2). As seen with the native producers, peaks 
corresponding to eight and seven-fold dehydrated peptides were also observed. 
3.3.d Bioactivity of geobacillin I 
 The antimicrobial spectrum of geobacillin I was investigated with a range of Gram- 
positive bacteria. Modified GeoAI was produced in E. coli as described above, treated with 
trypsin, purified by RP-HPLC (blue trace, Figure 3.2), and used for agar diffusion growth 
inhibition assays (Figure 3.3) and MIC determinations in liquid medium (Table 3.3). The 
compound was active against a wide range of Gram positive bacteria but it was not active against 
Gram negative E. coli. Interestingly, in parallel experiments, geobacillin I demonstrated three-
fold higher activity against Streptococcus dysgalactiae ATCC 27957 than nisin (Figure 3.3 and 
Table 3.3). This bacterium is one of the causative agents of bovine mastitis (14). Geobacillin I 
displayed similar activity as nisin against vancomycin-resistant enterococci (VRE) and Bacillus 
anthracis Sterne 7702, and had five-fold lower activity against methicillin-resistant 
Staphylococcus aureus (MRSA) and Bacillus subtilis ATCC 6633. Its antimicrobial activity 
against Lactococcus lactis HP is about seven-fold lower than nisin (Table 3.3).  
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Figure 3.3. Agar diffusion growth inhibition assay. A) Zones 1, 2, and 3 represent inhibition of S. dysgalactiae 
ATCC 27957 by three different batches of geobacillin I (50 µM). Zones  4, 5, and 6 represent inhibition by nisin (50 
µM). B) Zones 1 and 3 represent inhibition of VRE by two different batches of geobacillin I (50 µM). Zone 2 
represents inhibition by nisin (50 µM). C) Zone 1 represents inhibition of MRSA by geobacillin I (50 µM). Zones 2 
and 3 represent zones of inhibition by two different batches of nisin (50 µM). 
 
3.3.e Comparison of chemical stability of geobacillin I and nisin 
Given the larger number of conformation-restraining crosslinks and the thermophilic 
producing strain, we anticipated that geobacillin I might be inherently more stable than nisin. 
Geobacillin I was indeed found to be more stable than nisin at pH 7 and 8.5 at 37 oC and at 60 oC 
(Figure 3.4, 3.5, 3.6, and 3.7). The samples at 37 oC were also analyzed by HPLC but for a 
shorter time period (Figure 3.8). At later time points, the amount of remaining intact peptides 
was difficult to determine because of closely eluting breakdown products. The main breakdown 
product of geobacillin I appeared to be an oxidation product (M+16) but this did not appear to 
significantly affect the antimicrobial activity.  Nisin has been shown to undergo chemical 
degradation at neutral pH at Dha5 (12). One intriguing difference in geobacillin I compared to 
nisin is the presence of a Lys at position 4 (in ring A). In light of a previous report that the nisin 
analogue I4K/Dha5F/L6I had higher activity against spores of B. subtilis 168 and cells of 
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Micrococcus luteus NCDO 8166, Lactobacillus johnsonii 10533 and Leuconostoc mesenteroides 
20343 (25), we speculated that the replacement of Dha5 with Phe in this mutant may contribute 
to increased activity by virtue of increased stability. These considerations lead us to investigate 
whether the introduction of lysine at position four in nisin might also increase its stability. The 
geobacillin I and nisin analogues with amino acid residues KFI at positions 4-6 were generated 
by coexpression of the corresponding precursor peptides with the appropriate tailoring enzymes 
in E. coli and were not significantly higher in stability than the wild type geobacillin I and nisin, 
respectively, (Figure 3.9) while displaying similar MIC values (Table 3.4, and Figure 3.10 and 
3.11 for mass spectra). Thus, more complex biological factors and differences in overall structure 
may be responsible for the higher stability of geobacillin I.  
 
 
 
Figure 3.4. Agar diffusion growth inhibition assay with B. subtilis 6633 to determine the relative stabilities of 
geobacillin I and nisin A at pH 7.0 and 60 °C. Aliquots of 60 L of 30 µM solutions of compound that had been 
incubated for the time shown (in hours) were added to each well.  
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Figure 3.5. Agar diffusion growth inhibition assay with B. subtilis 6633 to determine the relative stabilities of 
geobacillin I and nisin A at pH 8.0 and 60 °C. Aliquots of 60 L of 30 µM solutions of compound that had been 
incubated for the time shown (in hours) were added to each well.  
 
 
Figure 3.6. Agar diffusion growth inhibition assay with B. subtilis 6633 to determine the relative stabilities of 
geobacillin I and nisin A at pH 7.0 and 37 °C. Aliquots of 60 L of 30 µM solutions of compound that had been 
incubated for the time shown (in days) were added to each well. Nisin standards (60 L per well) are shown on the 
left. 
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Figure 3.7. Agar diffusion growth inhibition assay with B. subtilis 6633 to determine the relative stabilities of 
geobacillin I and nisin A at pH 8.0 and 37 °C. Aliquots of 60 L of 30 µM solutions of compound that had been 
incubated for the time shown (in days) were added to each well. Nisin standards (60 L per well) are shown on the 
left. 
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Figure 3.8. Assessment of the relative stabilities of nisin A and geobacillin I (Geo) using HPLC analysis.  
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Figure 3.9. Agar diffusion growth inhibition assay with B. subtilis 6633 at pH 7.0 and 37 °C. A) geobacillin I, B) 
geobacillin I S5F/L6I, C) nisin, and D) nisin I4K/S5F/L6I. Aliquots of 60 µL of 50 μM solutions of compound 
dissolved in MOPS buffer and 100 mM NaCl that had been incubated for the time shown (in days) were added to 
each well.  
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Figure 3.10. MALDI-MS spectra of purified A) geobacillin I, B) geobacillin I L19NVA,  C) geobacillin I L19P, and 
D) geobacillin I S5F/L6I. 
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Figure 3.11. MALDI-MS spectra of purified A) nisin B) nisin I4K/S5F/L6I. 
 
3.3.f Investigation of membrane disruption using flow cytometry analysis  
 Nisin contains a flexible hinge region of three amino acids between the C and D rings 
that has been shown to be indispensable for pore formation activity (26-28). For instance, the 
ΔN20ΔM21 and N20P/M21P mutants of nisin lost pore formation ability against Gram-positive 
bacteria (26-27). Geobacillin I has only a single amino acid between the C and D rings, similar to 
the ΔN20ΔM21 mutant of nisin as shown by NMR analysis by Weixin Tang and discussed later 
(Figure 3.17). Thus, we sought to explore whether geobacillin I, similar to nisin, binds to lipid II 
and forms pores in the membrane of Gram-positive bacteria. Flow cytometry was used to 
examine changes in the polarization of the bacterial membrane of B. subtilis ATCC 6633 upon 
incubation with geobacillin I using the membrane potential sensitive dye 3,3′-
diethyloxacarbocyanine iodide (DiOC2) (15, 29). Incubation with geobacillin I resulted in a 
significant decrease in mean fluorescence intensity (MFI) similar to the observations with nisin 
(Figure 3.12A and Figure 3.13), and hence implying efficient pore formation in the membrane of 
B. subtilis, despite the lack of a hinge region. The efficiency of pore formation by geobacillin I 
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was also investigated using propidium iodide (PI), a membrane impermeable fluorescent dye. 
Upon pore fomation, PI can enter the cell resulting in an increase in fluorescence intensity 
because of the interaction of PI with nucleic acids. PI uptake was monitored at nine different 
concentrations with each experiment conducted in triplicate (Figure 3.12B and Figure 3.14). In 
antimicrobial activity assays in liquid medium, geobacillin I  exhibited a four-fold increase in the 
minimal inhibitory concentration (MIC) against B. subtilis compared to nisin (Table 3.4), but 
showed only two-fold lower efficiency in pore formation (Figure 3.12B). 
 Previously, site-saturation mutagenesis was performed on the amino acids in the hinge 
region of nisin. The antibiotic activity of the nisin mutants N20V and M21A was increased 
against pathogenic bacteria (30). Conversely, introduction of Pro into the hinge region abolished 
pore formation. For comparison, these same mutations were chosen for introduction into the 
region between rings C and D in geobacillin I. Site-directed mutagenesis was used to replace the 
naturally occurring Leu19 with Pro and with the tripeptide AsnValAla that is found in the 
improved nisin variants. These analogues were generated by coexpression of mutants of the 
precursor peptide with the modification enzymes GeoB and GeoC in E. coli (31). The geobacillin 
analogue with NVA and P at the hinge region had eight-fold and two-fold increased MIC values 
as compared to geobacillin I (Table 3.4), respectively.  The ability to induce pore formation by 
these analogues was also investigated. Although the efficiency of pore formation was reduced, 
replacement of Leu19 with Pro at the hinge region did not abolish this activity, unlike the 
observations for nisin. Furthermore, introduction of the amino acid residues NVA at the hinge 
region greatly reduced formation of pores in the bacterial cell wall by geobacillin I. Thus, it 
seems likely that the detailed mechanism of pore formation by geobacillin I differs from that of 
nisin.  
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Figure 3.12. Membrane depolarization assay to investigate the effect on the membrane potential of B. subtilis 
ATCC 6633 by geobacillin I and nisin measured using DiOC2 and propidium iodide fluorescence by flow 
cytometry. (A) Average mean fluorescence intensity (MFI) of triplicate measurements with different concentrations 
of nisin and geobacillin I using DiOC2. The different bars represent concentrations of 0, 0.2, 2, and 20 µM (left to 
right). (B) Increase in MFI resulting from propidium iodide uptake for nisin and geobacillin I (average of three 
measurements). The different bars represent concentrations of 0, 0.31, 1.25, 2.5, 5 and 10 µM (left to right). 
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Figure 3.13. Representative histogram of cell count versus DiOC2 fluorescence intensity at various geobacillin I and 
nisin concentrations (red: no antibiotic; yellow: 0.2 µM nisin; dark red: 2 µM nisin; black: 20 µM nisin; blue: 0.2 
µM geobacillin I; turquoise: 2 µM geobacillin I; green: 20 µM geobacillin I). 
 
 
Figure 3.14. The histograms of cell count versus PI fluorescence intensity at various concentrations are shown for 
A) geobacillin I, B) nisin, C) geobacillin I L19P and, D) geobacillin I L19NVA (black: 0 µM; red: 13 µM; blue: 10 
µM; violet: 5 µM; green: 2.5 µM; yellow: 1.25 µM; dark red: 0.63 µM; teal: 0.31 µM; grey: 0.16 µM; turquoise:  
0.08 µM). 
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3.3.g Investigation of lipid II binding by geobacillin I 
 The ability of geobacillin I to bind lipid II was investigated using an in vitro inhibition 
assay of transglycosylation reaction catalyzed by E. coli PBP1b by Dr. Trent Oman. PBP1b uses 
lipid II as a substrate for glycan polymerization (16). Geobacillin I produced in my studies 
inhibited PBP1b-catalyzed peptidoglycan formation using 4 μM heptaprenyl lipid II (Figure 
3.15) with a half-maximal inhibitory concentration (IC50) of 4.55 ± 0.76 M. For comparison, 
inhibition by nisin displayed an IC50 of 2.91 ± 0.61 M (Figure 3.12). Thus, the inhibitory 
activity of the two peptides was found to be very similar. 
 
 
Fig. 3.15. Inhibition of PBP1b-catalyzed peptidoglycan (PG) formation by geobacillin I (A) and nisin (B), at a lipid 
II concentration of 4 μM and a PBP1b concentration of 100 nM. Error bars represent the standard deviation from 
triplicate experiments.  
 
3.3.h Determination of stereochemistry of (methyl)lanthionine crosslinks in geobacillin I 
using GC/MS analysis 
 The stereochemical purity of (methyl)lanthionine was determined by acid hydrolysis of 
geobacillin I and chemical derivatization of the resulting amino acids as previously described 
(32-33). The derivatized material was then analyzed by GC/MS. The total ion chromatogram for 
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geobacillin I is shown in Figure 3.16A. The derivatized lanthionine and methyllanthionine 
present in hydrolyzed geobacillin I and nisin samples are shown in Figure 3.16B and C, 
respectively. The Lan and MeLan derivatives eluted at identical retention times with 
(methyl)lanthionine standards confirming that (methyl)lanthionines in nisin and geobacillin I 
have the same configuration, (2S, 3S, 6R)-methyllanthionine and (2S, 6R)-lanthionine. 
 
Figure 3.16. (A) Total ion gas chromatogram of derivatized amino acids obtained by acid hydrolysis of geobacillin 
I. (B) GC/MS trace (SIM 379 Da for MeLan, and 365 Da for Lan) of derivatized (methyl)lanthionine obtained from 
geobacillin I (black) overlayed with a GC/MS trace of a synthetic (2S, 3S, 6R)-methyllanthionine standard (blue) 
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and a (2S, 6R)-lanthionine standard (red). The intensities were normalized to 1.0 for the largest peak. The small 
shoulders on the derivatized lanthionine peak have been reported previously and arise from partial epimerization 
during the acid hydrolysis (32). (C) GC/MS traces (SIM 379 Da, 365 Da) for derivatized (methyl)lanthionine 
obtained from hydrolyzed geobacillin I (black) compared with derivatized (methyl)lanthionine obtained from nisin 
A (pink). The stereochemistry of the derivatized (methyl)lanthionines is the same for both compounds and the 
relative ratio of Lan to MeLan of the two compounds is close to the predictions from the structures in Figure 3.1B (1 
Lan, 4 MeLan in nisin A and 4 Lan, 3 MeLan in geobacillin I. The intensities were normalized to 1.0 for the largest 
peak. 
 
3.4 Discussion 
The availability of a rapidly increasing number of bacterial genomes is starting to shift 
the search for new gene-encoded peptide natural products from activity-based discovery 
platforms to gene-based discovery approaches (34-36). In the lantibiotic group of compounds, 
genome mining has resulted in the discovery of several new family members (37-39), including 
the first lantibiotic from an alkaliphilic organism (40-41). In addition, a large number of 
biosynthetic gene clusters has been identified that remain to be explored experimentally (20, 42). 
Our attention was drawn to genomes of thermophiles since only one lantibiotic from a 
moderately thermophilic organism has been reported (43). The lantibiotics produced by 
thermophiles could find potential applications as they may be more stable than lantibiotics 
produced by mesophilic bacteria. Particularly interesting was the discovery of nisin precursor 
genes in the genomes of Geobacillus because their sequence suggested that the 
posttranslationally modified products would contain additional rings. Indeed, the masses of the 
compounds produced by five Geobacillus strains and the corresponding lantibiotic 
heterologously produced in E. coli showed nine dehydrations and the NMR structure determined 
by Weixin Tang (31) for the latter compound demonstrated seven thioether crosslinks, including 
conservation of the A and B rings found in nisin that are important for lipid II binding (5-6, 44) 
(Figure 3.17). In all, 16 out of the 33 residues in the core peptide of GeoAI are 
posttranslationally modified, and the final product geobacillin I was shown to have high 
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antimicrobial activity against several pathogens. Furthermore, the compound is more stable than 
nisin A at pH 7 and 8.5 and at high temperatures. 
Compared to nisin, ring C of geobacillin I is reduced in size by one amino acid, the hinge 
region is reduced in length by two amino acids, and ring D is a lanthionine ring as opposed to a 
methyllanthionine ring (Figure 3.17). In addition, geobacillin I contains two additional thioether 
bridges at its C-terminus. However, although there appear to be differences in regards to the 
importance and role of the hinge region, the overall mode of action of the two lantibiotics 
appears to be quite similar: binding to lipid II and pore formation. These findings suggest that the 
previously proposed role of the hinge region for pore formation activity by elongated type A 
lantibiotic peptides may not be universal.  
This study demonstrates that lantibiotics may be produced in nature at temperatures as 
high as 50-80 °C, the temperature of the deep sub-surface Dagang oilfield where G. 
thermodenitricans NG80-2 was isolated. The successful production of geobacillin I in E. coli 
was therefore somewhat surprising because many enzymes from thermophilic organisms are 
non-functional at 37 °C. However, GeoB and GeoC carried out dehydrations and cyclizations 
with apparently high efficiency at this temperature. Future work will focus at producing non-
natural analogues of geobacillin I using the coexpression technology in E. coli. 
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Figure 3.17.  A) Structure of geobacillin I, and B) Structure of nisin. Hinge region residues are shown in brown 
color. 
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3.5 Tables 
 
Table 3.1. Sequences of oligonucleotide primers used in this study. 
 
Primer name Primer sequence 
GeoAI_BamHI_F CTA GAT GGA TCC GAT GGC CAA ATT TGA TGA TTT TGA TC 
GaoAI_HindIII_R CTA GAA GCT TTT ATT AGC AAC GAA TAC AGC TAT TAC AGC 
GeoB_NdeI_F ACA GCC GCA TAT GAA TGA TCT GGT GTT TAA AAA TAT TG 
GeoB_XhoI_R TCT AGC TCG AGTTAA TTT TTC AGC ACC AGG CCA TGG GC 
GeoC_NdeI_F AAG CAG CCG CAT ATG TCT ATT AGC ATG AAA GCC CTG G 
GeoC_XhoI_R CTA GCT CGA GTAAAA CTT CGC TCA G CA GAA ATG CAC AAT CC 
GeoAI (N−1K)_F CAG GAT GAT GTT GTT CAG CCG AAA GTT   ACC AGC AAA AGC CTG 
GeoAI(N−1K)_R CGG CTG AAC AAC ATC ATC CTG TTT TTT CAC C 
GeoAI_L19P_F AT TAC CGG TGT TCT GAT GTG TCCGAC CCA GAA TAG CTG TG 
GeoAI_L19P_R ACA CAT CAG AAC ACC GGT AAT ACA ACC CGG 
GeoAI_L19NVA_F AT TAC CGG TGT TCT GAT GTG TAA CGT GGC AAC CCA GAA TAG CTG TG   
GeoAI_L19NVA_R ACA CAT CAG AAC ACC GGT AAT ACA ACC CGG 
GeoAI_ S5F/L6I _F AGC CGA AAG TTA CCA GCA AAT TTA TTT GTA CAC CGG GTT G 
GeoAI_S5F/L6I_R TTT GCT GGT AAC TTT CGG CTG AAC AAC ATC 
NisA_I4K/S5F/L6I_
F 
CAT CAC CAC GCA TTA CAA GTA AAT TCA TTT GTA CAC CCG GTT GTA AAA C 
NisA_ I4K/S5F/L6I 
_R 
GTT TTA CAA CCG GGT GTA CAA ATG AAT TTA CTT GTA ATG CGT GGT GAT G 
 
 
  
107 
 
Table 3.2. Growth conditions for indicator strains used in this study. 
Strain Media Conditions 
Streptococcus dysgalatiae subsp dysgalactiae BHI 37 °C, aerobic 
Vancomycin resistant Enterococcus faecium BHI 37 °C, aerobic 
Methicillin resistant Staphylococcus aureus BHI 37 °C, aerobic 
Bacillus anthracis Sterne 7702 BHI 37 °C, aerobic 
Bacillus subtilis ATCC6633  LB 30 °C, aerobic 
Lactococuus lactis HP GM17    30 °C, anaerobic 
 
 
Table 3.3. Specific activity of geobacillin I and nisin in liquid growth inhibition assay.  
 
Strain Source 
Geobacillin I 
IC50 (µM) 
Geobacillin I 
IC90 (µM) 
Nisin 
IC50 (µM) 
Nisin 
IC90 (µM) 
Streptococcus dysgalatiae 
subsp dysgalactiae 
ATCC a 
27957 
0.69 ± 0.05 0.87 2.12 ± 0.04 3.87 
Vancomycin resistant 
Enterococcus faecium CNRZ
b 481 0.84 ± 0.05 1.1 0.39 ± 0.03 0.57 
Methicillin resistant 
Staphylococcus aureus C5
c 2.23 ± 0.03 3.39 0.42 ± 0.01 0.77 
Bacillus anthracis Sterne 
7702 
Gut et al.d 0.49 ± 0.02 0.071 0.21 ± 0.014 0.52 
Bacillus subtilis ATCC 6633 0.55 ± 0.01 0.81 0.11 ± 0.01 0.16 
Lactococuus lactis HP ATCC 11602 0.12 ± 0.09 0.13 0.017 ± 
0.005 
0.019 
 
aATCC: American type Culture Collection. bCNRZ: National Centre for Zootechnical Research. cClinical isolate 
from Carle Foundation Hospital (Urbana, IL). dReference (45). 
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Table 3.4. Specific activity of nisin, geobacillin I and the analogues generated in this study 
against B. subtilis ATCC6633 in liquid growth inhibition assay. 
 
 
 
 
 
 
Table 3.5. Theoretical and observed molecular weights ([M+H]1+) of modified peptides reported 
in this study. 
 
 
  
Peptide  IC50 (µM) MIC (µM) 
Nisin 0.12 ± 0.01 0.25 
Geobacillin I N−1K 0.56 ± 0.01 1.0 
Geobacillin I L19P 1.00 ± 0.03 2.0 
Geobacillin I L19NVA 5.70 ± 0.08 8.0 
Nisin  I4K/S5F/L6I 0.25 ± 0.05 0.5 
Geobacillin I  S5F/L6I 0.45 ± 0.09 1.0 
Peptide 
Protease 
used 
Theoretical 
[M+H]1+ 
Observed 
[M+H]1+ 
Geobacillin I (from GeoA-N−1K) Trypsin 3265.5 3265.3 
Nisin - 3352.6 3352.5 
Nisin-I4K/S5F/L6I Trypsin 3445.7 3445.9 
Geobacillin-S5F/L6I Trypsin 3340.6 3341.4 
Geobacillin-L19P Trypsin 3246.5 3246.1 
Geobacillin-L19NVA Trypsin 3433.6 3433.4 
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3.6 Codon optimized nucleotide sequence for GeoAI 
        1 ATGGCCAAAT TTGATGATTT TGATCTGGAT ATTGTGGTGA AAAAACAGGA TGATGTTGTT 
       61 CAGCCGAATG TTACCAGCAA AAGCCTGTGT ACACCGGGTT GTATTACCGG TGTTCTGATG 
      121 TGTCTGACCC AGAATAGCTG TGTTAGCTGT AATAGCTGTA TTCGTTGCTA ATAA 
 
3.7 Codon optimized nucleotide sequence for GeoB 
        1 ATGAATGATC TGGTGTTTAA AAATATTGAT ACCTTTATGA TTCGTACACC GGTTCTGAGC 
       61 GTTGATAATT ATCTGCGCTT TTTTGATCAG AAACTGACCG AAGGCGAAAT GAAAGAACGT 
      121 CTGCTGGAAA TTTGTCATAA TCCGGTGTTT CGTGAAAGCA TTCTGGTTGC AAGCAAAAGC 
      181 CTGTATAACA AAATGATTGA TTTTTGCAAT GGCAAAGAGA TTAAGAAATA CGATTACTTT 
      241 ATCAAAGCCA TCTATAAATA TCTGATTCGC ATTAGCACCC GTCCGACCCC GTTTGGTCTG 
      301 TTTGCAGGTG TTGATTTTGG CGAATATACC GATGAAAATA CCAGCATTCG CTATGGCACC 
      361 AATAAATATA AAAAATTTGC CCGTCCGGAT CTGGAATGGC TGATGAAAAT TATTAAAAAA 
      421 CTGGAACAGG AACAGTACGA ACAGCTGTGG TTTACCGTGA ATGATAGCAT TTTTCTGAAA 
      481 GGCGAACGTG CATATCTGCT GCATAGCACC CGTAAAGATG ATGATAAACG CGTGAATGAA 
      541 ATTAGCGTTC GTGTTACCCT GCCGTTTAAA ATTACCTGTG AACTGGCTCG CCATCTGATT 
      601 CATTATCAGA CCCTGAAAAA AGAACTGATT AAACAGTTTC CGAATACCAG CGAAGAAAAA 
      661 ATTGAACGCT TTCTGAAACA GCTGATTGAA AATGAATTTC TGATTAGCAA TCTGCGTCCT 
      721 CCGCTGACCG TTATGGATCA GCTGGATTAT CTGATTAAAC GCCTGAAAGA AAGCCATATT 
      781 GAAGAATGGT CCAATGAACT GATTGATATT CAGCAGAAAA TTCGCACCTA TACCATGACA 
      841 CCGCTGGGTG AAGGTGAGCA GATTTATAAA GAACTGCATA AAAAAATGAA AAAACTGGCC 
      901 GATACCAAAA ATGTTCTGCA GGTGGATATG AAACTGAATC TGCAGGAAAA AAAACTGAAT 
      961 AAACAAGTGA TTAAAGATGT GAATGAACTG ATGCATATTC TGCTGCCGTT TAGCATGACC 
     1021 TATCAGCAGA CCGATTCTCC GCTGTCTCGT TATAAACAGG AATTTATTGA AAAATACGGC 
     1081 GTGGATCGTG AAGTTCCGCT GCTGGAAATG CTGGATAATG ATCTGGGTAT TGGTGCACCG 
     1141 ATGGATTATA CCAATCCGAA AAATGCACGT CTGGCCGTTG GTGTTCCGCA TCAGCTGATT 
     1201 GATGAACAGC TGCGCGAATA TTTTCTGCAT AAATATATTG AAGCCGTGAA AGATAAAAAA 
     1261 AGCATTACCA TTACCGAAGA TGAAATTAAA GAACTGGGCC TGGATGATTA TGATTATCAG 
     1321 AGCATTCCGG ATAGCCTGGA TATTAATGTG ATTGTGAAAT GCGATAGCGA ACAGGATCTG 
     1381 GAAAATAATC ATTTTAAATA TTATATTGGT CCGAATCTGG GTAGCACACA TGCAGGTAAA 
     1441 TCTTTCGGTC GCTTTAGCTA TATGATGGAA GGCGAAGAAA AACTGTTTGA AACCCTGAAT 
     1501 AAAGAAATGC TGAATCTGAA TAATGATAGC GGTGAATATG TTACCTGCGA ACTGGTTTAT 
     1561 CTGCCGAATG AAACCCGTCA TGCAAATGTG ACCCGCAATA TTCATAATAG CGAATATGAA 
     1621 CTGGCCCTGT TTACCAATAA TAGCAAAGAT GAATATCATC GTCTGAGCCT GAATGATATT 
     1681 CTGATCGGCA TTGAAAATGA TATGTTTTAT GCCAAAAGCA AAACACTGAA TAAAAAGCTG 
     1741 ATTATTACCA TGAATAATAT GCTGAATACC CAGAATGCAC CGAATGCAAT TCGCTTTCTG 
     1801 TATGATATTA GCCTGGATGG TAAAAAAATT TGGTGTAATT TTCCGTGGGA TACCATTTTT 
     1861 CAGGATTATG CCTATATTCC GGCAATTGAA TATAAAAATT TTGTGATTGC ACCGCGTAAA 
     1921 TGGGTGATTA ATAAGATTAT CAAAACAAAC GATAAAATCA GCTTTACCGA ATTTGAAAAA 
     1981 CGCTTTAAAA AATTTTGCAG CGATTATGAT GTGCCGAAAT ATGTGTATCT GACCTTTGCC 
     2041 GATAATCGTA TTCTGCTGAA TACGGAAGAT GAAAATTGCC TGCGCATTCT GCATCATGAA 
     2101 TTTAATAATC GCTATGGTAA TATTATTCTG AGCAGCTATG AAGAAGCAGA TCTGCATCTG 
     2161 GTGAAAGATG ATGATGAAAA AGAATATGTG TGCGAACTGG TGATTCCGCT GGTTAAAGTG 
     2221 AAACAAGAAA ATCGTCAGTG GTACGCCAAA GCCAAAAAAA GCAATCATAT TCCGAGCTTT 
     2281 AGCGATATTC GTGTGAAACT GCCGTTTGAA AATTGGCTGT ATCTGAAACT GTATGGTGTT 
     2341 CATAGCCGTG CCGATGATTT TATTGCCTTT TATCTGAGCG AATATTGCCG TGAAAAACTG 
     2401 GCCAAAGGTG AAATTGAAAA ATATTTTTTT ATTCGCTATG CCGATCCGGA ACAGCATATT 
     2461 CGTCTGCGTC TGAATGCATC TGAAGAAAAA CTGCTGCAGA TTTATCCGGA TATGAAACAG 
     2521 TGGCTGCGTA CCCTGATTGA AAAACGTGTT GTGAGCCGCT TTAGCATTGA TTGCTATGAA 
     2581 CGCGAAATTG AACGTTATGG TGGCACCGAA CTGATCGATC TGGCCGAAAA TTTATTTTTT 
     2641 TTTGATAGCA TTGTGGTGGA AGATATTCTG AAACTGAAAC GTCTGAAGCA TATTCAGTTT 
     2701 TCCGATGAAG TGATTGGTAT GGTGAGCATT ATTCATTATA TGGAACAGTT TGGCCTGAAT 
     2761 TATGAAAGCC AGCTGGATTT TCTGCAGCAG CAGGTTAATA AACAGGATTA TCGCGAAGAT 
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     2821 TTTCAGAAAA ATCGCAGCGT GTATATGAAA GTGTGCAATA CCGATAATGA TTGGCAGGGT 
     2881 CTGCGTGATA CCGATGAAGG TATGCTGCTG CTGAATGTTC TGAATCAGCG TAATCGCAGC 
     2941 ATTAAAGAAT ATGCCAGCAA AATTCAGGAT GGTCTGGAAG CAAGCAGCGA ACTGAGCATT 
     3001 CTGGATTCTG TTGTTCATCT GCATTGCAAT CGTCTGTTTG GTATTGATCG TGAATTTGAA 
     3061 AAAAAAATTC GCACCCTGGT TGCACATACC CTGTATGCCC TGAAATATAT TAAAGCCCAT 
     3121 GGCCTGGTGC TGAAAAATTA A 
 
 
3.8 Codon optimized nucleotide sequence for GeoC 
 
        1 ATGTCTATTA GCATGAAAGC CCTGGTTTGT AATCTGGCAA AAAAACTGAG CGATTATGAA 
       61 AATATGAAAC GCATTGTGAA TCATCCGAGC AATTATATTA AAATTGGCAA CAAAACCATT 
      121 AATCCGTTTA ATGAACTGAG CCTGAGCCAT GGTCTGCCTG CACTGTGTGC ACTGTATGGT 
      181 GAACTGAGCG AACAGTATCC GGATGAAGGT TGGGATCTGC TGGGTCATCA GTATATGAAA 
      241 AAAATTGGCG AACAAATGAA TCAGCATGGT TTTCCGAGCC TGAGCATGTT TACCGGTCTG 
      301 GCAGGTATTG GTCTGGCAGC AGTTTGTCTG AGCAAAGGTG GTAAACGCTA TCAGAATTTC 
      361 ATTAGCACCA TTAATCAGGT GATTGAAGAA CGCATTGGCG AAATGATTGA ATATCTGAAA 
      421 CAGAAACCGT ATCCGAATAT GGATGATTAT GATGCAATTA GCGGTGTTGC AGGTATTGCA 
      481 AGCTATTGTC TGCTGTTTCC GCAAGAAATG AAAAAAAGCA TTACCCTGAT TCTGAAATAC 
      541 ATTATTGATC TGAGCCAGGA TAAACAAATG GAAGATATTA ATGTTCCGGG TTGGTATATT 
      601 CCTCCGATGA ATGCATTTAG CGATACCGAA CGTCGTAAAT GGCCGAGCGG TTTTTTTAAT 
      661 ATTGGTCTGA GTCATGGCAT TCCGGCACTG CTGATTGTTC TGTGTAATGC CAAAAAACTG 
      721 AATATTTATG TGCATGGCCA GGATGAATGT ATTCAGCGTA TTGCAGATTT TCTGATGAAA 
      781 TTTCAGATTA AAGATGAAAA TGGCAGCTAT TGGGGCACCC ATGTTAGCCT GGAAGAATAT 
      841 AAAAATGGCA GCGTGCTGAA TAAAGATACC CGTGATGCAT GGTGTTATGG TACACCGGGT 
      901 GTTGCATATA GCCTGCTGAT TGCAGGTAAA ACCCTGAATA ATCAGAGCTA TATTGATTGT 
      961 GCCGTGAGCG GTATGAAACT GGCAAGCAAA CGTCTGTATA ATATTTTTAG CCCGAGCTTT 
     1021 TGCCATGGAC TGAGCGGTGT TGCCTATATT TGCAATCGCT TTTATGAAGA AACCAATATT 
     1081 AGCGATTTTA AAGAAGCAGC CTGCAAACTG GTGGATGATA TTATCAAATT TTATAATGAA 
     1141 GAATTCCCGT TTGGCTTTAA AAATATTGAA GAAAGCGAAG GCAGCACCAA ATATTATGAT 
     1201 TATGTGGGTC TGATTGATGG CACCGCAGGT ATTCTGCTGA CCATTCTGGC AATTCAGAAT 
     1261 AGCAAAAAAA CCCCGTGGGA TTGTGCATTT CTGCTGAGCG AAGTTTAA  
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Chapter 4: Discovery, heterologous production, and characterization of geobacillin II, and 
in vitro reconstitution of its synthetase enzyme GeoM 1 
4.1 Introduction 
The class II lanthipeptide synthetases are bifunctional enzymes that carry out the 
dehydration of serines and threonines in the core region of the precursor peptide followed by 
intramolecular addition of cysteines to the dehydro-amino acids (1). The N-terminal domain of 
class II lanthipeptide synthetases catalyzes the phosphorylation of Ser/Thr followed by 
elimination of phosphate yielding the Dha/Dhb residues (2-3). The C-terminal domain displays 
homology with class I cyclases and catalyzes the formation of the thioether crosslinks between 
Dha/Dhb residues and the cysteine side chain (4-5). Removal of the leader peptide by the 
bifunctional protease/transporter LanT and, in some cases a second proteolysis step, results in the 
production of the final lanthipeptide (3, 6-8). The class II enzymes also occur in the gene clusters 
of two-component lantibiotics such as haloduracin (3, 9), cytolysin (6, 10-11) and lacticin 3147 
(12-16). Such gene clusters encode for two LanAs and sometimes two LanMs. The modified 
molecules act in synergy to produce their biological activities. The stereochemistry at the 
thioether crosslinked amino acids of select class I and class II lanthipeptides including nisin (17), 
epidermin (18), subtilin (19), Pep5 (20), mersacidin (21), lactocin S (22), and several 
prochlorosins (23) was found to be 2S,6R for lanthionine and 2S,3S,6R for methyllanthionine 
1Parts of this chapter have been adapted with permission from: 
Garg N, Tang W, Goto Y, Nair SK, van der Donk WA,. Proc Natl Acad Sci U S A. 2012 Apr 3; 109(14):5241-6. Reproduced 
with permission of the publisher and available from http://www.pnas.org/ (DOI: 10.1073/pnas.1116815109). 
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(abbreviated hereafter as DL stereoisomers, Figure 4.1A). Recently, a different stereochemical 
configuration of the thioether rings for the two-component lantibiotics cytolysin and haloduracin 
that are biosynthesized by the class II enzymatic machinery was reported (Figure 4.1) (24). 
Cytolysin and haloduracin were shown to contain unusual stereochemistry (2R,6R for lanthionine 
and 2R,3R,6R for methyllanthionine) at the N-terminal thioether bridges as opposed to the more 
commonly reported DL stereochemistry for lanthipeptides characterized in the past (25). The 
methyllanthionine A-ring and lanthionine B-ring of CylLL (Figure 4.1B), the methyllanthionine 
A-ring of CylLS (Figure 4.1C), and the methyllanthionine A ring of Halβ all had the LL 
stereochemical configuration (Figure 4.1D). Based on the studies performed on cytolysin, it was 
suggested that the presence of a Dhx-Dhx-Xxx-Xxx-Cys sequence motif in the precursor 
peptide, where Dhx is dehydroalanine (Dha) or dehydrobutyrine (Dhb), and Xxx is any amino 
acid except Ser/Thr/Cys, may be dictating the formation of the LL stereochemical configuration 
of the thioether crosslinks. Further, a recent report highlighted the biological significance of 
unique stereochemistry of the thioether bridges of lacticin 481 (26). Using solid phase support, 
analogues of lacticin 481 with alternative stereochemistry were synthesized. The analogues with 
non-native stereochemical configuration were shown to lack biological activity.  
Reported herein is the discovery and characterization of the lantibiotic geobacillin II and 
its class II biosynthetic enzyme GeoM. In vivo of production of geobacillin II in E. coli was 
achieved, and the precursor peptide expressed in E. coli was also modified in vitro using the 
thermostable lanthipeptide synthetase GeoM at temperatures ranging between 37 °C and 80 °C. 
Similar to cytolysin and haloduracin, the LL stereochemical configuration was observed in the A-
ring of geobacillin II. Various analogues of geobacillin II were produced using co-expression of 
the precursor peptide GeoAII and GeoM in E. coli. The findings in this study suggest that the 
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stereochemical outcome of the A-ring in geobacillin II is not solely dependent on the peptide 
sequence as previously suggested for the two-component lantibiotic haloduracin and cytolysin.  
 
 
Figure 4.1. Structure of lantibiotics with unusual stereochemistry. (A) Chemical structure of DL and LL 
stereoisomers observed for thioether bridges in lanthipeptides. (B) CylLL". (C) CylLS". (D) Haloduracin β 
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4.2 Experimental procedures 
4.2.a Construction of pRSFDuet-1/His6-GeoAII+GeoM 
 Codon-optimized synthetic genes for GeoAII and GeoM (for sequences see the end of 
this chapter) were synthesized by GeneArt (Invitrogen, USA). For geobacillin II production, 
geoAII was inserted in MCS1 of a pRSFDuet-1 vector using BamHI and HindIII restriction sites 
and geoM in MCS2 using NdeI and XhoI sites. A second copy of geoM was provided in a pET15 
vector inserted using NcoI and BamHI restriction sites. QuikChange site directed mutagenesis 
was performed to change the glycine at position −8  to lysine (pRSFDuet-1/His6GeoAII-
G−8K+GeoM). Two other constructs were made in which glutamine at position −1 was either 
mutated to lysine (pRSFDuet-1/His6GeoAIIQ−1K+GeoM) or glutamate (pRSFDuet-
1/His6GeoAII-G−8K/Q−1E+GeoM) (for primers see Table 4.1). Expression and purification of 
these constructs was performed as described for geobacillin I in Chapter 3. Briefly, 
electrocompetent BL21(DE3) cells were transformed with the appropriate plasmids and a single 
colony was picked to inoculate a culture used to overexpress modified GeoAII. Ring A 
analogues (GeoAII-S1T, GeoAII-S1T/T2A, GeoAII-S1T/T2A/I3R, GeoAII-G−8K/T2A, and 
GeoAII-G−8K/T2G), ring B analogues (GeoAII-G−8K/S7T and GeoAII-G−8K/S7T/L8T), ring 
C analogues (GeoAII-G−8K/S14T and GeoAII-G−8K/S14T/L15T), and ring D analogues 
(GeoAII-G−8K/S20T and GeoAII-G−8K/S20T/F21T) were generated using QuikChange site 
directed mutagenesis (for primers see Table 4.1) and were produced as described above (also see 
notebook 5 page 62 and 64). 
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4.2.b Cleavage of modified GeoAII and antimicrobial activity assay. 
 For preparation of geobacillin II, GeoM-modified and HPLC-purified GeoAII-
G−8K/Q−1E (100 µM) was treated with either 0.1 µM trypsin (20 min) or 0.5 µM GluC (2 h). 
GeoAII-Q−1K (100 µM) was also treated with 0.1 µM trypsin. The GluC-cleaved GeoAII-
G−8K/Q−1E peptide (25 µL, 100 µM) was further treated with 8 µL of Leu aminopeptidase (97 
units/mL, porcine kidney, Sigma L5006) for 24 h at 37 °C. For preparation of ring A analogues 
(GeoAII-S1T, GeoAII-S1T/T2A, GeoAII-S1T/T2A/I3R, GeoAII-G−8K/T2A, and GeoAII-
G−8K/T2G), ring B analogues (GeoAII-G−8K/S7T and GeoAII-G−8K/S7T/L8T), ring C 
analogues (GeoAII-G−8K/S14T and GeoAII-G−8K/S14T/L15T), and ring D analogues 
(GeoAII-G−8K/S20T and GeoAII-G−8K/S20T/F21T), 150 µM peptide solution was incubated 
with 0.5 µM GluC for 4 h. Antimicrobial assays were performed as described for nisin in 
Chapter 2 (also see notebook 5 page 51, 55, and 75). 
4.2.c Tandem mass spectrometry analysis to determine the ring topology of geobacillin II 
 GeoAII modified by GeoM and treated with GluC was subjected to ESI-MSMS analysis 
using collision induced dissociation. For tandem MS, 10 μL of the peptide was injected into a 
BEH C8 column (1.7 μm, 1.0 × 100 mm), and separated by UPLC using a gradient of 3% mobile 
phase A (0.1% formic acid in water) to 97% mobile phase B (0.1% formic acid in methanol) 
over 12 min. The instrument settings used included capillary voltage and cane voltage of 3500 V 
and 40 V, respectively, 120 °C as source temperature; 300 °C as desolvation temperature, cone 
gas flow of 150 L/h, and desolvation gas flow of 600 L/h. A transfer collision energy of 4 V was 
used for both MS and tandem MS, while the trap collision energy was set to 6 V for MS and a 
fixed energy of 25 V was used for tandem MS (also see notebook 5 page 55). 
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4.2.d GC/MS analysis of modified GeoAII  
The stereochemistry of (methyl)lanthionine residues was determined by acid hydrolysis 
of geobacillin II and chemical derivatization of the resulting amino acids as previously described 
(22-23). The derivatized material was then analyzed by GC/MS. Wild type GeoAII fully 
modified by GeoM in E. coli and with its leader attached (1.0 mg) was dissolved in 3 mL of 6 M 
HCl. The protocol used for derivatization is described in  Chapter 3 (27) (also see notebook 5 
page 56).  
4.2.e Overexpression and purification of His6-GeoM 
Single colony transformants of E. coli Rossetta2 cells containing pET28/His6GeoM 
(provided by Dr. Yuki Goto) were grown in a 37 oC shaker for 12-15 h in 30 mL of LB medium 
supplemented with 50 μg/mL kanamycin and 25 μg/mL chloramphenicol. These cultures were 
used to inoculate 3 L of LB media and grown at 37 oC until the OD600 was ~ 0.6. IPTG was 
added to a final concentration of 0.1 mM and the cultures were grown at 18 oC for an additional 
12 h. Cells were harvested by centrifugation at 11,900 × g for 25 min at 4 oC. The cell paste was 
resuspended in 20 mM Tris-HCl, 1 mM NaCl, and 10% glycerol, pH 8.0. The cells were lysed 
using a C3 Homogenizer (Avestin Inc.). The lysed cells were pelleted by centrifugation at 23,700 
× g for 25 min. The purification by nickel column chromatography was accomplished using a 5 
mL HiTrap chelating HP nickel affinity column (GE Healthcare) on an AKTA FPLC system 
(Amersham Pharmacia Biosystems). The supernatant from the centrifugation step was applied to 
the column using a 50 mL superloop. The protein was detected by absorbance at 280 nm. The 
column was washed with buffer A containing 20 mM Tris-HCl, pH 8.0, 1 M NaCl, and 30 mM 
imidazole to remove any non-specifically bound proteins until a flat baseline was observed. A 
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gradient of 0-100%B over 40 min was used to elute the bound proteins where buffer B contained 
1 M NaCl, 20 mM Tris-HCl, pH 8.0, and 200 mM imidazole.  The most concentrated fraction (4 
mL) was loaded onto an S-200 gel filtration column (Amersham Biosciences) equilibrated in 20 
mM HEPES pH 7.5, 300 mM NaCl, and 10% glycerol. The eluted protein was stored at −80 ˚C 
until use (also see notebook 5 page 75).  
4.2.f Production and purification of GeoAII 
The plasmid used to express and purify GeoAII was provided by a former lab member 
Dr. Yuki Goto. Single colony transformants of E. coli BL21 (DE3) containing plasmid pET15/ 
His6-GeoAII were picked and grown in LB media overnight. The culture after centrifugation and 
resuspension in fresh LB media was used to inoculate 12 L of LB media containing 100 mg/L 
ampicillin. The culture was shaken at 200 rpm at 37 °C until the OD600 reached between 0.6 and 
0.8. At this point, the culture was induced with 1 mM IPTG. The induced cells were shaken 
continually at 37 °C for an additional 2 h, and the cells were harvested by centrifugation 
(11,900×g for 10 min, Beckman JLA-10.500 rotor). The cell pellet was resuspended in 50 mL of 
start buffer (20 mM Tris, pH 8.0, 500 mM NaCl, and 10% glycerol), and cell lysis was carried 
out using a MultiFlex C3 homogenizer (Avestin). The lysed cells were centrifuged at 23,700×g 
for 30 min at 4 °C. The supernatant was loaded onto a HiTrap HP nickel affinity column (GE 
Healthcare) pre-equilibrated with start buffer. The column was washed with wash buffer (start 
buffer containing 30 mM imidazole), and the peptide was eluted from the column with elution 
buffer (start buffer containing 1 M imidazole) (also see notebook 5 page 42). To increase the 
yield, GeoAII was also recovered from the insoluble fraction after cell lysis. The pellet was 
homogenized using a sonicator (35% amplitude, 4.4 s pulse, 9.9 s pause for 20 min total) in start 
buffer to remove any soluble proteins. The suspension was centrifuged and the pellet was 
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homogenized in 30 mL of denaturing buffer (4 M guanidine hydrochloride, 20 mM NaH2PO4, 
500 mM NaCl, pH 7.5). The supernatant after centrifugation was loaded onto a HiTrap HP nickel 
affinity column, the column was washed with denaturing buffer containing 30 mM imidazole, 
and the product was eluted with 15 mL of denaturing buffer containing 1 M imidazole. Small 
aliquots of eluent were desalted using a ZipTip (µC18) and analyzed for the presence of GeoAII 
using MALDI-MS. For large scale purification, the eluent was desalted using preparative scale 
RP-HPLC using a Waters Delta-pak C4 15 μm; 300 Å; 25 ×100 mm PrepPak Cartridge. 
Following injection, the column was kept at 2% solvent A (solvent A = 0.086% TFA in 2% 
ACN/98% water) for 2 min followed by a gradient of 2-100% of solvent B (0.086% TFA in 80% 
ACN/20% water) over 45 min. The fractions containing GeoAII were lyophilized.  
4.2.g In vitro enzymatic assay of GeoM 
The activity assay contained 20 µM His6-GeoAII, 5 µM His6-GeoM, 20 mM HEPES pH 
7.5, 10 mM MgCl2, 2 mM tris(2-carboxyethyl)phosphine (TCEP), and 2.5 mM ATP. The activity 
assays were incubated at various temperatures (37 °C, 45 °C, 55 °C, 65 °C, 75 °C, and 80 °C) for 
2 h, desalted using µC18 Ziptip devices, and analyzed by MALDI-MS. In order to determine the 
effect of temperature on enzyme activity, time dependent in vitro assays were carried out at 37 
°C, 55 °C, and 70 °C with 1 µM GeoM. The reactions (20 µL) were quenched with 5 µL of 3% 
TFA at 30 min, 60 min, and 2 h. The reaction mixture obtained at different time points was 
desalted using µC18 Ziptip and analyzed by MALDI-MS (also see notebook 5 page 64 and 75). 
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4.3 Results 
4.3.a Description of the gene cluster of geobacillin II from Geobacillus thermodenitrificans 
NG80-2 
The gene cluster of geobacillin II was annotated in the database as having homology with 
the enzymes involved in the biosynthesis of the class II lantibiotic mersacidin produced by 
Bacillus sp. HIL Y85,54728  (accession numbers YP_001126158 & YP_001126159). The 
cluster of geobacillin II had also been noted in bioinformatic genome mining studies (28), but the 
product of the gene cluster was not known.  The gene cluster contained a short open reading 
frame for the precursor peptide, which we designated geoAII (Figure 4.2A). A search of the non-
redundant protein database for homologs of the precursor peptide GeoAII did not find 
homologous precursor peptides of known lantibiotics suggesting it might be a novel class II 
lantibiotic (Figure 4.2B and C). A gene encoding a precursor peptide differing in only one amino 
acid was found in the genome of Geobacillus sp. G11MC16 (Figure 4.2C). Two start codons are 
present in frame in the gene encoding the leader peptide of GeoAII preventing prediction of the 
initiation codon and resulting in two possible precursor peptides (Figure 4.2B). GeoAII contains 
a typical double glycine motif for proteolytic removal of the leader peptide in class II lantibiotics 
(29-30). Leader sequence removal after the double Gly site is supported by the presence of a 
gene product (GeoTII) that shows homology with the family of AMS (ABC transporter 
maturation and secretion) proteins whose peptide substrates share the double-glycine type 
cleavage site (30). Like other family members, GeoTII contains an N-terminal Cys protease 
domain for leader peptide removal. The predicted biosynthetic scheme for the production of 
geobacillin II based on bioinformatic analysis is given in Figure 4.3. The class II lanthionine 
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synthetase GeoM is encoded by a gene located next to geoAII (Figure 4.2A) and has 35% 
sequence identity to known LanM enzymes such as MrsM, HalM1 and HalM2.     
 
Figure 4.2. Gene cluster and primary sequence alignment of geobacillin II from G. thermodenitrificans NG80-
2. A) Gene cluster for the biosynthesis of geobacillin II. The gene for the precursor peptide (GeoAII) is shown in 
red, modification enzyme (GeoM) in yellow, and transporter/protease (GeoTII) in purple. B) The two possible Met 
residues that could be the start of the leader peptide are underlined in the sequence of the leader peptide (top). 
Sequence alignment of the leader peptides of selected known class II lantibiotics (bottom). C) Sequence alignment 
of the core region of the precursor peptide GeoAII with the core peptides of class II lantibiotics that undergo a 
second proteolytic processing step after removal of the leader peptide at the double Gly cleavage site (indicated by a 
blue arrow, see section 4.3.c). The second cleavage site for this group of lantibiotics is indicated with a red arrow. 
The ring topology of these compounds, when known, is also shown at the top and the ring topology deduced in this 
study for geobacillin is shown at the bottom.  
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Figure 4.3. Predicted biosynthesis of geobacillin II. The steps leading to incorporation of post-translational 
modifications in the biosynthesis of lantibiotic geobacillin II. The dehydration and cyclization reactions are 
catalyzed by the bifunctional enzyme, GeoM. GeoATII is a bifunctional transporter/protease catalyzing transport of 
modified GeoAII followed by cleavage of the leader peptide. A second proteolysis step catalyzed by an unknown 
enzyme leads to the synthesis of fully modified geobacillin II (see section 4.3.c). 
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4.3.b Heterologous production of geobacillin II in E. coli 
 Synthetic genes encoding GeoAII and GeoM were inserted into MCS-1 and MCS-2 of a 
pRSFDuet-1 vector, respectively. Site-directed mutagenesis was performed to mutate the second 
Gly in the double Gly motif of the GeoAII peptide to Lys to incorporate a trypsin cleavage site 
for leader peptide removal (GeoAII-G−8K). Co-expression of GeoM with its substrate precursor 
peptide in E. coli at 37 °C and subsequent purification as described for geobacillin I in Chapter 3 
resulted in five-fold dehydrated peptide (Figure 4.4).  
 
 
Figure 4.4. Biosynthesis of geobacillin II. MALDI-MS spectrum of GeoAII-G−8K modified by GeoM in E. coli 
and treated with trypsin.  
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4.3.c Bioactivity of geobacillin II 
To determine the bioactivity of geobacillin II, purified five-fold dehydrated GeoAII-
G−8K was treated with trypsin and checked for bioactivity. No antimicrobial activity was 
observed against any of the strains listed in Table 4.2. Although it is not unprecedented that 
lanthionine-containing peptides do not demonstrate any antimicrobial activity (23, 31-33), we 
wondered whether perhaps a second proteolytic cleavage event might be required.  Removal of 
six additional N-terminal residues after leader peptide cleavage at a double glycine site has been 
reported previously for several class II lantibiotics (3, 6-7, 34). In some examples, such as 
cytolysin from Enterococcus faecalis, removal of these additional residues from the N-terminus 
of the modified core peptide is necessary for bioactivity (6), but in other examples (eg  
haloduracin (8)) such removal is not required. A sequence alignment of the predicted core 
peptide of GeoAII with the core peptides of lantibiotics that are currently known to undergo a 
second proteolytic step is shown in Figure 4.2C. The N-terminal amino acids of GeoAII display 
only low level sequence homology with the sequences that are removed in the other peptides, but 
the presence of a Pro-Gln sequence and the observation that the GeoAI leader peptide is removed 
at a Pro-Asn site (Chapter 3) prompted us to investigate whether removal of additional amino 
acids might result in bioactivity. First, a trypsin cleavage site was introduced into wild type 
GeoAII by mutation of Gln−1 to Lys (this numbering assumes cleavage after ProGln, Fig ure 
4.2C). Unfortunately, this mutant was not processed well in E. coli (predominantly 4 
dehydrations, Figure 4.5A), presumably because introduction of a positively charged residue is 
detrimental for GeoM activity.  A different mutant was constructed next (GeoAII-Gln−1Glu) and 
co-expressed with GeoM in E. coli resulting in the desired five-fold dehydrated peptide.  
Proteolysis with endoproteinase GluC did not result in efficient cleavage after the introduced 
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Glu−1 (Figure 4.5B), presumably because the posttranslationally modified Ser at position 1 
deactivates the engineered cleavage site. Instead GluC cleaved predominantly after Glu−5 
(Figure 4.5B) resulting in the removal of only three residues (Tyr, Thr, and Glu) at the N-
terminus compared to cleavage at the double Gly site (see Figure 4.2C). Interestingly, this GluC-
treated core peptide induced zones of growth inhibition of Bacillus strains in agar well diffusion 
assays (Figure 4.5D). Thus, removal of Tyr or Thr (or both) may be required for bioactivity. 
Geobacillin II only showed bioactivity against Bacillus species and no activity against any other 
tested bacteria (Table 4.2). Attempts to increase the observed bioactivity by treatment with Leu 
aminopeptidase (35) to remove additional amino acids (Figure 4.5C) did not result in 
significantly increased zones of growth inhibition (compare spots 1 and 2, Figure 4.5D).  
Authentic geobacillin II was not produced by the seven Geobacillus strains we evaluated 
for the production of geobacillin I (Chapter 3). Thus, it is not clear where the core peptide of 
geobacillin II starts. We favor removal of the entire heptapeptide sequence YTEVSPQ after 
initial removal of the leader peptide at the double Gly site for the following reasons. Firstly, 
removal of this peptide would result from cleavage after Gln similar to the cleavage site for 
haloduracin from B. halodurans and similar to lantibiotic proteases such as NisP involved in 
nisin biosynthesis (36). A LanP-type protease is not present in the gene cluster or elsewhere in 
the genome and therefore, like for haloduracin, the identity of the protease is not known, but the 
same protease may remove the leader of GeoAI at its Pro-Asn cleavage site. Secondly, cleavage 
after the ProGln sequence would result in an N-terminal structure very similar to that of 
haloduracin β, plantaricin β, and cytolysin CylLS (Figure 4.2C).  
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Figure 4.5. MALDI-MS spectra of analogues of geobacillin II produced to investigate the antimicrobial 
activity of geobacillin II. A) MALDI-MS spectrum of GeoAII-Q−1K modified by GeoM in E. coli and treated with 
trypsin. B) MALDI-MS spectrum of GeoAII-Q−1E modified by GeoM in E. coli and treated with GluC. Peptide 1 
arises from cleavage at Glu−5, whereas peptide 5 arises from cleavage at Glu−1 . C) MALDI-MS spectrum of 
GeoAII-Q−1E modified by GeoM in E. coli and treated first with GluC and then Leu aminopeptidase. Peptide 1 is 
initially formed upon GluC cleavage. The aminopeptidase then partially removed additional amino acids from the N 
terminus as shown in the inset. The aminopeptidase treated sample gave the same size of the zone of growth 
inhibition as pure peptide 1 from panel B suggesting that further removal of the amino acids from the N terminus 
does not result in more active peptides. D) Agar well diffusion assay with B. subtilis ATCC 6633. Zone 1: 10 µL of 
100 µM GeoAII-Q−1E modified by GeoM and treated with GluC.  Zones 2 and 3: the material used for zone 1 was 
treated with aminopeptidase for 24 and 48 h, respectively. Zone 4: 10 µL of 300 µM GeoAII-Q−1K modified by 
GeoM and treated with trypsin. This sample contains a mixture of four- and five-fold dehydrated peptide (see text 
and panel A). Zone 5: trypsin-cleaved GeoAII-G−8K. Spot 6: negative control containing GluC and aminopeptidase.  
  
130 
 
4.3.d Structure determination of geobacillin II 
 
 Tandem MS was used to determine the ring pattern of geobacillin II because the amount 
of material obtained from co-expression in E. coli was insufficient for NMR studies. The 
precursor peptide GeoAII was co-expressed with GeoM in E. coli, purified by IMAC 
chromatography, and treated with GluC to remove most of the leader peptide. The resulting five-
fold dehydrated peptide was fragmented by collision induced dissociation resulting in the 
fragment ions indicated in Figure 4.6A and C.  The observed ions are inconsistent with 
overlapping rings and agree very well with four non-overlapping rings. Based on these data, the 
structure shown in Figure 4.6B is proposed for geobacillin II. The structure of in vitro modified 
GeoAII was determined by Dr. Yuki Goto and identical ring topology was deduced from those 
results. In vitro GeoM-catalyzed modification of GeoAII is described in section 4.3.f.  
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Figure 4.6. A) ESI fragmentation pattern of GeoAII modified by GeoM in E. coli and treated with GluC. The b5 
and y”26 ions appear to indicate that the A-ring is formed from Cys5 and Dhb2, but three observations argue against 
this interpretation. First, if the ring were formed between Cys5 and Dhb2, the N-terminal Dha1 would hydrolyze to a 
pyruvate group (37), decreasing the mass by 1 Da; the masses in Figure 4.5B and C  (Table 4.3) do not support this. 
Second, as shown in Figure 4.2C, A-rings formed from Cys5 and a dehydro amino acid at position 1 are well 
conserved amongst various lantibiotics, and third, acid hydrolysis of the modified GeoAII peptide followed by 
derivatization and amino acid analysis by gas chromatography/mass spectrometry only showed the presence of 
lanthionines for geobacillin AII (section 4.3.d). Thus, we attribute the b5 and y”26 ions to fragmentation in the A-
ring. Similar fragmentation is also observed in the A-ring of nisin (see Figure S7 of reference (38). B) Ring topology 
of geobacillin II derived from the tandem MS results. Arrows indicate the position and direction of lanthionine 
formation. C) Tandem MS spectrum of GeoAII modified by GeoM in E. coli and treated with GluC. The b and y" 
ions are marked. Ions marked with asterisks and crosses are not fragment ions but arise from multiply charged ions.  
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4.3.e Determination of stereochemistry of lanthionine rings of geobacillin II 
Like cytolysin and haloduracin β, ring A of geobacillin II also contains a Dha-Dhb-Xxx-
Xxx-Cys motif and hence, prompted us to determine the stereochemical configuration of the 
thioether crosslinks in this molecule. In order to produce sufficient quantities of geobacillin II, 
the hexa-histidine tagged precursor peptide GeoAII-G−8K was coexpressed with untagged 
GeoM in E. coli (38-39). The modified precursor peptide thus obtained was hydrolyzed and 
derivatized for gas chromatography/mass spectrometry (GC/MS) analysis. As predicted, 
geobacillin II contained a mixture of DL and LL stereoisomers of lanthionine suggesting that ring 
A might have LL stereochemistry (Figure 4.7A). In order to determine unambiguously the 
position of the lanthionine with LL stereochemical configuration, the Ser residue at position 1 
was mutated to Thr using site directed mutagenesis such that ring A would contain a unique 
methyllanthionine. Coexpression of the precursor peptide GeoAII-S1T with GeoM resulted in 
five-fold dehydrated and cyclized peptide. The modified GeoAII-S1T was hydrolyzed, 
derivatized, and the derivatized amino acids were analyzed by GC/MS. The A-ring, now 
methyllanthionine, was found to have the LL configuration (Figure 4.7B) and the lanthionine B, 
C, and D rings had the DL configuration (Figure 4.7A). Thus, unlike other characterized 
lanthipeptides but similar to cytolysin and haloduracin β, ring A of geobacillin II with the amino 
acid sequence Dha-Dhb-Ile-Val-Cys had the LL configuration.  
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Figure 4.7. Stereochemical configuration of the thioether bridges of wild type geobacillin II and geobacillin II 
S1T. (A) GC-MS traces of hydrolyzed and derivatized Lan residues from GeoM-modified His6GeoAII (black), 
His6GeoAII-S1T (red), DD-Lan standard (blue), DL-Lan standard (pink), and LL- Lan standard (green). (B) GC-MS 
traces of hydrolyzed and derivatized MeLan residues from GeoM-modified His6GeoAII-S1T (blue), DL-MeLan 
standard (red), and LL-MeLan standard (black). The small shoulders on the Lan peaks result from partial 
epimerization during hydrolysis and/or derivatization as previously reported (22). 
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To further investigate the importance of the suggested motif in determining the 
stereochemical outcome, analogues of geobacillin II were produced with the amino acid 
composition of ring A changed to Dha-Gly-Ile-Val-Cys (generated from GeoAII-G−8K/T2G) 
and Dha-Ala-Ile-Val-Cys (from GeoAII-G−8K/T2A). Coexpression of the precursor peptides 
GeoAII-G−8K/T2G and GeoAII-G−8K/T2A with GeoM resulted in fourfold dehydrated 
products. The modified GeoAII-G−8K/T2G and GeoAII-G−8K/T2A peptides were hydrolyzed, 
derivatized, and the derivatized amino acids were analyzed by GC/MS. The stereochemistry of 
the lanthionine rings in these analogues was found to be a mixture of DL and LL stereoisomers 
that was similar to that of the parent sequence (Figures 4.8 and 4.9). Thus, it appeared that the 
second Dhx in the sequence motif Dhx-Dhx-Xxx-Xxx is not essential for a stereochemical 
outcome of LL configuration of the A-ring of geobacillin II.  
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Figure 4.8. GC-MS traces of hydrolyzed derivatized Lan residues of modified His6GeoAII-G−8K/T2A (black), 
wild type modified His6GeoAII (red, for comparison), DD-Lan standard (blue), DL-Lan standard (pink), and LL- Lan 
standard (green).  
 
 
Figure 4.9. GC-MS traces of hydrolyzed derivatized Lan residues of modified His6GeoAII-G−8K/T2G (black) 
compared with the wild type modified His6GeoAII (red).  
136 
 
The presence of four additional Lan in geobacillin II and the partial epimerization during 
hydrolysis and derivatization confounds the analysis of the stereochemistry of the A-ring. In 
order to clearly establish the stereochemical configuration of the ring A lacking the Dhx-Dhx-
Xxx-Xxx-Cys motif, a ring A analogue of geobacillin II with amino acid sequence Dhb-Ala-Ile-
Val-Cys (GeoAII-S1T/T2A) was generated in a similar fashion using coexpression with GeoM 
in E. coli to distinguish the derivatized MeLan residue of ring A from derivatized Lan residues 
arising from the B, C and D rings. The derivatized methyllanthionine residue originating from 
ring A showed a mixture of DL and LL configuration with the LL isomer as the major product 
(Figure 4.10). Note that GeoAII-S1T mutant resulted in a product in which the LL-isomer was 
favoured more but the DL isomer enriched compared to the wild type sequence (Figure 4.10, blue 
trace). This observation suggests that the second Dhx in the sequence Dhx-Dhx-Xxx-Xxx-Cys 
motif increases the amount of LL product formed but may not be the only governing factor for a 
stereochemical outcome of LL configuration by GeoM.  
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Figure 4.10. GC-MS traces of hydrolyzed derivatized MeLan residues of modified His6GeoAII ring A analogues 
with amino acid sequence Dhb-Ala-Arg-Val-Cys (black), Dhb-Ala-Ile-Val-Cys (red), Dhb-Dhb-Ile-Val-Cys (blue), 
DL-MeLan standard (pink), and LL-MeLan standard (green).   
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Figure 4.11. GC-MS traces of hydrolyzed derivatized Lan residues of modified His6GeoAII ring A analogues with 
amino acid sequence Dhb-Ala-Arg-Val-Cys (black), Dhb-Ala-Ile-Val-Cys (red), DD-Lan standard (blue), DL-Lan 
(pink), and LL-Lan standard (green).   
 
The B, C and D rings of geobacillin II all have a positively charged amino acid residue 
while ring A does not. To investigate whether the presence of a charged amino acid is (in part) 
responsible for the observed stereochemistry, we constructed a ring A analogue with amino acid 
sequence Dhb-Ala-Arg-Val-Cys (GeoAII-S1T/T2A/I3R) in order to investigate a possible role of 
a charged residue in determining the fate of stereochemistry in the case of GeoM-catalyzed 
formation of thioether bridges. Although the abundance of the DL isomer in the GC-MS trace 
was lower, the derivatized methyllanthionine residue of this analogue showed a mixture of DL 
and LL configuration (Figure 4.10, black trace). As expected, the stereochemistry of all 
lanthionine rings in these analogues was DL (Figure 4.11). Thus, in light of results obtained in 
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this study, we speculate that in geobacillin II the presence of the sequence Dhx-Dhx-Xxx-Xxx-
Cys motif alone is not enough to produce the LL stereoisomer of the thioether bridge. 
In order to investigate whether GeoM can catalyze the formation of LL stereoisomers at 
positions other then the A-ring, each of the B, C, and D rings were individually converted to 
methyllanthionine rings with amino acid sequences Dhb-Leu-Arg-Ile-Cys (GeoAII-G−8K/S7T) 
and Dhb-Dhb-Arg-Ile-Cys (GeoAII-G−8K/S7T/L8T) for ring B, Dhb-Leu-Arg-Phe-Cys 
(GeoAII- G−8K/S14T) and Dhb-Dhb-Arg-Phe-Cys (GeoAII-G−8K/S14T/L15T) for ring C, and 
Dhb-Phe-Lys-Val-Arg-Cys (GeoAII-G−8K/S20T) and Dhb-Dhb-Lys-Val-Arg-Cys (GeoAII-
G−8K/S20T/F21T) for ring D. The peptides were produced using co-expression with GeoM in 
E. coli. Unfortunately, following co-expression, five-fold dehydrated peptides were obtained for 
the mutants GeoAII-G−8K/S7T/L8T, GeoAII-G−8K/S14T/L15T, and GeoAII-
G−8K/S20T/F21T as opposed to the desired six-fold dehydrated peptides. A likely explanation 
may be the inability of GeoM to catalyze the conversion of the second Thr in the motif Dha-
Dhb-Xxx-Xxx-Cys to Dhb in these rings thus resulting in modified amino acid sequences of the 
B, C and D ring analogues as Dhb-Thr-Xxx-Xxx-Cys instead of Dhb-Dhb-Xxx-Xxx-Cys. The 
lack of dehydration may possibly occur because of rapid closure of the thioether bridge 
preventing access of the threonine residue to the enzyme active site involved in catalyzing the 
dehydration reaction. The stereochemistry of the B, C and D ring analogues was determined as 
described above. All newly introduced methyllanthionines in these analogues had the DL 
configuration (Figures 4.12, 4.13, and 4.14). Similar to wild type geobacillin II, all lanthionines 
in the unperturbed A, B, C, and D rings in these analogues contained a mixture of LL and DL 
stereochemical configuration (Figures 4.12, 4.13 and 4.14).  
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Figure 4.12. Stereochemical configuration of the thioether bridges of geobacillin II B-ring analogues. (A) 
Amino acid composition of B-ring analogues generated in this study. (B) GC-MS traces of hydrolyzed and 
derivatized MeLan residues from GeoM-modified His6GeoAII B-ring analogues with amino acid sequence Dhb-
Thr-Arg-Ile-Cys (blue), Dhb-Leu-Arg-Ile-Cys (pink), DL-MeLan standard (black), and LL-MeLan standard (red). (C) 
GC-MS traces of hydrolyzed and derivatized Lan residues from GeoM-modified His6GeoAII B-ring analogues with 
amino acid sequence Dhb-Thr-Arg-Ile-Cys (blue), and Dhb-Leu-Arg-Ile-Cys (pink). 
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Figure 4.13. Stereochemical configuration of the thioether bridges of geobacillin II C-ring analogues. (A) 
Amino acid composition of C-ring analogues generated in this study. (B) GC-MS traces of hydrolyzed and 
derivatized MeLan residues from GeoM-modified His6GeoAII C-ring analogues with amino acid sequence Dhb-
Thr-Arg-Phe-Cys (blue), Dhb-Leu-Arg-Phe-Cys (pink), DL-MeLan standard (black), and LL-MeLan standard (red). 
(C) GC-MS traces of hydrolyzed and derivatized Lan residues from GeoM-modified His6GeoAII C-ring analogues 
with amino acid sequence Dhb-Thr-Arg-Phe-Cys (blue), and Dhb-Leu-Arg-Phe-Cys (pink). 
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Figure 4.14. Stereochemical configuration of the thioether bridges of geobacillin II D-ring analogues. (A) 
Amino acid composition of D-ring analogues generated in this study. (B) GC-MS traces of hydrolyzed and 
derivatized MeLan residues from GeoM-modified His6GeoAII D-ring analogues with amino acid sequence Dhb-
Thr-Lys-Val-Arg-Cys (blue), Dhb-Phe-Lys-Val-Arg-Cys (pink), DL-MeLan standard (black), and LL-MeLan 
standard (red). (C) GC-MS traces of hydrolyzed and derivatized Lan residues from GeoM-modified His6GeoAII D-
ring analogues with amino acid sequence Dhb-Thr-Lys-Val-Arg-Cys (blue), and Dhb-Phe-Lys-Val-Arg-Cys (pink). 
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4.3.f Antimicrobial assay of geobacillin II analogues generated in this study 
The bioactivity of the geobacillin II analogues produced in this study was tested using an 
agar diffusion growth inhibition assay (Figure 4.15). The purified modified peptides were 
incubated with GluC in order to remove the leader peptide (see Figures 4.16 and 4.17 and Table 
4.3 for mass spectra). GluC cleaved at the −5 position leaving a four amino acid overhang at the 
N-terminus of core peptide.  This overhang does not inhibit the antibacterial activity of 
geobacillin II as described above (39). The cleavage products were tested for biological activity. 
All analogues resulted in comparable activity as wild type geobacillin II treated in the same 
manner, except the A-ring analogues with amino acid compositions Dhb-Ala-Ile-Val-Cys (zone 
13) and Dhb-Ala-Arg-Val-Cys  (zone 14) resulting in methyllanthionine bridges, and the B-ring 
analogues (zones 4 and 5) constructed in this study (Figure 4.15). The modified core peptide of 
the methyllanthionine A-ring analogues (Dhb-Ala-Arg-Val-Cys and Dhb-Ala-Ile-Val-Cys) 
eluted as two separate peaks while the core peptide for lanthionine A-ring analogues (Dhb-Ala-
Ile-Val-Cys and Dha-Gly-Ile-Val-Cys) eluted as a single peak on RP-HPLC (Figure 4.18). The 
other modified geobacillin II analogues produced in this study also eluted as single peak (Figure 
4.19). In order to further investigate the identity of the two peaks, the geobacillin II analogue 
GeoAII-S1T/T2A/I3R was produced in larger quantities. The two peaks obtained in RP-HPLC 
after GluC cleavage of the corresponding modified peptide were collected separately and 
lyophilized. The lyophilized peptides were ran on a RP-HPLC column to determine their purity 
(Figure 4.20). The isolated peptides were hydrolyzed and derivatized for GC/MS analysis. Peak 
1 contained a mixture of DL and LL stereoisomers of MeLan whereas only a very small signal for 
MeLan was observed in the analysis of peak 2 (Figure 4.21). The lack of cyclization of ring A 
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was also confirmed by alkylation of free cysteines in these peptides with iodoacetamide (IAA) 
using a previously published protocol (3). MALDI-MS spectra showed no IAA adducts were 
present in the reaction containing the product of the peptide corresponding to peak 1 whereas one 
IAA adduct was present in the reaction containing the product of the peptide corresponding to 
peak 2 (Figure 4.22). Similar results upon incubation with IAA were obtained for the geobacillin 
II analogue GeoAII-S1T/T2A that also consisted of two peaks by HPLC. The observed 
incomplete cyclization upon mutation of these residues in the A-ring suggests that the wild type 
sequence of this ring is important for efficient modification by GeoM. 
For both analogues, the cyclized material (peak 1) inhibited the growth of B. subtilis 
whereas the uncyclized material (peak 2) resulted in no inhibition (Figure 4.23). When the 
cyclized and uncyclized material were applied together, no zone of inhibition was observed 
(zone 4 and 5, Figure 4.23). This observation suggests that the uncyclized material serves as 
antagonist of the fully cyclized peptides. In turn, this finding suggests formation of an oligomeric 
active complex involving multiple geobacillin II molecules may be required for antibacterial 
activity. For instance, the lantibiotic nisin has been shown to form a multimeric complex in the 
cell membrane upon lipid II binding (40). Formation of an inactive complex between fully 
cyclized and partially cyclized compounds, and potentially a target molecule may explain the 
lack of activity of geobacillin II S1T/T2A/I3R and geobacillin II S1T/T2A. Since ring B 
analogues had identical stereochemistry as wild-type geobacillin II and eluted as single peaks, 
the reduction in biological activity observed in zones 4 and 5 in Figure 4.15 may arise from 
mutation of the Dha residue to a Dhb residue. This mutation may inhibit binding to the target, 
which may specifically require a Lan at this position. Alternatively, a Lan B-ring may be 
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important for interactions between geobacillin II molecules. Deeper investigation of these results 
requires additional mechanism-of-action studies. 
 
 
  
 
Figure 4.15. Agar diffusion growth inhibition assay of geobacillin II analogues produced in this study. Zone 1: 
nisin (10 µL of 75 µM), Zone 2: nisin (10 µL of 50 µM).  Zones 3-14 represent inhibition by geobacillin II  and the 
analogues produced in this study (20 µL of  150 µM solution from GluC cleavage of each modified precursor 
peptide). Zone 3: geobacillin II, Zone 4: geobacillin II with ring B amino acid sequence Dhb-Leu-Arg-Ile-Cys, Zone 
5: geobacillin II with  ring B amino acid sequence Dhb-Thr-Arg-Ile-Cys, Zone 6: geobacillin II with ring C amino 
acid sequence Dhb-Leu-Arg-Phe-Cys, Zone 7: geobacillin II with ring C amino acid sequence Dhb-Thr-Arg-Phe-
Cys, Zone 8: geobacillin II with ring D amino acid sequence Dhb-Phe-Lys-Val-Arg-Cys, Zone  9: geobacillin II 
with ring D amino acid sequence Dhb-Thr-Lys-Val-Arg-Cys, Zone 10: geobacillin II with ring A amino acid 
sequence Dha-Ala-Ile-Val-Cys, Zone 11: geobacillin II with ring A amino acid sequence Dha-Gly-Ile-Val-Cys, 
Zone 12: geobacillin II with ring A amino acid sequence Dhb-Dhb-Ile-Val-Cys, Zone 13: geobacillin II with ring A 
amino acid sequence Dhb-Ala-Ile-Val-Cys, and Zone 14: geobacillin II with ring A amino acid sequence Dhb-Ala-
Arg-Val-Cys. 
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Figure 4.16. MALDI-MS spectra of modified His6-GeoAII and A-ring analogues generated by coexpression of the 
corresponding precursor peptide with untagged GeoM in E. coli. The amino acid sequences of the A-rings were: (A) 
Dha-Dhb-Ile-Val-Cys (wild type), (B) Dhb-Dhb-Ile-Val-Cys, (C) Dhb-Ala-Ile-Val-Cys, (D) Dhb-Ala-Arg-Val-Cys, 
(E) Dha-Ala-Ile-Val-Cys, and (F) Dha-Gly-Ile-Val-Cys. 
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Figure 4.17. MALDI-MS spectra of modified His6-GeoAII analogues of rings B, C, and D generated by 
coexpression of the corresponding precursor peptide with untagged GeoM in E. coli. The amino acid sequence of the 
B-ring analogues were: (A) DhbLeuArgIleCys, and (B) Dhb-Thr-Arg-Ile-Cys; analogues of the C-ring were: (C) 
Dhb-Leu-Arg-Phe-Cys, and (D) Dhb-Thr-Arg-Phe-Cys; and analogues of the D-ring were: (E) Dhb-Phe-Lys-Val-
Arg-Cys, and (F) Dhb-Thr-Lys-Val-Arg-Cys. 
  
148 
 
 
Figure 4.18. Analytical HPLC traces of modified His6-GeoAII and A-ring analogues after GluC cleavage. The 
amino acid sequences of the A-ring were: wild type Dha-Dhb-Ile-Val-Cys (black), Dhb-Dhb-Ile-Val-Cys (red), Dha-
Ala-Ile-Val-Cys (blue), Dha-Gly-Ile-Val-Cys (pink), Dhb-Ala-Ile-Val-Cys (green), and Dhb-Ala-Arg-Val-Cys 
(navy). 
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Figure 4.19. Analytical HPLC traces of modified His6-GeoAII and analogues of the B, C, and D rings after GluC 
cleavage. The amino acid sequences of the B-ring were: Dhb-Leu-Arg-Ile-Cys (green), and Dhb-Thr-Arg-Ile-Cys 
(navy). The amino acid sequences of the C-ring sequences were: Dhb-Leu-Arg-Phe-Cys (blue), and Dhb-Thr-Arg-
Phe-Cys (pink). The amino acid sequences of the D-ring were: Dhb-Phe-Lys-Val-Arg-Cys (black), and Dhb-Thr-
Lys-Val-Arg-Cys (red). 
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Figure 4.20. Analytical HPLC trace of modified wild type His6-GeoAII-S1T/T2A/I3R (blue) after GluC cleavage. 
Peak 1 and Peak 2 were collected separately and lyophilized. The lyophilized powder was dissolved in water and 
analyzed by analytical HPLC. The black and red traces correspond to purified peak 1 and peak 2. 
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Figure 4.21. Stereochemical configuration of hydrolyzed and derivatized Lan/MeLan residues of peptides 
present in peak 1 and peak 2 (Figure 4.20). (A) Hydrolyzed and derivatized MeLan residue in sample generated 
from peak 1 (black trace) and peak 2 (red trace). (B) Hydrolyzed and derivatized Lan residue in samples generated 
from peak 1 (black trace) and peak 2 (red trace).  
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Figure 4.22. MALDI-TOF mass spectra of peptides present in peak 1 and peak 2 after treatment with 5 mM TCEP 
and 50 mM iodoacetamide.  The peak corresponding to M-4 H2O + 9 is generated by one IAA adduct of 
dethiomethyl geobacillin II. Dethiomethyl geobacillin II is generated by loss of part of the side chain of an oxidized 
methionine (UNIMOD accession number 526) or by the reaction of the methionine side chain with IAA, followed 
by elimination resulting in a mass shift of −48 Da. 
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Figure 4.23. Bioassay with the indicator strain B. subtilis ATCC6633.  Zone 1: 20 µL of GluC treated geobacillin 
II-G−8K/T2A (150 µM). Zone 2: 10 µL of geobacillin II-S1T/T2A/I3R corresponding to peak 2 (150 µM) + 10 µL 
sterile water.  Zone 3: 10 µL of geobacillin II-S1T/T2A/I3R corresponding to peak 1 (150 µM) + 10 µL sterile 
water.  Zone 4: 10 µL each of geobacillin II-S1T/T2A/I3R corresponding to peak 1 and 2 (150 µM each). Zone 5: 10 
µL each of geobacillin II-S1T/T2A corresponding to peak 1 and 2 (150 µM each).  Zone 6: 10 µL of geobacillin II-
S1T/T2A corresponding to peak 1 (150 µM) + 10 µL sterile water. Zone 7: 10 µL of geobacillin II-S1T/T2A 
corresponding to peak 2 (150 µM) + 10 µL sterile water. 
 
4.3.g In vitro reconstitution of enzymatic activity of GeoM 
Promiscuous thermostable lanthionine synthetases may provide promising candidates for 
generation of cyclic peptide libraries. Towards this aim, we sought to characterize the enzymatic 
activity of GeoM. The genes encoding the precursor peptide GeoAII and the modification 
enzyme GeoM were heterologously expressed as recombinant His6-tagged fusion proteins in E. 
coli by former lab member Dr. Yuki Goto. The precursor peptide was purified using nickel 
affinity chromatography followed by reverse phase high performance liquid chromatography 
(RP-HPLC). The enzyme GeoM was purified using nickel affinity chromatography followed by 
gel filtration chromatography. In vitro activity assays were carried out at 37 °C, 45 °C, 55 °C, 65 
°C, 75 °C, and 80 °C for 2 h in the presence of ATP, Mg2+, TCEP, and 5 µM enzyme. 
Commercial GluC protease was used for the removal of most of the leader peptide. GluC cleaved 
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at the −5 position leaving a four amino acid overhang at the N-terminus of the core peptide. The 
GluC cleavage product was analyzed by MALDI-MS analysis. The temperature-activity analysis 
showed that GeoAII was processed by GeoM in 2 h at all temperatures demonstrating the 
thermostability of the enzyme (Figure 4.24). The efficiency of modification of GeoAII by GeoM 
was investigated at 37 °C, 55 °C, and 70 °C with 1 µM enzyme (a five-fold decrease compared 
to Figure 4.24). The reaction was analyzed at 30 min, 60 min, and 2 h for each temperature using 
MALDI-MS (Figure 4.25). The modification efficiency increased with increase in temperature. 
Full conversion was observed by 2 h at 55 °C and 60 min at 70 °C whereas a significant amount 
of starting material was left by 2 h at 37 °C.  
 
 
Figure 4.24.  In vitro reconstituition of GeoM activity. MALDI-MS spectra of His6GeoAII incubated with 
His6GeoM (5 µM), ATP (2.5 mM), Mg2+ (10 mM), and TCEP (2 mM) in HEPES pH 7.5 and cleaved with GluC. 
 
155 
 
 
Figure 4.25. Temperature-time dependence of GeoM in vitro activity. MALDI-MS spectra of His6GeoAII 
incubated with His6GeoM (1 µM), ATP (2.5 mM), Mg2+ (10 mM), and TCEP (2 mM) at 70 °C, 55 °C, and 37 °C at 
time points (A) 30 min, (B) 60 min, and (C) 2 h. 
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4.4 Discussion 
 A novel class II lantibiotic, geobacillin II, was discovered and characterized in 
this study. The structure of geobacillin II revealed two unique features. First, the ring topology of 
geobacillin II is different from known class II lantibiotics. Second, similar to cytolysin and 
haloduracin, the first lanthionine ring (ring A) of geobacillin II has unusual LL stereochemistry. 
The B, C, and D rings have the more common DL stereochemistry. It seems likely that the 
stereochemical outcome of the ring A analogues generated in this study does not depend only on 
the sequence motif Dhx-Dhx-Xxx-Xxx-Cys. The findings in this chapter suggests that more 
complex factors such as amino acid sequence and/or differential binding in the enzyme active 
site, and perhaps even some features of the leader peptide might play a concerted role in 
determining the stereochemistry of the thioether bridges synthesized by GeoM. A role of the 
leader peptide is suggested by the position of nearly all (methyl)lanthionines with LL-
stereochemistry at the N-termini of the mature lantibiotics. Although, at present we cannot 
determine the precise location of the start of geobacillin II, the demonstration that removal of 
additional amino acids past the double Gly protease cleavage site resulted in bioactivity along 
with the sequence homology with other lantibiotics that undergo a second step of proteolytic 
processing support the lantibiotic structure shown in Figure 4.7. Geobacillin II had a narrow 
spectrum of antibacterial activity suggesting a different mechanism of action when compared to 
known lantibiotics. Future work should focus on characterizing the mode-of-action of geobacillin 
II. 
The lantibiotic synthetase GeoM is a thermostable enzyme and is active up to at least 
temperatures of 80 °C. Phosphorylated intermediates were observed both in vivo and in vitro 
(Figure 4.5C and 4.24) suggesting that dehydro-amino acids are installed via phosphorylation of 
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Ser/Thr followed by subsequent elimination of the phosphate. Comparison of enzyme activity at 
37 °C, 55 °C, and 70 °C demonstrated higher dehydration efficiency with increase in 
temperature. 
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4.5 Tables 
 
Table 4.1. Sequences of oligonucleotide primers used in this study. 
 
  
Primer name  Primer sequence 
GeoAII_BamHI_F  CTA GAT GGA TCC GAT GAA AGG TGG CAT TCA GAT GG 
GeoAII_HindIII_R  CTA GAA GCT T
GeoM_NdeI_F 
TT ACA TCG GAC AAC GAA CTT TAA AGC 
 AAG CAG CCG CAT ATG
GeoM_XhoI_R 
 AAC GAA ATC GTG GAA AAT AAC C 
 CTA GCT CGA G
GeoAII(G-8K)_F 
TT AAT GGT TCA GCT GCA GAG TCA GCA CG 
 GAA AAA ACT GGC TGG CAA ATA TAC CGA AGT TTC TCC G 
GeoAII(G-8K)_R  GCC AGC CAG TTT TTT CAG TTC TTC TTC GC 
GeoAII(Q-1E)_F  GTT ATA CCG AAG TTT CTC CG GAAAGCA CCA TTG TTT GTG 
GeoAII(Q-1E)_R  CGG AGA AAC TTC GGT ATA TTT GCC AGC CAG 
GeoAII(Q-1K)_F  GTT ATA CCG AAG TTT CTC CGA AAA GCA CCA TTG TTT GTG 
GeoAII(Q-1K)_R  CGG AGA AAC TTC GGT ATA ACC GCC AGC CAG 
GeoAII(S1T)_F  AAT ATA CCG AAG TTT CTC CGC AGA CCA CCA TTG TTT GTG TTA GCC 
GeoAII(S1T)_R  CTGCGGAGAAACTTCGGTATATTTGCCAGC 
GeoAII(G−8K/T2A)_F  ACC GAA GTT TCT CCG CAG AGC GCG ATT GTT TGT GTT AGC 
GeoAII(G−8K/T2A) _R  GCTCTGCGGAGAAACTTCGGTATAACCGCC 
GeoAII(G−8K/T2G)_F  CGA AGT TTC TCC GCA GAG CGG CAT TGT TTG TGT TAG CCT G 
GeoAII(G−8K/T2G)_R  CAG GCT AAC ACA AAC AAT GCC GCT CTG CGG AGA AAC TTC G 
GeoAII(S1T/T2A)_F  ACC GAA GTT TCT CCG CAG ACC GCG ATT GTT TGT GTT AGC 
GeoAII(S1T/T2A)_R  GGTCTGCGGAGAAACTTCGGTATAACCGCC 
GeoAII(S1T/T2A/I3R)_F  TTT CTC CGC AGA CCG CGC GTG TTT GTG TTA GCC TG 
GeoAII(S1T/T2A/I3R)_R  ACG CGC GGT CTG CGG AGA AAC TTC GGT ATA AC 
GeoAII(G−8K/S7T)_F  CAG AGC ACC ATT GTT TGT GTT ACC CTG CGT ATT TGT AAT 
TGG 
GeoAII(G−8K/S7T)_R  AAC ACA AAC AAT GGT GCT CTG CGG AGA AAC 
GeoAII(G−8K/S7T/L8T)_F  CAG AGC ACC ATT GTT TGT GTT ACC ACA CGT ATT TGT AAT 
TGG 
GeoAII(G−8K/S7T/L8T)_F  GGT AAC ACA AAC AAT GGT GCT CTG CGG AGA AAC 
GeoAII(G−8K/S14T)_F  CCT GCG TAT TTG TAA TTG GAC CCT GCG TTT TTG TCC GAG 
GeoAII(G−8K/S14T)_R  CTC GGA CAA AAA CGC AGG GTC CAA TTA CAA ATA CGC AGG 
GeoAII(G−8K/S14T/L15T)F  CCT GCG TAT TTG TAA TTG GAC CAC ACG TTT TTG TCC GAG 
GeoAII(G−8K/S14T/L15T)R  GGT CCA ATT ACA AAT ACG CAG GCT AAC ACA AAC 
GeoAII(G−8K/S20T)_F  GGA GCC TGC GTT TTT GTC CGA CCT TTA AAG TTC GTT GTC 
GeoAII(G−8K/S20T)_R  CGG ACA AAA ACG CAG GCT CCA ATT ACA AAT AC 
GeoAII(G−8K/S20T/F21T)_F  GGA GCC TGC GTT TTT GTC CGA CCA CAA AAG TTC GTT GTC 
GeoAII(G−8K/S20T/F21T)_R  GAC AAC GAA CTT TTG TGG TCG GAC AAA AAC GCA GGC TCC 
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Table 4.2. Bioactivity spectrum of geobacillin II assessed by zones of growth inhibition in 
agar well diffusion assays.  
Strain Source Geobacillin II 
 Micrococcus luteus   ATCC 4698 - 
Streptococcus dysgalatiae 
subsp dysgalactiae ATCC 27957 - 
Staphylococcus epidermidis 
15X 
Ekkelenkamp 
et. al.a - 
Staphylococcus epidermidis ATCC12228 - 
Bacillus cereus Z4222 INRAb Z4222 + 
Bacillus subtilis  ATCC 6633 + 
Lactococuus lactis HP ATCC 11602 - 
E. coli DH5α UIUC-CMFc - 
aReference (41). bINRA: Institut National de la Recherche Agronomique. cUIUC-CMF: 
University of Illinois Urbana-Champaign Cell and Media Facility. 
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Table 4.3. Theoretical and observed molecular weights ([M+H]1+) of modified peptides 
reported in this study. 
 
Peptide 
Protease 
used 
Theoretical 
[M+H]1+ 
Observed 
[M+H]1+ 
Geobacillin II (from GeoA-G−8K) GluC 3470, 3057 3470, 3057 
Geobacillin II (from GeoA-G−8K) GluC and aminopeptidase 
3470,3371, 
3187,3057 
3470,3371, 
3187,3058 
Geobacillin II (from GeoA-G−8K/Q−1E) Trypsin 3863 3863 
Geobacillin II (from GeoA-Q−1K) Trypsin 3057, 3075 3057, 3075 
Geobacillin II (S1T) GluC 3479 3479 
Geobacillin II (S1T/T2A) GluC 3468 3468 
Geobacillin II (S1T/T2A/I3R) GluC 3511 3511 
Geobacillin II (G−8K/T2G) GluC 3440 3440 
Geobacillin II (G−8K/T2A) GluC 3454 3454 
Geobacillin II (G−8K/S7T) GluC 3480 3480 
Geobacillin II (G−8K/S7T/L8T) GluC 3550 3467 
Geobacillin II (S14T) GluC 3480 3480 
Geobacillin II (G−8K/S14T/L15T) GluC 3450 3467 
Geobacillin II (G−8K/S20T) GluC 3480 3480 
Geobacillin II (G−8K/S20T/F21T) GluC 3416 3439 
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4.6 Codon optimized nucleotide sequence for GeoAII 
        1 ATGAAAGGTG GCATTCAGAT GGAAAAACAG GAACAGACCT TTGTTAGCAA AATTAGCGAA 
       61 GAAGAACTGA AAAAACTGGC TGGCGGTTAT ACCGAAGTTT CTCCGCAGAG CACCATTGTT 
      121 TGTGTTAGCC TGCGTATTTG TAATTGGAGC CTGCGTTTTT GTCCGAGCTT TAAAGTTCGT 
      181 TGTCCGATGT AA 
 
4.7 Codon optimized nucleotide sequence for GeoM 
        1 ATGAACGAAA TCGTGGAAAA TAACCTGATG GAAATCATCA AAGATAAACT GCTGTACCCG 
       61 AGCGAAAAAA AAAAAGAAAT CGAAAACAAC GTGCCGATTA ACGAGCTGCT GTTCCAAGAA 
      121 AAAACCAACA AATGGATCGA CCTGTTCTAT CAGTATCTGA ACGTGTGCAA AAACAACATT 
      181 GAAGTGGATC AGCTGTATAG CAACGAAGAA AACCTGAGCA ATCCGTTTAG CAGCTTTTTC 
      241 AAAGAATTTC TGGAAATTGC GAGCCGTTAT CTGGATAGCA GCCTGAAAAG CCAGGTGAAC 
      301 AACTATGATG ATCTGAGCCG TATTTGCAAC CTGACCAGCA TCAAAAATGA TATCATGAAA 
      361 TTCATCCACG AAAACCTGGT GTATGTGAGC ATTCGTACCC TGATTCAGGA TCTGAATGAA 
      421 GAACGTGAAA AAGGCAACCT GATTGGCGAT ACCCCGAAAG AACGCTATAA CTTCTACGTG 
      481 GATCAGATTC TGAGCAGCCC GGATAAAAAA TTCGAGCTGA TCAAAAAATA TCCGGTGCTG 
      541 GTGCGTATTC TGATTGAATT TATCCTGAAC AAAATCGATA GCATCGTGGA AAGCATTTAC 
      601 CGCTTTCTGA AAGATCGTAG CGAGCTGGTG CATATTTTCC ACCTGAGCGA TGATGATATT 
      661 CTGACCAGCC TGACTCTGCA GAGCGGCGAT AGCCATAACA ACGGCCGTAG CGTGATCATT 
      721 TTTCAGTTCA GCAGCAAAAA AAAAATCGTG TACAAACCGC GTAGCCTGAG CATTGATCTG 
      781 CATTTTCAGC AGTTTCTGGA ATGGATCAAC GGCAAAAAAC CGAGCCTGCA GCTGAAAACG 
      841 ATTACCATTC TGAACAAAGA TCAGTATGGC TGGCAGGAAT TTGTTGAATA TAAACCGTGC 
      901 AGCTCTAACA ACGAGCTGTC TCGTTTTTAT GAACGTCAGG GCAACTATAT TGCGATTCTG 
      961 TATATTCTGA ACGCGACCGA TTTTCATTTT GAAAACCTGA TTGCGAACGG CGAACACCCG 
     1021 GTGCTGATTG ATCTGGAAGG CCTGGTGCAG AACACCGTGA AACTGCCGCG TAAAGCGAGC 
     1081 AGCGCGTATG ATATTGCGTT TAGCAAACTG ACCGATAGCG TTCTGAGCAC CGGCATGCTG 
     1141 CCGGCGACCT TTATGCAGGC GAATATCTAT GATTTTGATC TGAGCGGCCT GGGCGGTGAT 
     1201 GAAGGTCAGC CGACCGGCCT GGAAACCTTT ACCATTGAAA ATCCGCTGAC CGATGAAATG 
     1261 CGTGTGATTA AAGTGCCGGC GTTTAGCCAG AGCAGCAAAA ACAAACCGTA TCTGAAAGAA 
     1321 GAAAAAGAAA TTGCGGTGAC CGATTATAGC AGCGAAATCA TTAAAGGCTT CCGCGAAATG 
     1381 TATACCCTGC TGCTGCATAA CAAAAAGGAG CTGCTGTCTC AGAACGGCCC GATTTACCTG 
     1441 TTTAAAGGCG ATAAAGTGCG TATTATTCTG CGTAGCACCC AGGTGTATAG CACCTTCCTG 
     1501 GATAGCAGCT TTCATCCGGA TTATCTGAAA GATGGCTATG AACGTGAACG CCTGATTAAC 
     1561 TTTCTGTGGA TCGGCAAAGA AAACCATCCG GAATATCAGG ATGCGATCAT GTATGAATGC 
     1621 CGCGATATTC TGAATGGCGA TATCCCGTAT TTCTATTGCT ATACCGATAG CAGCGATCTG 
     1681 TATCATCCGA TTGGCATCGT GAAACACAAC TTTTTCTATG AAAGCAGCTT TAACAGCCTG 
     1741 CTGGAAAAAG TGAAAATGAT CAACGAAGAA GATCTGAATT TCCAGATCGA AATTCTGACC 
     1801 AATAGCCTGC TGGCCCAGTA TAGCAACAAA ACCCATAGCC ATGCGAACGT GAGCAACCGT 
     1861 GTGTATAACC TGGATAAAAT CAGCGGCAAC TTTCGTCGTG AATCTTTTCT GGAAGTGAGC 
     1921 GAAAAAATTG CGGATAACAT CAAAGAAAAC GCGATCTTCG GTAAAGAAAA CGATGTGACC 
     1981 TGGCTGGGCC TGAACCTGAC CATTGAAGAT AAATGGACCT TCAAACCGCT GGATTTCGAT 
     2041 CTGTATGATG GCGTGCTGGG CATTGGCCTG TTTTATGCGA ACCTGTATAA CCTGAACAAA 
     2101 CGCAAAGAAT ACAAAATCCT GGCCGAAAAA ACCGTGCAGA CCGCGCTGAA CTATCTGGAA 
     2161 TATTATCCGG CGAAACTGCC GCTGTCTGCG TTTTATGGCT ATGGCGCGTA TGCGTATGTG 
     2221 CTGGGCAACT TTAGCATCAT CTTTAATAAC AGCGAATACC TGACCTATGT GAAAAAAGTG 
     2281 CTGAACAAAG CGGCGAACAC CATCGAAGAT GATCAGCTGC TGGATTTTCT GGGCGGTGCG 
     2341 GCGGGTCTGA TTATTGTGTG CATCCACCTG TATAAAAAAA CCGGCGAACA GTATCTGCTG 
     2401 GATATTGCGA ACAAATGCGG TGAGCTGCTG CTGCGTAAAA AAGAAAAACA GGCCATGGGC 
     2461 ATTGGCTGGC GTCCGAACCA GGTGAATAAA CCGCTGGCCG GTCTGGCCCA TGGTAGCAGC 
     2521 GGCTTTACCT GGGCGCTGAT GGCGCTGTAT AAATTCACCA AAAACTACAA CTATAAAGAA 
     2581 ACCTTCCTGC AGAGCTTCGA ATATGAAAAA AGCCTGTTTA ATAAAAAAGA AGAAAACTGG 
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     2641 CTGGTTCTGA GCGACGATGG CGATTATTAT GGCAACAGCA TGTGGTGCCA TGGTGCGGCC 
     2701 GGTATTGGCA TGAGCCGTAT CATGATGAGC GAATACTATA ACAGCCACGA TCTGAAAAAC 
     2761 GATATTGAAA TCGCGATTCG TCAGACCCTG AAAAGCGGCT TTGGCGGCAC CCATTGCCTG 
     2821 TGCCATGGCG ATCTGGGCAA CCTGGACCTG TTTCTGCTGG CCTCTAGCAA ATTTAAAAAC 
     2881 GAAGAAATGA AAGAAACCGC GCTGAAAATT GGCGAATATA TCGCGAGCGA TATTACCTAT 
     2941 GGCAACCTGA AATATGGCAC CCCGAGCGGC ACCAAAAATC TGGGTCTGAT GCTGGGCCAG 
     3001 GCGGGTATTG GCTATGGCTT TCTGCGTCTG GCCTATCCGG AAATTGTGCC GAGCGTGCTG 
     3061 ACTCTGCAGC TGAACCATTA A 
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Appendix: Structural characterization of lantibiotic dehydrogenase ElxO1 
A.1 Introduction 
 The lantibiotic epilancin 15X is a member of the epilancin-group of peptides and is 
produced by Staphylococcus epidermidis 15X154 (1-2). S. epidermidis 15X154, a clinical strain 
isolated from a wound infection, is a colonizer of the human skin (3). Other staphylococcal 
lantibiotics include Pep5 (4), epidermin (5), epicidin 280 (6), and epilancin K7 (7-8). Epilancin 
15X was shown to have potent antimicrobial activity against pathogenic bacteria, including 
MRSA and VRE (9). Epilancin 15X contains ten post-translationally modified amino acids, one 
lanthionine, two methyllanthionine bridges, and an unusual N-terminal 2-hydroxypropionyl 
group (D-lactate, Figure 1.1 and 1.3, Chapter 1). The gene cluster and biosynthetic pathway of 
epilancin 15X was recently characterized (2). The N-terminal lactate was shown to be produced 
by dehydration of the first serine residue in the core peptide by the lantibiotic dehydratase ElxB, 
followed by proteolytic removal of the leader peptide by the lantibiotic protease ElxP. The 
spontaneous hydrolysis of the N-terminal dehydroalanine to a pyruvate group and reduction of 
the newly generated pyruvate to lactate by the nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent oxidoreductase ElxO complete the biosynthesis of epilancin 15X. The N-
terminal lactate group was shown to impart stability to epilancin 15X against bacterial 
aminopeptidases. Three lantibiotics namely, epilancin K7 (7-8), SWLP1 (10), and epicidin 280 
(6)  have also been reported to contain an N-terminal lactate group. The biosynthetic gene cluster 
of epicidin 280 contains a homologous oxidoreductase EciO and was suggested to be involved in 
the biosynthesis of its N-terminal lactate (6). The enzymatic activity of ElxO has been 
reconstituted in vitro and ElxO was shown to have relaxed substrate specificity by Dr. Juan 
Esteban Velásquez, as various N-terminal ketone-containing peptides were tolerated as 
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substrates. The N-terminal lactate group generated by ElxO can be engineered into other 
lantibiotics in order to enhance their biological stability. In this study, the crystal structure of 
ElxO was determined providing insights into the catalytic mechanism.  
A.2 Experimental procedures 
A.2.a Expression and purification of ElxO 
The plasmid pET28/His6-ElxO encoding hexahistidine tagged ElxO was provided by 
former lab member Dr. Juan Esteban Velásquez. The overexpression and purification was carried 
out in Prof. Satish K. Nair’s laboratory. Chemically competent E. coli Rossetta2 cells were 
transformed with pET28/His6-ElxO. An overnight culture grown from a single colony 
transformant was used as inoculum for 2 L of LB medium containing 50 µg/L kanamycin and 25 
µg/L chloramphenicol, and the culture was grown at 37 °C until the OD600 reached about 0.6. 
The incubation temperature was then changed to 18 °C and the culture was induced with 0.1 mM 
IPTG. The induced cells were shaken continually at 18 °C for an additional 12 h. The cells were 
harvested by centrifugation (11,900 × g for 10 min, Beckman JLA-10.500 rotor). The cell paste 
was resuspended in 20 mM Tris-HCl, 1 mM NaCl, and 10% glycerol, pH 8.0. The cells were 
lysed using a C5 Homogenizer (Avestin Inc.). The lysed cells were pelleted by centrifugation at 
23,700 x g for 25 min. The purification by nickel column chromatography was accomplished 
using a 5 mL HiTrap chelating HP nickel affinity column (GE Healthcare) on an AKTA FPLC 
system (Amersham Pharmacia Biosystems). The supernatant from the centrifugation step was 
applied to the column using a 50 mL superloop. The protein was detected by absorbance at 280 
nm. The column was washed with buffer A containing 20 mM Tris-HCl, pH 8.0, 1 M NaCl, and 
30 mM imidazole to remove any non-specifically bound proteins until a flat baseline was 
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observed. A gradient of 0-100% B over 45 min was used to elute the bound proteins where 
buffer B contained 1 M NaCl, 20 mM Tris-HCl, pH 8.0, and 200 mM imidazole.  The most 
concentrated fraction (4 mL) was loaded onto an S-200 gel filtration column (Amersham 
Biosciences) equilibrated in 20 mM HEPES pH 7.5 containing 100 mM KCl.  
A.2.b Protein crystallization, X-ray diffraction data collection and structure determination 
Apo-ElxO was concentrated to a final concentration of 0.4 mM by centrifugal filters, and 
incubated with five fold excess of freshly prepared NADPH. The solution was incubated on ice 
for 2 h prior to crystallization. Crystals of the ElxO wild type enzyme in complex with NADPH 
were grown using the hanging drop vapor diffusion technique. Commercially available sparse 
matrix crystallization screens were used to identify initial crystallization conditions using the 
Hampton Natrix crystallization screen. The initial condition (Natrix 39) was optimized to 0.1 M 
ammonium acetate, 0.02 M magnesium chloride, 0.05 M HEPES-Na (pH 7.5), 8% PEG 8000, 
and 5% glycerol. Crystals were obtained by adding 1 L of the protein to an equal volume of the 
crystallization mother liquor equilibrated against the same solution at 9 oC. Crystals grew within 
three days and were harvested after one week. Crystals were vitrified by soaking in 
crystallization condition supplemented with 30% glycerol prior to direct immersion in liquid 
nitrogen. All X-ray diffraction data was collected at the Life Sciences Collaborative Access 
Team (Sector-21), Argonne National Laboratory, Lemont- IL. 
The diffraction data was indexed and scaled using HKL2000 (11) to a limiting resolution 
of 1.85 Å. The coordinates from three models (PDB ids: 2HQI, 2UVD and 2CFC) were 
superimposed to generate a search model for molecular replacement. All water and ligand atoms 
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from the search model were deleted, and non-conserved amino acid side chain reduced to 
alanines. A five fold redundant native dataset for the ElxO-NADPH complex crystals was used.  
Following rigid body refinement of the initial MR solution, phases from the resultant 
model were further improved by two-fold density averaging allowing for a significant portion of 
the model to be manually rebuilt using XtalView (12).  Further manual fitting was interspersed 
with automated rebuilding using ARP/wARP (13) and rounds of refinement using REFMAC5 
(14-15). Cross-validation, using 5% of the data for the calculation of the free R factor (16), was 
utilized throughout the model building process in order to monitor building bias.  Although clear 
density for NADPH could be observed prior to crystallographic refinement, the ligand was 
manually built into the model only after the free R factor dropped below 30%. The 
stereochemistry of the models was routinely monitored throughout the course of refinement 
using PROCHECK (17).  
A.3 Results and Discussion 
 In order to investigate and understand substrate specificity and the catalytic mechanism 
of ElxO, crystallographic structure determination was performed. The crystallographic 
asymmetric unit consists of two protein molecules with extensive contacts between the 
monomers, consistent with the existence of ElxO in solution as a dimer. The crystal structure of 
ElxO reveals it to contain a single domain Rossmann fold (18), with high structural homology to 
members of the short-chain dehydrogenases (19). A DALI server based structure homology 
search identified the closest homologs to be hydroxypropyl-coenzyme M dehydrogenase (PDB 
id: 2CFC, root mean square deviation (RMSD) = 1.4, 35% sequence identity) (20), 3-oxoacyl-
[acyl carrier protein] dehydrogenase FabG (PDB id: 4JRO, RMSD = 1.6, 36% sequence 
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identity), and a putative acetoacetyl coenzyme A reductase (PDB id: 4K6F, RMSD = 1.4, 31% 
sequence identity). Hence members of the short chain dehydrogenase superfamily share a 
conserved structural core despite a moderate degree of sequence conservation. 
Central to the structure of ElxO is a seven membered parallel β-sheet. This β-sheet is 
decorated by three α-helices on either side (Figure A.1). The ElxO-NADPH co-crystal structure 
identifies the cofactor binding interactions. The cofactor is bound in a shallow surface cavity of 
the protein in a fully extended conformation (Figure A.2). The nicotinamide dinucleotide is 
bound at the top of the β-sheet, with the diphosphate moiety bound between the loops emanating 
from the third and the fourth β-strands. The binding site for the diphosphate is provided by the 
canonical Rossmann fold, comprising the conserved TGX3GXG (Thr9 – Gly16 for ElxO) motif. 
This motif provides the primary stabilizing interactions for the diphosphate of the cofactor by 
interactions with the main chain amide atoms. The adenine moiety of the cofactor is bound by 
the hydrophobic pocket defined by Leu58, Val60, Ile70, Ala87, and Ile89 at one face of the ring, 
with Arg34 on the other face of the ring. The nicotinamide moiety is similarly bound by the 
hydrophobic pocket defined by the side chains of Ile14, Pro182, Ile223 and Val219. The primary 
amine of the side chain of Lys156 forms hydrogen bonds to both the 2’ and 3’ ribose sugar 
hydroxyls of the nicotinamide ribose. The adenine ribose 2’-phosphate of NADPH is coordinated 
by salt bridge interactions to the basic side chains of Arg35 and Lys39. These interactions likely 
provide the basis for cofactor specificity for ElxO.  
Though the majority of the residues can be traced in the electron density map, residues 
188 to 204 are not visible. This region has been postulated to be responsible for binding to the 
substrate. Hence disorder in this region can be attributed to the lack of substrate in the structure. 
This region is expected to fold into a helix structure forming a protective lid over the active site 
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that may undergo an open to closed conformational change upon substrate binding (21) (Figure 
A.2). By homology to other members of the short chain dehydrogenase family, several key 
catalytic residues can be readily identified from the structure of ElxO in complex with NADPH, 
despite the absence of the substrate peptide. Primary among these are Ser139, Tyr152 and 
Lys156.  Based on the mechanism of known short-chain dehydrogenases (19) and the active site 
architecture of ElxO, a reaction mechanism is proposed (Figure A.3). The protonated hydroxyl 
group of Tyr152 and Ser139 hydrogen bond with the N-terminal carbonyl oxygen of 
dehydroepilancin 15X promoting transfer of hydride from the reduced nicotinamide ring to the 
carbonyl carbon of dehydroepilancin 15X. The resulting positive charge on the oxidized 
nicotinamide ring and the adjacent ε-amino group of Lys156 may lower the pKa of tyr152 
allowing the transfer of a proton to the newly formed alkoxide in the substrate, thereby 
generating the lactate moiety at the N-terminus. Extensive co-crystallization trials, including 
screening for crystal growth in the presence of substrate peptides, and soaking of ElxO-NADPH 
crystals were tried with four short peptides pyruvate (Pyr)-DAIVK, Pyr-VAIVK, 2-oxobutyryl 
(OBut)-AAIVK, and OBut-RAIVK without success. This may be due to high Km values of these 
substrate peptides (unpublished data from previous lab member Dr. Juan Esteban Velásquez). 
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Figure A.1. Cartoon representation of the three dimensional crystal structure of the ElxO monomer in complex with 
NADPH. Helices are colored blue, and the beta-sheets are colored red. NADPH is shown in stick representation 
with the carbon atoms colored green. 
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Figure A.2. Surface representation of ElxO with NADPH shown in stick representation. The ElxO surface is 
colored brown, with the carbon atoms of NADPH shown in yellow. Note the postulated substrate binding empty 
cavity positioned above the nicotinamide ring of the cofactor. 
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Figure A.3. The proposed reaction mechanism for ElxO and the postulated contributions of individual side chains 
based on homology to other members of the short chain dehydrogenase family of enzymes.  
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